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Abstract 
High-grade serous ovarian cancer (HGSC) is the most common and aggressive form of ovarian 
cancer, accounting over 60% of cases and up to 90% of ovarian cancer related deaths. Mutant 
TP53 appears to be a consistent and defining feature, reported to occur in over 96% of HGSC. 
This suggests mutant TP53 is an important feature in HGSC tumourigenesis. Several years ago, 
our laboratory identified an immortalised ovarian surface epithelial cell line (IOSE) that had 
undergone spontaneous transformation, acquiring different, successive TP53 mutations. This 
suggested different TP53 mutations could have varying transformative potential. To investigate 
this hypothesis, IOSE cell lines from different patients were transduced with R175H or 
R273H mutant TP53 and examined for the acquisition of transformed traits. The cell line 
IOSE21-R175H demonstrated the greatest acquisition of transformed traits; suggesting 
R175H mutant TP53 may have greater transformative potential than R273H. However, 
IOSE21-R175H could not form tumours in immunodeficient mice, suggesting mutant TP53 is 
insufficient to induce malignant transformation. The expression of a number of other 
transformed traits could also not be directly linked to mutant TP53. This suggests other 
molecular events may have facilitated the premalignant transformation of IOSE cell lines. In 
this respect, we conclude that mutant TP53 is permissive of other tumourigenic events 
necessary for premalignant transformation. 
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Chapter 1:  Introduction 
1.1 Ovarian cancer 
‘Ovarian cancer’ is a general term used to describe a number of cancers that share the same 
anatomical location [1]. Of these cancers, over 90% are epithelial-derived and are classified as 
mucinous invasive, endometrioid, clear cell, low or high-grade serous ovarian cancer (HGSC) 
(Figure 1.1) [1, 2]. HGSC is the most common and aggressive, accounting for over 60% of 
cases and up to 90% of ovarian cancer related deaths [3]. Mortality is thought to be 
disproportionately high, largely due to late stage presentation [4, 5]. Early diagnosis is 
impeded by the lack of clearly defined symptoms and reduced efficacy of screening strategies 
[6, 7]. As a result, early HGSC remains elusive, confounding understanding of HGSC 
pathogenesis.  
 
 
Figure 1.1: Epithelial ovarian cancer subtypes 
A: Percentage incidence of epithelial ovarian cancer subtypes. High-grade serous is the most common epithelial 
subtype. B: Haematoxylin and eosin (H&E) staining of mucinous invasive, endometrioid, clear cell and high-
grade serous ovarian cancer sections. Images courtesy of Dr Ronny Drapkin. Figure adapted from Vaughan et al, 
2011 and Auersperg, 2013 [1, 2]. 
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1.2 Pathogenesis of HGSC  
One of the greatest obstacles to understanding HGSC pathogenesis is controversy surrounding 
its site of origin. HGSC was traditionally thought to arise from the ovarian surface epithelium 
(OSE), either directly or through the formation of intra-ovarian inclusion cysts [8, 9]. During 
ovulation the OSE is subject to physical trauma, resulting in successive rupture and repair as 
well as exposure to inflammatory cytokines and reactive oxygen species that can cause DNA 
damage [10]. Repeated exposure to these potentially carcinogenic mediators could facilitate 
malignant transformation, with increased ovulation associated with increased ovarian cancer 
risk [11, 12]. However, the OSE is separated from the stroma and circulation by a thick 
collagenous layer known as the tunica albuginea. This could reduce the likelihood of 
carcinogenic interaction and the potential for OSE transformation [2, 9]. Alternatively, the 
OSE could invaginate and pinch off, forming inclusion cysts within the ovarian stroma (Figure 
1.2) [9, 13, 14]. OSE cells lining inclusion cysts would be chronically exposed to hormones 
and inflammatory mediators, predisposing the cells to malignant transformation [15, 16]. 
However, few inclusion cysts have been observed at the ovary, and cysts have been identified 
in normal ovaries with pre-cancerous events rarely seen [17, 18]. As a result, the concept of 
the OSE as the site of HGSC has been challenged, with suggestions instead that tumours arise 
from the adjacent fallopian epithelium [19-21].  
 
 
Figure 1.2: Formation of a cortical inclusion cyst 
A: Normal ovarian surface epithelium (OSE). B: Invagination of the OSE. C: Occlusion of the invagination to 
form a cortical inclusion cyst within the ovarian stroma. 
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Figure 1.3: Fallopian fimbriae and HGSC 
A: A cross-section of fallopian tube H&E stained. Fallopian ciliated and secretory cells highlighted. B: Cross-
section of a fallopian fimbria highlighting the key lesions associated with HGSC pathogenesis. HGSC is thought 
arise from p53-signatures and serous tubal intraepithelial carcinomas (STICs). Cells of the resulting invasive 
carcinoma can slough off and migrate to the adjacent ovary or peritoneum. Figure adapted from Karst and 
Drapkin, 2009 [24]. 
 
Histological similarities between tubal carcinomas and HGSC initiated early suggestions that 
HGSC could be fallopian-derived [22]. Premalignant lesions displaying molecular 
characteristics similar to HGSC have been identified at the fallopian fimbriae [23]. The 
fimbriae are small, finger-like projections, located at the distal end of the fallopian tube. 
Found in close proximity to the OSE, the fallopian fimbriae could be subject to the same, 
potentially carcinogenic microenvironment [24]. This suggests tumour initiation at the 
fallopian fimbriae could be similar to the OSE. The fallopian epithelium is comprised of two 
cell types: ciliated and secretory (Figure 1.3:A). HGSC is thought to arise from fallopian 
secretory cells, with p53-signatures the earliest premalignant lesion to be identified [25]. p53-
signatures consist of 12 or more benign fallopian secretory cells that demonstrate p53 
immunoreactivity [26]. The cells can be contiguous or interrupted by fallopian ciliated cells, 
but have a low proliferative index and normal cell structure [27]. The signatures are thought 
to be precursor lesions to serous tubal intraepithelial carcinomas (STICs) [20, 28], 
demonstrating identical TP53 mutations to concurrent STIC lesions [29-31]. STIC lesions are 
histologically similar to HGSC but without invasion of the basement membrane. This suggests 
STICs are precursory to HGSC [4], demonstrating identical TP53 mutations to concurrent 
high-grade serous tumours [20, 28, 31]. STICs have been identified in 50-60% of sporadic 
ovarian, tubal and primary peritoneal HGSCs, and ~15% of fallopian tubes removed from 
BRCA1/2 mutant women [23, 34, 35]. STIC lesions also demonstrate peritoneal 
dissemination prior to local invasion of the fallopian tube [4, 32]. This could account for the 
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high dissemination rate of HGSC, and the observation of peritoneal carcinomas following 
prophylactic oophorectomy in women with germline BRCA1/2 mutations [33]. Combined, 
this data suggests a pathogenic model in which HGSC arises from the fallopian tube via 
neoplastic progression of a p53-signature, to STIC lesion, to an invasive carcinoma (Figure 
1.3:B). However, not all HGSCs demonstrate tubal involvement. 40-50% of cases do not 
demonstrate STIC lesions upon sectioning of the fallopian tubes [23, 34, 35]. In this instance, 
pathogenesis could precede independent of the fallopian fimbriae. The proximity of the 
fimbriae to the ovary could facilitate the implantation of fallopian secretory cells at the OSE 
[16, 24]. Implanted cells could then be incorporated into cortical inclusion cysts, undergoing 
malignant transformation at the ovary. Indeed, cortical inclusion cysts often demonstrate the 
expression of Müllerian markers associated with fallopian-derived cells [2, 21, 36]. In this 
respect, HGSC pathogenesis could involve both fallopian and ovarian tissue.  
HGSC expresses of a number of markers associated with Müllerian tissue, including the 
fallopian epithelium [2, 21, 36]. To account for the expression of Müllerian markers in 
HGSC, mesothelial derived OSE cells would require the inappropriate activation of Müllerian 
differentiation [37]. The OSE has been described as an pluripotent epithelium, capable of 
differentiation towards a Müllerian phenotype [9]. OSE cells lining inclusion cysts have been 
found to express Müllerian marker PAX8, suggesting differential marker expression could 
form part of OSE transformation [38, 39]. The ability of OSE cells to initiate Müllerian 
differentiation could be due to the common developmental origin of ovarian and Müllerian 
tissue. The OSE and fallopian tubes arise from adjacent regions of the coelomic epithelium 
(Figure 1.4) and remain contiguous throughout adulthood, connected by a narrow epithelia 
isthmus [2, 40, 41]. As a result, the OSE and fallopian fimbriae reside at a transitional zone 
between ovarian (mesothelial) and Müllerian tissue. Indeed, immunohistochemical analysis 
reveals a transition in the expression of mesothelial-Müllerian markers but no clear differential 
boundary between OSE and fallopian fimbriae [24, 26]. As a result, the OSE and fallopian 
fimbriae could be viewed as a unit of transitional epithelia from which HGSC is derived [39]. 
Transitional epithelia have previously been associated with increased risk of neoplastic 
progression. For example, the oesophageal-gastric junction and the squamo-columnar junction 
at the uterine cervix [2]. In this respect, HGSC could arise from ovarian-fallopian transitional 
epithelia. 
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Figure 1.4: Development of the OSE and Müllerian ducts 
A: Cross-section of a developing embryo. B: Development of the OSE and Müllerian duct at the gonadal ridge. 
Part of the coelomic epithelium overlying the gonadal ridge will from the OSE. Thickening of the epithelium will 
form the sex cords, from which the primordial follicles develop. The Müllerian ducts form through an 
invagination of the coelomic epithelium adjacent to the OSE. Figure adapted from Auersperg, 2013 [2]. 
 
Although disputed, pathogenic models of HGSC (Figure 1.5) highlight common themes in the 
pathogenesis of HGSC. An inflammatory microenvironment induced by incessant ovulation 
could be an initiating factor, with mutant TP53 an early genetic alteration. Early dissemination 
also appears to be a feature, with the lack of OSE precursor lesions and STIC peritoneal 
dissemination suggesting rapid tumour progression or early acquisition of metastatic traits. 
Pathogenic models of HGSC therefore identify general trends in disease progression but 
further investigation is required understand disease pathogenesis.  
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Figure 1.5: Pathogenic models of HGSC 
HGSC has been proposed to arise from the ovarian surface epithelium (OSE) either directly or through the 
formation of cortical inclusion cysts. HGSC has also been proposed to arise from fallopian tube secretory 
epithelial cells (FTSE) by exfoliation to the ovary and incorporation into cortical inclusion cysts. HGSC may also 
be derived from FTSE cells by the formation of p53 signatures and serous tubal intraepithelial carcinomas 
(STICs). Alternatively, the OSE and fallopian fimbria may represent a unit of transitional epithelia prone to 
malignant transformation. HGSC could therefore be derived from both OSE and FTSE cells. 
 
1.3 Molecular characteristics of HGSC 
Analysis of the molecular characteristics of HGSC may provide some insight into the cancer’s 
pathogenesis. TP53 mutations appear to be a consistent and defining feature, reported to occur 
in over 96% of HGSCs [42]. BRCA pathway disruption also appears to be a hallmark, with 
22% of HGSCs reported to harbour BRCA1/2 somatic or germline mutations [42, 43]. 
BRCA1 and BRCA2 are crucial components of the homologous recombination repair pathway 
that resolves DNA double strand breaks [44]. As a result, HGSC is associated with widespread 
genomic instability, manifesting in structural and numerical chromosome alterations.  
Only a handful of other statistically significant genetic alterations have been associated with 
HGSC, albeit at a low frequency (2-6%). These include mutant NF1, FAT3, CSMD3, GABRA6, 
RB1 and CDK12 (Figure 1.6) [42]. Due to the low frequency of these mutations, the 
aberrations are unlikely to be driver mutations, rather passenger events resulting from 
widespread genomic instability. However, integration of low frequency mutations into cancer 
associated pathways, identified FOXM1, homologous recombination (HR) repair, RB1, 
PI3K/RAS and NOTCH signalling pathways as deregulated in 87%, 50%, 67%, 45% and 
22% of HGSCs respectively (Figure 1.6) [42].  
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Overexpressed in 87% of HGSC, the FOXM1 transcription pathway is associated with 
increased proliferation [45]. However, FOXM1 appears to be regulated by wild type p53, 
suggesting overexpression of FOXM1 could be a bystander affect of mutant TP53 [46]. 
Defective HR signalling has already been implicated in HGSC due to the prevalence of 
BRCA1/2 mutations. However, integration of low frequency aberrations into the pathway 
increased the frequency of HR-deficiency to over 50% of cases. HR-deficiency is a major 
determinant of platinum sensitivity and provides a rational for the use of poly (ADP-ribose) 
polymerase (PARP) inhibitors [47-49]. As a result, identification of HR-deficient HGSCs 
could facilitate that application of anti-cancer therapies. The molecular features of HR-
competent HGSC are poorly defined, although ~30% demonstrate amplification of cyclin E1 
[42]. Cyclin E1 is a critical mediator of RB1 signalling, associated with cell cycle progression. 
This suggests defective RB1 signalling could be an alterative mechanism for HR-competent 
HGSC tumourigenesis. In this respect, targeted inhibition of cyclin E1, or RB1 could provide 
a novel therapeutic approach for HR-competent HGSC [50, 51]. 
Increased PI3K/RAS signalling was observed in 45% of HGSC. The signalling pathway 
promotes cell proliferation and survival, and is frequently mutated in cancer [52]. The 
NOTCH signalling pathway is also frequently deregulated in cancer, affecting cell survival, 
proliferation and differentiation [53]. Both pathways have been subject to anti-cancer 
therapies. Interestingly, NOTCH related drug resistance is seen in colon cancer following 
treatment with oxaliplatin via activation of PI3K/AKT [54]. This suggests PI3K/NOTCH 
signalling could be complementary to each other in tumour progression. 
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Figure 1.6: Frequency of commonly mutated genes and pathway alterations in HGSC 
A: Common mutations in HGSC. TP53 and BRCA1/2 mutations are the most common mutations observed in 
HGSC. B: Frequency of commonly altered signalling pathways in HGSC. FOXM1 pathway appears to be the 
most altered in HGSC, followed by RB1 and homologous recombination (HR) repair pathways. Figures adapted 
from The Cancer Genome Atlas Research Network, 2011 [42]. 
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1.4 Molecular subtypes of HGSC 
Molecular subtypes of HGSC could facilitate the identification genetic alterations critical to 
cancer progression. Detailed molecular profiling of HGSC has lagged behind other cancers, 
largely due to widespread genomic instability and cancer heterogeneity [55]. As a result, 
large-scale passenger events are observed in addition to recurrent driver mutations, increasing 
the complexity of interpretation [55]. High-throughput transcriptomics has proved useful in 
the identification of HGSC subtypes, as similar expression patterns can be distinguished from 
disparate events, with genetic alterations with strong expression phenotypes prioritised over 
those with lesser effect [55]. Gene expression profiling of HGSC has focused largely on the 
identification of four transcriptional subtypes associated with varying clinical outcome (Table 
1.1) [42, 56, 57]. These subtypes are classified as immunoreactive, differentiated, 
proliferative and mesenchymal [42]. The immunoreactive subtype demonstrates extensive 
intratumoural T-cell infiltration, associated with improved patient outcome [57]. The subtype 
is characterised by the expression of T-cell chemokine receptor CXCR3 and its associated 
ligands CXCL11 and CXCL10 [42]. Differentiated HGSC demonstrates intermediate patient 
outcome and is associated with similar gene expression signatures to serous borderline 
tumours [57]. The subtype is characterised by high expression of MUC1, MUC16 and fallopian 
secretory marker SLP1 [42]. Proliferative HGSC is associated with poor patient outcome and is 
characterised by low differentiation marker expression, limited inflammatory infiltrate and 
poor patient outcome [57]. The subtype demonstrates low expression of MUC1 and MUC16, 
and high expression of HMGA2, SOX11 and PCNA [42]. The mesenchymal subtype is associated 
with poor patient outcome and demonstrates extensive myofibroblast infiltrate (desmoplasia) 
and epithelial-mesenchymal gene expression [57]. The subtype is characterised by high 
expression of HOX genes and stromal components, including FAP, ANGPTL1 and ANGPLT2 
[42].  Classification into immunoreactive, differentiated, proliferative and mesenchymal 
subtypes suggests stromal interactions could be an important factor in HGSC tumourigenesis. 
However, many studies highlight the complexity of assigning these subtypes, as tumours can 
exhibit properties of multiple subtypes [58]. This is likely due to cancer heterogeneity, with 
over 95% of ovarian cancers demonstrating heterogeneity of four or more sub-clones [59]. In 
this respect, the molecular subtypes of HGSC could be viewed as somewhat arbitrary [60]. 
Analysis of late stage tumours also fails to inform of early events in disease pathogenesis. In 
this respect, it is unclear exactly which molecular alterations took place and when to induce 
the molecular subtypes observed.  
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Molecular subtype Molecular features Prognosis 
Immunoreactive High expression of CXCR3, CXCL11 and CXCL10 Good 
Differentiated High expression of MUC1, MUC16 and SLP1 Intermediate 
Mesenchymal High expression of HOX genes, FAP, ANGPTL1/2 Poor 
Proliferative Low expression of MUC1 and MUC16; high expression of HMGA2, SOX11 and PCNA Poor 
Table 1.1: Molecular subtypes of HGSC 
The key molecular features and prognosis associated with the molecular subtypes of HGSC.  
 
1.5 Structure of p53 
The prevalence of TP53 mutations suggests loss of wild type TP53 is a critical mediator HGSC 
tumourigenesis. Located on the short arm of chromosome 17 (17p13.1) TP53 encodes the 
tumour suppressor protein p53. The protein consists of an N-terminal transactivation domain, 
a proline-rich regulatory domain, a central DNA binding domain and a C-terminal 
tetramerisation domain (Figure 1.7) [61, 62]. The resulting p53 protein functions as a 
tetramer, consisting of four identical subunits [63]. Once activated, p53 will translocate to the 
nucleus and regulate the expression of a number of genes involved in cell cycle arrest, 
senescence and apoptosis [61]. As a result, loss of wild type p53 can disrupt a number of 
regulatory pathways associated with cancer progression. 
 
 
Figure 1.7: Structural domains of p53 
Human p53 consists of 393 amino acids that form 4 major domains: Transactivation domain (amino acids 1-50), 
proline rich domain (amino acids 63-97), DNA binding domain (amino acids 102-292) and a tetramerisation 
domain (amino acids 323-356). Also dispersed at the N-terminal and C-terminal are nuclear export and 
localisation signals that determine the nuclear/cytoplasmic location of p53. Figure adapted from Toledo and 
Wahl, 2006 and Vousden and Lu, 2002 [62, 64]. 
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1.6 Regulation of p53 
Ubiquitously expressed, p53 is predominately regulated by post-translational modifications 
that affect protein stability, subcellular localisation and transcriptional activity [65-67]. The 
modifications include ubiquitination, phosphorylation, acetylation, methylation, sumoylation 
and neddylation (Figure 1.9) [65, 66]. 
 
1.6.1 Ubquitination of p53 
During homeostasis, p53 levels are kept low, primarily through the actions of mouse double 
minute 2 (MDM2). MDM2 is an E3 ubiquitin ligase that ubiquitinates p53, targeting the 
protein for nuclear export (monoubiquitination) and proteasomal degradation 
(polyubiquitination) [68]. Association of MDM2 also reduces the transcriptional activity of 
p53 by masking the transactivation domain and promoting the recruitment of transcriptional 
co-repressors [69-71]. In this respect, MDM2 inhibits the stability, nuclear localisation and 
transcriptional activity of p53. Activation of p53 therefore requires disruption of the MDM2-
p53 axis (Figure 1.8). This is achieved through numerous factors, including the alternative 
reading frame of the INK4a locus (ARF). ARF activates p53 by sequestering MDM2 at the 
cytoplasm and blocking the E3 ubiquitin ligase activity of MDM2. This prevents the nuclear 
export and proteasomal degradation of p53. Once stable, p53 induces the expression of 
MDM2 in an auto-regulatory feedback loop. This results in the rapid turnover of p53 [72-74]. 
Other ubiquitinating enzymes have also been implicated in the regulation of p53, including 
PIRH2, COP1, and TOPORS [75-78]. However, MDM2 is thought to be the predominant 
negative regulator, as MDM2 knockout mice are embryonic lethal, rescued only upon double 
knockout with TP53 [79]. This suggests other E3 ubiquitin ligases fail to supersede MDM2, 
defining a central role for MDM2 in the regulation of p53. 
De-ubiquitinating enzymes have also been implicated in the regulation of p53. Herpes virus-
associated ubiquitin-specific protease (HAUSP) and ubiquitin specific protease 10 (USP10) de-
ubiquitinate p53 to promote the nuclear localisation and transactivation of p53 [80, 81]. 
However, HAUSP-mediated regulation is thought to be more dynamic, as demonstrated by 
down-regulation of HAUSP by RNA interference (RNAi). Partial reduction of HAUSP by 
RNAi reduces the stabilisation and activation of p53. Total ablation however, promotes the 
stabilisation and activation p53 [81]. These contrasting results are thought to be the result of 
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HAUSP inducing the auto-ubquitination and stabilisation of MDM2. In this respect, HAUSP 
not only promotes the activation and stabilisation of p53, but also facilitates its down-
regulation by MDM2 in a negative feedback loop.  
 
 
Figure 1.8: p53-MDM2 central axis 
Under normal conditions, wild type p53 is down-regulated by mouse double minute 2 (MDM2). MDM2 is an E3 
ubquitin liagase that ubquiquitinates and targets p53 for proteasomal degradation. In response to cell stress, stress 
induced kinases ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-related) activate 
and phosphorylate p53. Phosphorylation of p53 prevents its association with MDM2, resulting in the stabilisation 
and nuclear translocation of p53. Once at the nucleus, p53 will regulate the expression of a number of genes 
involved in cell cycle arrest, senescence and apoptosis. Among the target genes induced is MDM2, resulting in the 
down-regulation of p53 in a negative feedback-loop.  
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1.6.2 Phosphorylation of p53 
The phosphorylation of p53 is primarily associated with the stabilisation and activation of p53. 
Phosphorylation sites span the entire p53 protein but the majority are located at the N-
terminal and C-terminal domains (Figure 1.9) [65]. N-terminal phosphorylation is particularly 
associated with the induction of p53 in response to cell stress. DNA damage induces the 
phosphorylation of serine 15 by ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia 
and Rad3-related (ATR) proteins [82]. ATM and ATR induce the activation of checkpoint 
kinase 1 (Chk1) and 2 (Chk2), resulting in the phosphorylation of threonine 18 and serine 20 
respectively. Phosphorylation of these sites prevents the association of p53 with MDM2, 
promoting the stabilisation and activation of p53 (Figure 1.8) [61, 65]. Phosphorylation of p53 
at C-terminal serine 392 is also associated with the stabilisation of p53 tetramer [83]. This 
facilitates the induction of DNA binding, promoting the transactivation of p53 target genes 
[84, 85]. In this respect, phosphorylation influences the activation, stabilisation and 
transcriptional activity of p53.  
 
1.6.3 Acetylation of p53 
Similar to phosphorylation, acetylation is associated with the activation of p53. C-terminal 
lysine residues 370, 372, 373, 381, 382, and 386 are ubiquitinated by MDM2 and acetylated 
by CREB-binding protein (CBP) and p300 (Figure 1.9) [65]. As a result, acetylation of these 
sites by CBP/p300 is associated with the inhibition of MDM2-mediated ubquitination, 
promoting the stabilisation and activation of p53. C-terminal acetylation may also influence 
the DNA binding activity of p53. For example, acetylation of lysine 320 is associated with the 
increased transcription of p21 [86]. Histone deacetylase sirtuin1 (SIRT1) will deacetylate p53 
at lysine 382, reducing the induction of p53 pro-apoptotic genes PUMA, NOXA and BAX [87, 
88]. In this respect, acetylation and de-acetylation can promote the transcriptional activity of 
p53. However, some reports suggest mutant CBP/p300 acetylation sites (lysine 
372,373,381,382) do not appear to affect p53 transcriptional activity; suggesting C-terminal 
acetylation is not critical to p53-mediated transcription [89, 90]. In this respect, the 
transcriptional significance of p53 acetylation remains unclear.  
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1.6.4 Methylation of p53 
Methylation of p53 is associated with the induction and repression of p53 transcriptional 
activity. For example, mono-methylation of lysine 372 by lysine methyl-transferase 7 (KMT7) 
promotes the transcriptional activation of p53 target genes [91]. However, mono-methylation 
of lysine residues 382 and 370 by KMT5A and KMT3C represses the transcriptional activity of 
p53 [92, 93]. Mono-methylation and di-methylation can also yield differing affects. For 
example, mono-methylation of lysine 370 represses p53 transcriptional activity, whereas di-
methylation promotes p53 transcriptional activity by association of p53 co-activator binding 
protein 1 (53BP1) [94]. In this respect, the location and induction of mono-or di-methylation 
can influence the transcriptional activity of p53. 
Interestingly, there appears to be some cross talk between p53 methylation and acetylation. 
For example, repressive methylation of lysine 382 prevents acetylation of this same site by 
CBP/p300. Upon DNA damage however, methylation at lysine 382 decreases, enabling 
acetylation by CBP/p300 to increase p53 activity [93]. In this respect, alteration between 
methylation and acetylation can provide a rapid means to regulate the transcriptional activity 
of p53.  
 
1.6.5 Sumoylation and neddylation of p53 
Analogous to ubquitination, sumoylation and neddylation refer to the attachment of small, 
ubiquitin-like monomers to target proteins. Sumoylation of p53 occurs at a single site, lysine 
386, promoting the nuclear export and down-regulation of p53 (Figure 1.9) [95, 96]. 
Neddylation of p53 at lysine 370, 372, 373 is catalysed by MDM2, and by F-box protein 11 
(FBX011) at lysine 320 and 321 (Figure 1.9) [97, 98]. Neddylation of lysine 320 and 321 is 
associated with the inhibition of p53 transcriptional activity. In this respect, sumoylation and 
neddylation influence the transcriptional activity of p53.  
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Figure 1.9: p53 post-translation modifications 
An overveiw of p53 post-translation modifications. The major sites of p53 ubiquitination, phosphorylation, 
acetylation, methylation, neddylation and sumoylation are presented. Major p53 protein domains are indicated. 
Figure adapted from Dai and Gu, 2010 [65]. 
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1.7 Function of p53 
p53 is a major tumour suppressor protein. This is likely a reflection of the diverse cellular 
functions of p53. The anti-proliferative functions of p53 are thought to be the major means of 
p53-mediated tumour suppression [72, 99]. These functions include cycle arrest, apoptosis 
and senescence and are the most widely reported functions of p53.  
 
1.7.1 Cell cycle arrest 
Progression though the cell cycle is monitored by cell cycle checkpoints that ensure each stage 
of the cell cycle is successfully completed before entry into the next phase [100]. 3 major 
checkpoints have been identified, including G1 (restriction), G2-M and M phase [101]. Upon 
activation, cell cycle checkpoints induce cell cycle arrest, providing the necessary time to 
rectify incurred errors [100, 101]. p53 has been particularly implicated in G1 arrest, with 
mouse embryonic fibroblasts (MEFs) activating p53 and arresting in G1 in response to DNA 
damage [102]. Gene targeting has identified p21, a cyclin dependent kinase inhibitor, as the 
main transcriptional target of p53 mediated G1 arrest [103]. p21 will bind to and inhibit cyclin 
E/Cdk2, preventing the phosphorylation of RB1 and release of transcription factor E2F [103]. 
This prevents the expression of genes necessary for S phase entry, resulting in G1 arrest. 
Indeed, targeted disruption of p21 has been shown to compromise the G1 checkpoint in MEFs 
[104, 105]. However, p21-null MEFs appear only partially defective G1 arrest, suggesting 
other p53 target genes could mediate cell cycle arrest [104, 105]. 
Although classically associated with G1 arrest, p53 has also been implicated G2 arrest [106, 
107]. Transition from G2 to M phase is driven by a complex of cyclin B1 and Cdk1 [100]. p53 
induces G2 arrest by perturbing Cdc25c, a phosphatase that promotes M phase entry by de-
phosphorylation of cyclin B1 bound Cdk1 [108]. p53 also promotes the transcriptional 
activation of 14-3-3σ, preventing the nuclear localisation of cyclin B1/Cdk1 [109]. p53 
therefore facilitates both G1 and G2 cell cycle arrest. 
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1.7.2 Apoptosis 
Apoptosis can precede through either the intrinsic or extrinsic apoptotic pathways [110]. The 
intrinsic pathway converts internal death signals to induce mitochondrial outer membrane 
permeabilisation. This facilitates the release of pro-apoptotic mediators into the cytoplasm 
that induce cell death. For example, cytochrome C is released, binding to APAF1 and caspase 
9 to form the apoptosome. Association of caspase 9 to the apoptosome activates the zymogen, 
initiating a caspase cascade that induces cell death [110]. In contrast, the extrinsic pathway 
responds to external death signals following the association of pro-apoptotic ligands to death 
receptors located at the plasma membrane. This results in the recruitment of adaptor proteins 
that form the death-inducing signalling complex (DISC) [110]. DISC in turn facilities the 
activation of caspase 8, which by itself can induce apoptosis or initiate a caspase cascade that 
induces cell death [111]. p53 is classically associated with the intrinsic pathway, regulating the 
expression of a number of genes that influence mitochondrial outer membrane 
permeabilisation (MOMP). These genes include the pro-apoptotic BCL2 family members 
BAX, NOXA and PUMA [112-114]. PUMA appears to be the critical mediator of p53-mediated 
apoptosis, with PUMA-null mice failing to induce apoptosis in response to p53. PUMA will 
bind to anti-apoptotic proteins, promoting the release of sequestered pro-apoptotic proteins 
BAX and BAK. BAX and BAK will translocate to the mitochondrial outer membrane and 
induce MOMP [115]. p53 has also been implicated in the induction of intrinsic apoptosis 
through transcription-independent mechanisms. p53 will localise to the mitochondrial outer 
membrane and sequester anti-apoptotic proteins, facilitating MOMP [116]. Although largely 
implicated in the regulation of the intrinsic apoptosis, p53 regulated genes are involved in the 
extrinsic pathway. For example, p53 can induce the transcription death receptors FAS, DR5 
and PERP to promote extrinsic apoptosis [117-119]. In this respect, p53 can influence both 
intrinsic and extrinsic apoptosis. 
 
1.7.3 Cellular senescence 
Cellular senescence refers to permanent growth arrest following exit from the cell cycle [120, 
121]. Senescence can be induced by RB1 or p53, with p21 mediating crossover between the 
two [99]. For example, following the induction of cell stress, p53 induces the expression of 
p21. p21 binds to and inhibits cyclin E/Cdk2, preventing phosphorylation of RB1 and release 
of transcription factor E2F . This results in the induction of cell cycle arrest and entry into 
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senescence. Exactly how crossover from arrest to senescence takes place is unclear, although 
existing mechanisms for cell cycle arrest are presumably modified by senescence-associated 
signals.   
p53 has been implicated in the modulation of a senescence-associated secretory phenotype 
[122]. The secretory phenotype consists of the up-regulation of p53 target genes, including 
extracellular matrix (ECM) degrading enzymes, immune-modulating cytokines and 
chemokines, as well as the down-regulation of ECM production [99]. The ability of p53 to 
modulate this phenotype could contribute to its tumour suppressive role. Reactivation of 
endogenous p53 in p53-deficient mouse models of liver carcinoma was found to produce 
complete tumour regression, primarily through the induction of senescence [123]. Crucially, 
this senescence program was associated with the up-regulation of inflammatory cytokines that 
triggered an immune response that specifically targeted tumour cells. This suggests p53 
mediated senescence can act alongside the immune system to eliminate cancer cells.  
 
1.8 Mechanisms determining the function of p53  
The mechanism determining whether p53 induces cell cycle arrest, senescence or apoptosis 
has been subject to much debate. The abundance of p53 could play a role, with lower p53 
levels associated with cell cycle arrest, and increasing levels associated with apoptosis [124]. 
This could be due to the varying binding affinity of p53 transcriptional targets to p53. For 
example, pro-apoptotic genes may have lower binding affinity, requiring greater levels of p53 
or prolonged p53 signalling to induce transcription. However, p53 target genes for cell cycle 
arrest, senescence and apoptosis are often similar. For example, transactivation of p21 is 
required for both G1 arrest and senescence. Alternatively, variation in p53 transcriptional 
activities could be due to post-translational modifications to p53. For example, 
phosphorylation of p53 at serine 46 promotes association of AIP1, facilitating apoptosis [125]. 
Cell genetic background may also play a role, with T lymphocytes inducing apoptosis and 
MEFs inducing growth arrest in response to DNA damage [102, 126]. This suggests p53 
signals can be interpreted differently according to the expression of other genes. For example, 
susceptibility to apoptosis was increased in MEFs following introduction of Myc or E1A 
oncogenes [99, 127]. This suggests there is a degree of cross talk between p53 and other 
signalling networks that could determine p53 function. 
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1.9 Mutant p53 
The central role for p53 in tumour suppression means that p53 is nearly always compromised 
in cancer [62]. Most mutations fall within the DNA binding domain (Figure 1.10) at “hotspot” 
residues frequently mutated in cancer (R175, G245, R248, R249, R273 and R282) [128]. 
Most mutations are missense mutations, resulting in an amino acid substitution [129]. The 
mutations can be broadly divided into two categories- structural (R175H, G245S, R249S and 
R282H) and DNA binding (R273H, R248Q and R248W) [130]. Structural mutants induce a 
significant conformational change, whilst DNA binding mutants alter critical residues that 
affect DNA affinity. However, these classifications are somewhat arbitrary, as even wild type 
p53 demonstrates structural instability, and DNA binding mutants can induce some 
conformational change [131].  
 
 
Figure 1.10: Incidence and localisation of p53 mutations 
Structural representation of p53. Over 95% of p53 mutations occur at the central DNA binding domain. The 
majority of mutations occur at ‘hotspot’ residues R175, G245, R248, R249, R273 and R282. Most mutations 
are missense mutations that result in an amino acid substitution. 
 
Due to the tetrameric nature of p53, TP53 mutations have a dominant-negative effect, with 
mutant p53 monomers capable of influencing p53 tetramer function [132-134]. TP53 
heterozygous mutants therefore reside in a haploinsufficient state, often undergoing loss of 
heterozygosity (LOH) with tumour progression [135]. Dominant-negative activity has long 
been assumed to be the residing influence of mutant p53. However, accumulating evidence 
suggests mutant p53 may have gain-of-function activity [136, 137]. TP53 knockout mice 
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demonstrate less tumour invasion and metastasis than TP53 mutant, suggesting mutant p53 
confers a tumourigenic advantage [138-141]. Mutant p53 demonstrates reduced association to 
p53 response elements, suggesting mutant p53 may recognise unique DNA binding sites [142-
145]. However, a consensus mutant p53 response element has not been identified [146-148]. 
Mutant p53 can interact with other transcription factors to increase or decrease gene 
expression [149-151]. The most commonly documented are inhibition of p53 family members 
p63 and p73 [152, 153]. These proteins have been suggested to compensate for p53, such that 
their inactivation would result in complete abrogation of wild type p53 activity. Inhibition of 
p63 is also associated with the acquisition of a more migratory/invasive transcriptome that 
promotes tumour metastasis [154-156]. Mutant p53 can also directly interact with proteins in 
a transcription independent manner. For example, mutant p53 will bind to MRE11, 
preventing the activation of ATM in response to DNA damage [157, 158]. This would impair 
DNA repair, promoting the accumulation of genetic alterations necessary for malignant 
transformation. In this respect, mutant p53 promotes tumour formation not only through loss 
of wild type p53 activity but also through gain-of-function affects.  
 
1.10 Are different p53 mutations functionally equal? 
Most studies have indicated that different p53 mutations have broadly similar functional effects 
[159]. However, the exact mechanisms of induction appear to differ between DNA-binding 
and structural mutants. For example, structural mutants bind to p63 and p73 with greater 
affinity than DNA binding, but both mutants are equally capable of inhibiting p63 and p73 
[160-162]. Structural mutants promote H-RAS activation through inactivating BTG2, 
resulting in the expression of a number of genes. DNA-binding mutants do not inactivate 
BTG2 but co-operate with NF-κB to induce transcription of the same set of genes [163]. This 
suggests different p53 mutations elicit similar functional effects but through varying 
mechanisms of induction. However, some reports suggest different p53 mutations could have 
varying tumourigenic activity. For example, Li-Fraumeni patients carrying an R248Q 
mutation display earlier onset of cancer formation than p53-null or G245S mutant [164]. Mice 
expressing R172H or R270H (equivalent to human R175H and R273H) mutant p53 
demonstrate greater tumour formation than R246S (equivalent to human R249S) [139, 141, 
164, 165]. Interestingly, not only the position but also the type of p53 mutation could also 
influence mutant p53 function. For example, despite both mutations affecting the R248 
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codon, R248Q mutant mice demonstrate earlier tumour onset and reduced overall survival 
than R248W [157]. As a result, different p53 mutations could have varying tumourigenic 
potential.  
 
1.11 Mutant p53 and tumourigenesis  
The transition of a normal cell toward a cancerous one is complex process, accompanied by 
many genetic and epigenetic alterations. These alterations can induce a selective advantage, 
facilitating greater proliferation, survival, invasion, migration or a tumour promoting 
microenvironment [166]. The stoichiometry of theses alterations could be critical to cancer 
progression. For example, Fearon and Vogelstein propose a stepwise model for colorectal 
cancer in which the inactivation or mutation of specific genes at specific points determine 
progression to the next stage of tumourigenesis [167]. In this respect, the point at which 
mutant p53 is acquired could influence its tumourigenic potential. Unique transcriptional 
signatures have been identified according to the inactivation or mutation of TP53 at early or 
late stages of tumourigenesis [128, 168]. These findings suggest that early TP53 mutations 
contribute to uncontrolled proliferation, a feature of both benign and malignant tumours 
[169, 170]. In comparison, late stage TP53 mutations synergise with other mutations to 
promote tumour invasion and metastasis [171, 172]. These findings suggest that the diversity 
of p53 function could be utilised at different stages of tumourigenesis to promote benign or 
malignant transformation. Mutant TP53 is thought to be an early event in HGSC, suggesting 
mutant p53 induces benign transformative events rather than malignant ones. However, early 
TP53 mutations could facilitate the acquisition of malignant transformation by promoting 
genomic instability. David Bowtell proposes a model of HGSC in which early TP53 and 
BRCA1/2 mutations promote HR-deficiency, inducing widespread genomic instability that 
promotes the acquisition of molecular alterations necessary for malignant transformation 
(Figure 1.11) [173]. This model suggests that mutant TP53 is an early event in HGSC and 
facilitates the acquisition of other mutations necessary for HGSC tumourigenesis.  
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Figure 1.11: Mutant p53 facilitates the acquisition of molecular alterations in HGSC 
Loss of wild type p53 synergises with loss of BRCA1/2 to facilitate loss of homologous recombination (HR). This 
results in chromosome instability and the acquisition of widespread copy number changes associated with HGSC. 
Copy number changes could be molecular subtype specific, inducing global changes in gene expression. 
Subsequent molecular alterations could provide further advantages to tumour growth, defining individual tumour 
variation. Figure adapted from Bowtell, 2010 [173]. 
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1.12 In vivo models of HGSC 
In vivo models of ovarian cancer may provide some insight into HGSC pathogenesis. Several 
models have been created, with advantages and disadvantages regarding their suitability to 
model HGSC. 
 
1.12.1 Carcinogenesis models 
Early ovarian cancer models utilised biological and chemical carcinogens to initiate 
transformation of the ovarian surface epithelium. Biological carcinogens, such as estradiol and 
testosterone, failed to initiate OSE transformation but were associated with greater tumour 
progression [174]. Chemical carcinogens such as 7,12-dimethylbenz(a)antracene (DMBA) and 
N-methyl-N’-nitrosourea (MNU) demonstrated greater transformative potential, particularly 
upon application on coated sutures under the bursal membrane [175, 176]. Although they do 
not use carcinogens the body is routinely exposed to, these models can provide some insight 
into the role of random DNA damage in OSE transformation. However, as chemical 
carcinogens can pose a significant health risk, use of carcinogenesis models has declined in 
recent years. 
 
1.12.2 Xenograft models 
Xenograft models have been a popular research tool since the late 1960’s. Tumour cells are 
extracted from patients, cultured in vitro and injected into immunodeficient mice. Derived 
from clinical cases, these models could be considered more representative of human disease. 
However, in vitro culture can induce selective pressure, generating transplantable cell lines 
that are unrepresentative of the patient tumour. Indeed, recent evaluation of ovarian cancer 
cell lines revealed that many failed to express genomic profiles similar to HGSC [177]. As a 
result, xenograft models often differ in therapeutic response to source tumour, limiting 
clinical application [178, 179].  
In attempt to overcome this issue, patient derived xenograft (PDX) models have been 
developed. Tumour cells are extracted from patients and injected into immunodeficient mice 
without in vitro culture. This facilitates the retention of tumour heterogeneity, with PDX 
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tumours demonstrating tumour histology, gene expression, single-nucleotide polymorphisms 
and copy number variants similar to the derivative tumour [180-185]. As result, PDX models 
are associated with greater predictive outcome and clinical application than traditional 
xenograft models [186]. Clinical application can be further increased upon orthotropic 
transplantation at clinically relevant sites, as therapeutic response has been demonstrated to 
differ according to transplant location [187, 188]. This highlights the importance of tumour 
microenvironment cancer development.  
PDX models can be maintained by the direct transfer of xenograft tumour cells from one 
mouse to another. Serial PDX tumours demonstrate similar genomic profiles to source 
tumour, indicative of model stability. Initial engraftment is where most variation is incurred 
(if any), with genes associated with stromal ontology most altered [182, 184, 189]. 
Subsequent alterations resulting from sequential engraftment could represent genomic 
rearrangements intrinsic to tumour progression. As a result, PDX models could recapture 
tumour progression. However, most authors advocate using PDX models to low passage 
number (<10) to preserve tumour integrity [186, 190].  
PDX models of ‘ovarian cancer’ often lack histological classification of epithelial ovarian 
cancer subtype [191]. As a result, analyses of molecularly annotated PDX models derived 
from HGSC are limited. Those that have been classified appear to accurately recapture disease 
state, demonstrating similar therapeutic responses and acquisition of resistance mechanisms to 
patient tumours [191]. Despite the ability to recapture many aspects of patient tumours, 
derived from advanced clinical cases, PDX models fail to recapture early events in disease 
pathogenesis.  In attempt to understand early HGSC, xenograft models using transformed 
human OSE cell lines have been used.  
OSE derived xenograft models often genetically transform OSE cells in vitro prior to 
transplantation into immunodeficient mice [192]. This enables the systematic investigation of 
genetic alterations necessary for OSE transformation. Mutant RB and TP53 have consistently 
been reported to be transformative events, suggesting aberrant checkpoint signalling and 
failure to initiate DNA repair are important factors in HGSC [192].  
However, the use of immunodeficient mice in xenograft models fails to consider the role of 
immune interactions, increasingly implicated in cancer development. The use of humanised 
mice may partially overcome this issue. Humanised mice express human cytokines to produce 
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an innate human immune system [193]. This enables the retention of some human tumour-
immune interactions, improving xenograft utility. Humanised xenograft models have 
demonstrated increased sensitivity to humanised antibodies, providing a platform for the 
investigation of novel therapies [194]. Bankert et al., 2001 report a humanised PDX model of 
‘ovarian cancer’ that demonstrates improved retention of stromal counterparts such as 
tumour-associated fibroblasts [195]. This suggests humanised models may better facilitate the 
investigation of stromal/immune interactions. However, humanised models cannot recapture 
the entire human immune system. In order to assess immune interactions, syngeneic models 
must be used.  
 
1.12.3 Syngeneic models 
The use of syngeneic models enables the retention of tumour-immune interactions. Tissue of 
the same genetic background is transplanted into an animal host, facilitating the use of 
immunocompetent animals. Mouse OSE (MOSE) cell lines are often used following successive 
passaging in culture to generative spontaneously transformed MOSE cell lines [196]. These 
cell lines can then be transplanted into syngeneic hosts and assessed for tumour formation. For 
example, transformed MOSE cell line ID8 will form primary ovarian tumours, secondary 
peritoneal metastases and ascites in recipient mice [197]. Analysis of transformed MOSE cell 
lines and their derivative tumours can therefore provide an indication of the molecular 
alterations necessary for transformation. However, human OSE cell lines are less likely to 
undergo spontaneous transformation than their rodent counterparts, implying more stringent 
physiological barriers [198]. In this respect, syngeneic models may not give a true indication of 
the genetic alterations in HGSC. Indeed, genomic profiling ID8 cell line revealed few genetic 
similarities to HGSC. In vitro culture of cells prior to transplantation may also alter cell 
characteristics. A study conducted by Zorn et al (2003) demonstrated that even short-term 
cell culture could affect gene expression profiles [199]. In vitro culture may also ignore in situ 
events that could contribute to early cancer development. In this respect, models that 
stimulate tumourigenesis in situ may better recapture disease state.  
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1.12.4 Genetically engineered models 
Genetically engineered mouse models aim to induce tumour formation in situ. Initial HGSC 
models utilised cell specific promoters to target transgene expression at the OSE. The first 
successful model used Müllerian inhibiting substance receptor type II (MISIIR) promoter to 
drive transgene expression. 50% of female mice expressing SV40 large T antigen (TAg) 
developed bilateral ovarian cancers by 6-13 weeks of age [200]. However, subsequent MISIIR 
models expressing different transgenes reported pre-malignant lesions but failed to form 
malignant cancer [198]. For example, expression of constitutively active PI3KCA by the 
MISIIR promoter resulted in OSE hyperplasia [201], induction of dnSMAD generated inclusion 
cysts [202] and heterozygous expression of Disabled-2 lead to surface dysplasia and 
papillomatosis [203]. Un-regulated expression from the MISIIR promoter can also result in 
oncogenic expression in progenitor cells. This is in contrast to our perception of the majority 
of cancers, in which tumourigenic alterations occur predominately following organogenesis 
[198]. Late onset models or inducible model systems may therefore be preferable, such as the 
Cre-loxP recombination system. 
The Cre-loxP system utilises the recombinase activity of Cre to excise target DNA. DNA is 
flanked on either side by loxP sites (floxed) to which Cre recombinase binds, excising the 
DNA. Using this recombination system, critical exons or promoter transcription stop 
sequences can be removed, activating or inactivating transgenes respectively. Transgene 
expression can be targeted to the ovary by crossing transgenic mice with MISIIR-Cre 
recombinase mice, or administration of viral vectors under the bursal membrane. The use of 
viral vectors not only targets transgene expression to the ovary but also enables control of the 
time of expression, generating an inducible model system. Flesken-Nikiten et al., 2003 used 
adenovirus AdCre to target recombinase activity to the OSE of homozygous transgenic mice 
with loxP sites flanking regions of Tp53 and Rb. Mice with inactivated Tp53 and Rb developed 
ovarian tumours at a mean of 227 days following adenoviral administration [204]. Tumour 
pathology was reported to closely monitor clinical disease with ascites and metastasis to lungs 
and liver observed. However, viral preparations can induce an immune response, and slight 
variations in methodology can alter model outcome [198]. For example, Clark-Knowles et al., 
2009 reported the formation of leiomyosarcoma rather than serous adenocarcinoma upon 
repeating the model system [205]. 
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The Cre-loxP transgene system has been used to develop fallopian-derived models of ovarian 
cancer. Kim et al., 2012 used the Cre-loxP system to selectively inactivate Dicer, a gene 
involved in microRNA synthesis, and Pten, a negative regulator of PI3K-AKT signalling, at the 
Müllerian tract [206]. All females developed fallopian tube serous carcinomas that spread to 
the ovaries and metastasised throughout the peritoneal cavity. Although demonstrating ovarian 
cancer tumourigenesis from the fallopian tube, Dicer and Pten are not common mutations in 
HGSC [42]. However, aberrant PI3K signalling is reported in 45% of HGSC [42] and DICER 
is proposed to function downstream of p53, mediating microRNA function [42]. This suggests 
mutant Dicer results in some loss of p53 activity as commonly reported in HGSC.  
The most successful genetically engineered mouse model of HGSC is the Brca; Tp53; Pten 
model [207]. This model utilises the PAX8 promoter to conditionally inactivate Brca1, Brca2, 
Tp53 and Pten at fallopian secretory cells. STIC lesions were observed in addition to metastasis 
to the ovary and peritoneum, reminiscent of HGSC. Interestingly however, no obvious 
phenotypic difference was observed between deletion and mutation of Tp53, suggesting loss of 
wild type p53 activity is the critical mediator of mutant Tp53 function. Control cohorts of 
mice, in which Brca, Tp53 or Pten mutations/deletions were not included, revealed interesting 
features regarding the tumourigenic potential of each mutation and combinations of 
mutations. Tp53−/−;Pten−/− mice did not progress past the pre-invasive stage of tumour 
formation, suggesting Brca1 or Brca2 were necessary for the generation ovarian and peritoneal 
metastases. Brca2−/−;Tp53mut mice (Pten wild-type) demonstrated a prolonged latency period 
and reduced metastatic potential. This suggests that additional genetic alterations are required 
to co-operate with Brca and Tp53 to induce tumour initiation and progression. Interestingly, 
STICs were difficult to detect in the Brca2−/−;Tp53mut mice because invasive disease was widely 
present at the time animals were sacrificed. This could explain why STIC lesions are not 
identified in 100% of HGSCs and account for early dissemination in HGSC. Moreover, these 
results suggest loss of Pten or activation of the PTEN/PI3K pathway is necessary for efficient 
tumour development and STIC formation in the murine oviduct. This highlights a role for 
mutant TP53 in early HGSC but defines the necessary role of additional mutations for 
malignant transformation.   
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1.13 Human in vitro models of HGSC 
Although animal models are useful to assess in vivo interactions, mouse models cannot 
accurately recapture all features of human cancer [174, 192]. In this respect, it is important 
that human in vitro models are used in parallel with mouse models to recapture additional 
aspects of human tumourigenesis.  
 
1.13.1 HGSC tumour cell lines 
Recent evaluation of the genomic profiles of commonly used ovarian cancer cell lines revealed 
many are unsuitable to model HGSC [177, 208]. This included some of the most popular 
ovarian cancer cell lines, such as SKOV3, A2780, OVCAR3, CAOV3 and IGROV1. These 
cell lines have accounted for over 90% of publications and yet are unrepresentative of the 
most prevalent form of ovarian cancer [177]. One study demonstrated its top-ranking HGSC 
cell lines accounted for just 1% of ovarian cancer PubMed citations [177]. As a result, many of 
the conclusions drawn from these cell lines are unlikely to represent HGSC. The use of 
unrepresentative cell lines could be a result of the failure to classify source tumours according 
to ovarian epithelial cancer subtype, or the difficulty of maintaining genetically unstable cells 
in culture. As already indicated, cell culture conditions can induce selective pressure, resulting 
in the generation of cell lines that are unrepresentative of the original tumour. Many tumour 
samples were also isolated from ascites fluid rather than primary tumours. This could account 
for some genomic variation, as metastatic cells are likely to have undergone several rounds 
clonal expansion, acquiring sub-clone specific mutations not observed at the primary tumour 
[209]. As a result, in recent years the focus has shifted to the generation of new HGSC cell line 
models that better represent HGSC. These cell lines are largely characterised by mutant TP53, 
mutant BRCA1/2 and copy number alterations similar to HGSC [210, 211].  
 
1.13.2 OSE and fallopian secretory cell lines 
OSE and fallopian secretory cell lines are often used to model early HGSC [192]. The cell 
lines are generated by immortalisation of primary cell cultures with human telomerase 
(hTERT) or SV40 large and small T antigens (SV40 TAg) [5, 212-215]. SV40 TAg has 
previously been associated with the induction of transformation following the inhibition of 
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RB1 and p53 by TAg [216, 217]. As a result, hTERT immortalisation is more commonly 
adopted to maintain ‘normal’ cell phenotype. To investigate the transformative potential of 
different mutations, OSE and fallopian secretory cell lines have been sequentially transfected 
with tumour-associated mutations. Transformation is most commonly observed following the 
expression of mutant RB1 and TP53 [212-215], although Karst et al., 2011 demonstrated 
fallopian secretory transformation using oncogenic RAS and C-MYC [5]. While enabling the 
systematic investigation different tumourigenic alterations in HGSC, mutant RB1, RAS and C-
MYC are not common mutations in HGSC. Furthermore, the artificial induction of known 
mutations rather than spontaneous acquisition could pose a potential bias or dissociation from 
in situ events. Cell line tumourigenicity is also demonstrated by tumour formation in 
immunodeficient mice. In this respect, OSE and fallopian secretory cell line models are 
subject to the same potential pit-falls as xenograft models in the attempt to determine cell line 
tumourigenic potential. 
 
1.13.3 3D culture systems 
3D culture systems can provide a means to recreate the human microenvironment in vitro. 
Different cell types can be cultured together, enabling the assessment of cell-cell interactions. 
Ernst Lyngel’s group has devised an organotrophic 3D co-culture system representative of 
human omentum- a major site of ovarian cancer metastases. Collagen-I and human primary 
fibroblasts are mixed together, generating an ECM on which human primary mesothelial cells 
are grown [218]. Ovarian cancer cells can then be cultured above the mesothelial cells and 
examined for invasion through the collagen-fibroblast matrix. Although this cell culture 
system aims to model omentum and not the ovarian or fallopian microenvironments, the 
system enables improved modelling of cell invasive and migratory potential, as well as the 
consideration of stromal interactions. For example, mesothelial cells were found to inhibit 
ovarian tumour cell adhesion and invasion, whereas fibroblasts were found to promote these 
traits [218]. Similar systems have also been used to model OSE transformation. Lawrenson et 
al., 2010 demonstrated increased neoplastic transformation of C-MYC mutant OSE cells upon 
3D co-culture with senescent fibroblasts [219]. Although unable to render the OSE cells fully 
malignant, these findings suggest 3D culture could provide a means to induce or select for 
malignant traits. This could therefore provide a means to induce or select transformed OSE or 
fallopian secretory cell lines.  
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1.14 IOSE -TOSE model of early HGSC 
Several years ago our laboratory isolated normal human ovarian surface epithelial cells 
(NOSE) from ovarian brushings taken during surgery for non-ovarian related, benign disease. 
The NOSE cells were immortalised using hTERT and subsequently re-named immortalised 
ovarian surface epithelial cells (IOSE) (Figure 1.12) [220, 221]. IOSE from patient 25 
(IOSE25) underwent spontaneous transformation, acquiring many of characteristics of 
transformed cells, including anchorage independent growth, altered morphology and genomic 
instability (Figure 1.13). They were not, however, able to form tumours in immunodeficient 
mice, suggesting they were not fully transformed, malignant cells [222]. As a result, these 
premalignant cells were re-named ‘transformed’ ovarian surface epithelial cells (TOSE) and 
were proposed to represent a novel cell line model of premalignant HGSC. 
 
 
Figure 1.12: Generation of the IOSE-TOSE cell line model of early HGSC 
Schematic diagram of the generation of the IOSE-TOSE model of early HGSC. Normal ovarian surface epithelial 
cells from patient 25 (NOSE25) were immortalised using human telomerase (hTERT) to form the immortalised 
ovarian surface epithelial cells 25 (IOSE25). IOSE25 cells underwent spontaneous transformation, forming 
colonies in soft agar.  Colonies 1 and 4 were isolated re-named ‘transformed’ ovarian surface epithelial cells 1 
and 4 (TOSE1 and TOSE4).  
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Figure 1.13: Acquisition of transformed traits by TOSE cell lines 
A: Acquisition of transformed traits by IOSE25 and TOSE cell lines. TOSE cells demonstrate greater acquisition 
of transformed traits than IOSE25 cell line.  B: Evidence of anchorage independent growth. TOSE cells from 
more colonies in soft agar, indicative of greater anchorage independent growth. Representative images of n=3. 
C: Evidence of altered morphology. Confluent IOSE25 cells demonstrate elongated, spindle-like morphologies. 
TOSE1 cells demonstrate more condensed, circular morphologies, reminiscent of HGSC cell line AOCS1. 
Representative images of n=3. 
 
1.15 Molecular characteristics of TOSE cells 
TOSE cells were established from soft agar colonies of IOSE25 cell line. TOSE1 and TOSE4 
(colonies 1 and 4) demonstrated many molecular characteristics similar to HGSC, including 
copy number variations and mutant TP53 [222]. Digital PCR revealed a pattern of gain and 
loss of different TP53 mutations in the generation of IOSE25 and TOSE cell lines [222]. The 
original NOSE25 cell line appeared to contain a small population of cells that were 
heterozygous for an R175H TP53 mutation. This mutation, together with hTERT, may have 
conferred a selective advantage, selecting out these cells in the formation of the IOSE25 cell 
line. Through successive passaging, the R175H mutation was lost and an R273H mutation 
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acquired at the previously wild type allele (Figure 1.14). As a result, by the time we observe 
formation of the TOSE cell lines, loss of heterozygosity (LOH) has taken place, such that 
TOSE cells possess a single, R273H mutant TP53 allele. IOSE-TOSE cell lines therefore 
demonstrate a pattern of gain and loss of different TP53 mutations that suggests different TP53 
mutations could have varying transformative potential. 
 
 
Figure 1.14: Gain and loss of different TP53 mutations in IOSE-TOSE model 
IOSE25 cells were selected from a sub-population of NOSE25 containing a heterozygous R175H TP53 mutation. 
Through successive passaging, the R175H mutation was lost and an R273H mutation acquired in the previously 
wild-type allele. The remaining allele was lost, such that all TOSE cell harbour a single, R273H mutant allele. 
Figure from Archibald et al, 2012 [222]. 
 
1.16 Hypothesis and aims 
The spontaneous gain and loss of different TP53 mutations in the IOSE-TOSE model of early 
HGSC suggests different TP53 mutations could have varying transformative potential. To 
investigate this hypothesis, this project aimed to: 
§ Transduce IOSE cell lines from different patients (IOSE21 and IOSE25) with R175H 
and R273H mutant TP53 
§ Assess transduced IOSE cell lines for the acquisition of transformed traits relative to 
non-transduced cell lines to determine the transformative potential of mutant TP53 
§ Assess transduced IOSE cell lines for the acquisition of transformed traits relative to 
each other to determine the transformative potential of different TP53 mutations 
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Chapter 2: Materials and Methods 
2.1 Cell culture 
2.1.1 Cell lines 
The cell lines used in this project are presented in Table 2.1. IOSE21 and IOSE25 parental cell 
lines were derived from ovarian brushings taken during surgery for non-ovarian related benign 
disease [220]. TOSE1 and TOSE4 cell lines were derived from soft agar colonies of 
spontaneously transformed IOSE25-parental cells [223]. Transduced IOSE cell lines were 
generated by lentiviral transduction of R175H, R273H or wild type (pWT) TP53 cDNA 
transgene (refer to section 2.2.7). To ensure cell line integrity, cells were short tandem 
repeated sequenced and regularly checked for mycoplasma contamination. 
 
Cell Lines 
IOSE21-parental 
IOSE21-R175H 
IOSE21-R273H 
IOSE21-pWT 
IOSE25-parental 
IOSE25-R273H 
IOSE25-pWT 
TOSE1 
TOSE4 
Table 2.1: IOSE and TOSE cell lines 
Table presents a list of IOSE and TOSE cell lines used in this project. IOSE21-parental, IOSE25-parental, 
TOSE1 and TOSE4 cell lines were kindly donated by Dr Kyra Archibald. The remaining IOSE cell lines were 
generated by lentiviral transduction during the course of this project. Parental= non-transduced cell line, 
R175H= transduced with R175H mutant TP53, R273H= transduced with R273H mutant TP53, pWT= 
transduced with plasmid (p) wild type (WT) TP53.   
 
2.1.2 Cell culture media 
IOSE and TOSE cell lines were cultured in 1X NOSE (normal ovarian surface epithelial cell) 
medium, consisting of a 1:1 ratio of media MCDB105 (Sigma-Aldrich, M6395) and M199 
(Sigma-Aldrich, M2520).  Single vials of powdered MCDB105 and M199 media were 
dissolved in 2L of cell culture grade water and adjusted to pH7.0. Resulting 1X NOSE 
medium was filtered through 4X 500mL Stericup Filters (Merck Millipore, SCGPU05RE) and 
kept at 4°C for up to 2 weeks. 1X NOSE medium was additionally supplemented with foetal 
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bovine serum (FBS), bovine pituitary extract, human epidermal growth factor, 
hydrocortisone, insulin and penicillin-streptomycin (P/S) at concentrations outlined in Table 
2.2. 
 
Supplement Concentration Provider Catalogue number 
Foetal bovine serum 15% (v/v) HyClone SV30160.03 
Bovine pituitary extract 34ug/mL Invitrogen I3028-014 
Human epidermal growth factor 0.01ug/mL Invitrogen PHG0311 
Hydrocortisone 0.5ug/mL Sigma-Aldrich H-039-100MG 
Insulin  5ug/mL Sigma-Aldrich I1882-100MG 
Penicillin-streptomycin 1% (v/v) Sigma P4333-100ML 
Table 2.2: Supplements required for complete NOSE medium  
Supplements added to 1X NOSE medium to form complete NOSE medium. Concentrations, provider and 
catalogue numbers listed.  
 
2.1.3 Expansion of cell lines 
Cell lines were cultured at 37°C in a humidified atmosphere with 5% CO2. Cells were 
passaged using 0.05% Trypsin-EDTA (Sigma-Aldrich, 59418C) or Cell Dissociation Buffer 
(Gibco, Life Technologies, 13151-014), following washing in Dulbecco’s Phosphate Buffered 
Saline (PBS) without Ca & Mg (Sigma-Aldrich, D8537). Cells were incubated at 37°C until 
detached, removed from the culture flask and collected by centrifugation at 1100 x rpm for 4 
minutes. The resulting cell pellet was re-suspended in complete NOSE medium and cell lines 
passaged 1:3-1:10 according to requirements.  
 
2.1.4 Freezing down cell lines 
Cells were frozen in 1mL 10% of Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, D2650) in 
FBS (HyClone, SV30160.03). Cells were stored at -80°C overnight prior to long-term 
storage in liquid nitrogen at -196°C.  
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2.1.5 Recovery of cell lines 
Cells were recovered from liquid nitrogen by thawing at 37°C prior to addition to 10mL 
complete RPMI (Sigma-Aldrich, R8758) (10%FBS, 1% P/S). Cells were collected by 
centrifugation at 1100 x rpm for 4 minutes, re-suspended in complete NOSE medium and 
added to a T75 culture flask (Corning, Sigma-Aldrich, CLS430641).  
 
2.1.6 Cisplatin treatment 
Cells were seeded to achieve ~50% confluence the following day in a T175 culture flasks 
(Corning, Sigma-Aldrich, CLS431080). Cells were treated with 10µM Cisplatin (Accord, 
5060149314074) diluted in complete NOSE media and cultured until specified time points.  
 
2.1.7 Soft agar assay (anchorage independent growth) 
1% and 0.7% agar (Invitrogen, I5510-027) were prepared in PBS and sterilised by 
autoclaving. 1% agar was microwaved to melt and added to an equal volume of 2X NOSE 
medium. 2mL of resulting 0.5% agar/medium was added to each well of a 6 well plate and 
left to set at room temperature. 0.7% agar was microwaved to melt and added to an equal 
volume of 2X NOSE medium. 6mL of resulting 0.35% agar/medium was added to 100µL of 
200,000/mL cell suspension. 1.5mL of cell/agar suspension was added on top of the 0.5% set 
agar to obtain 5000 cells/well. Agar was left to set at room temperature for 30 minutes prior 
to incubation at 37°C, 5% CO2 for up to 3 weeks. Each condition was repeated in triplicate 
and resulting colonies either quantified (refer to section 2.1.8) or isolated (refer to section 
2.1.9) for further analysis.  
 
2.1.8 Quantification of soft agar assays 
Colonies were fixed and stained using 1mL 0.005% crystal violet in methanol (Sigma-Aldrich, 
C3886-100G) for 1 hour at room temperature. The agar was then washed with PBS and 
images taken using a Penguin 150Cl camera (Pixeria) coupled to a CKX41 microscope 
(Olympus) with Image-Pro Plus 5.1 software (Meida Cybergenetics). The size and number of 
colonies per field were recorded using ImageJ [224].   
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2.1.9 Isolation and expansion of soft agar colonies 
Colonies were isolated from soft agar by piercing the gel with a non-filtered p20 pipette tip. 
Isolated colonies were then flushed from the tip using PBS and placed in a microcentrifuge 
tube containing 0.005% Trypsin-EDTA in PBS. Cells were incubated in Trypsin 37°C for 30 
minutes before neutralisation in complete NOSE medium. Resulting colonies were added to a 
24 well plate and expanded upon confluence. 
 
2.1.10 Transwell migration assay 
Cells at ~60% confluence were serum starved overnight. 500µL of complete NOSE medium 
was added to each well of a 24 well plate, on top of which 8µm pore transwell inserts (Falcon, 
353182) were placed. 10,000 cells/500µL were added to each transwell in serum and 
supplement free 1X NOSE medium, and incubated at 37°C, 5% CO2. At specified time 
points, transwells were removed from culture and the inside of the insert cleaned using a 
cotton tip. Cells on the underside of the transwell were fixed and stained using 0.5% crystal 
violet in 2% ethanol (Sigma-Aldrich, C3886-100G) for 10 minutes at room temperature. 
Following fixation and staining, transwells were washed in tap water and left to dry overnight. 
The following day, transwells were placed in 10% acetic acid to dissolve the crystal violet 
stain and absorbance read at 595nm using Opsys MR plate reader (Dynex Technologies) with 
Revelation Quicklink software.  
 
2.1.11 Scratch assay 
Cells were seeded in a 6 well plate and left to grow to confluence. At 100% confluence, a 
scratch was inflicted down the centre of each monolayer using a p20 pipette tip. Cell culture 
medium was removed and replaced with Leibovitz’s L-15 medium (Life Technologies, 11415-
064) (15% FBS, 1% P/S). The scratch was imaged every 15 minutes for up to 24 hours using 
time-lapse microscopy. Percentage closure was assessed by: (size of wound at time zero/ size 
of wound at time point) x 100. Each condition was repeated in duplicate. 
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2.1.12 Cell monolayer and foci formation 
100,000 cells/well were seeded in a 6 well plate and cultured at 37°C, 5% CO2 for up to 2 
weeks. Images were taken after 24 hours, 5 and 10 days in culture using a Penguin 150Cl 
camera (Pixeria) coupled to a CKX41 microscope (Olympus) with Image-Pro Plus 5.1 
software (Meida Cybergenetics) 
 
2.1.13 β-galactosidase assay  
β-galactosidase activity was assessed using BioVision Senescence Detection Kit (K320-250) 
according to manufacture’s instructions for a 6 well plate format. Each condition was repeated 
in triplicate to time points specified. Images were taken using Image-Pro Plus 5.1 software 
(Meida Cybergenetics) with a Penguin 150Cl camera (Pixeria) coupled to a CKX41 
microscope (Olympus). Intensity of staining was assessed by adding 1mL DMSO (Fischer 
Scientific, 10293800) to each well with gentle rocking for 3 hours at room temperature. 
100µL of stain/DMSO solution was then read at 695nm using Opsys MR plate reader (Dynex 
Technologies) and Revelation Quicklink software. Percentage of β-galactosidase positive cells 
was calculated by:  (absorbance of test– absorbance of DMSO blank)/average number of cells 
at time point. Average number of cells was determined by cell density and proliferation assays 
(refer to section 2.1.15). 
 
2.1.14 Cell morphology 
100,000 cells/well were seeded into a 6 well plate and incubated at 37°C, 5% CO2. 24 hours 
later, cells were imaged using Image-Pro Plus 5.1 software (Meida Cybergenetics) with a 
Penguin 150Cl camera (Pixeria) coupled to a CKX41 microscope (Olympus). Every cell that 
could be clearly discriminated was outlined in ImageJ [224] and measured for average 
circularity and length. 
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2.1.15 Proliferation/ cell density assay 
100,000 cells/well were added to a 6 well plate and cultured at 37°C, 5% CO2 for up to 2 
weeks.  At specified time points, cells were trypsinised and counted using Vi-CELL image 
analyser (Beckman Coulter). Each condition was repeated in triplicate.   
 
2.1.16 Agarose cell pellets for immunohistochemistry 
Cells were grown to 60% confluence and removed from the culture flask using cell 
dissociation buffer. Cells were pelleted in 15mL flacons by centrifugation and fixed in formal 
saline (Adams Healthcare, Ecolab, BX1143CB0101) overnight at 4°C. Following 
centrifugation to remove fixative, cells were re-suspended in 2% agarose (Invitrogen, I5510-
027) in PBS (Sigma-Aldrich, D8537). Cell agarose pellets were left to set at room 
temperature before covering in 70% ethanol to avoid drying out. Agarose pellets were 
paraffin embedded and sectioned by the Pathology Department, Barts Cancer Institute.  
 
2.2 Transduction of IOSE cell lines 
2.2.1 Plasmid constructs 
Three plasmid constructs based on plasmid Lenti6/V5-D-TOPO (Invitrogen, K4950-00) 
were kindly donated by Bernard Futscher (Addgene, plasmids #22945, #22936 and #22934) 
[225]. The constructs expressed wild type (pWT), R175H or R273H mutant TP53 cDNA 
transgene (Refer to Appendix 1 for plasmid maps). Plasmids were acquired in pre-
transformed Stbl3 bacterial stabs, ready for clonal expansion and DNA extraction.  
 
2.2.2 Selection, expansion and storage of transformed bacteria 
Using a stile loop, bacterial colonies were isolated from the bacterial stab and streaked across a 
Luria Broth agar plate (LB; 10mg/mL tryptone, 5mg/mL yeast extract, 85mM NaCl, 
15mg/mL agar, pH7.4, autoclaved) containing 100ug/mL ampicillin (Sigma-Aldrich, 
A2804). Plates were incubated at 37°C overnight and colonies picked the following day. 
Colonies were expanded in 5mL LB medium containing ampicillin (100ug/mL) for 16 hours 
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at 37°C with shaking at 255 x rpm. 750µL of bacterial culture was added to 150µL of 
autoclaved 70% glycerol for long-term storage at -80°C. The remaining bacterial culture was 
pelleted by centrifugation for mini-prep plasmid DNA extraction or expanded in 250mL LB 
medium for maxi-prep plasmid DNA extraction (refer to section 2.2.3).  
 
2.2.3 Plasmid DNA extraction 
Mini-prep (QIAprep spin mini-prep kit, 27104) and maxi-prep (QIAfilter plasmid maxi kit, 
12262) plasmid DNA extraction was preformed according to manufacturers instructions. 
Purity of DNA was assessed using NanoDrop spectrometer (ND-1000 spectrometer) prior to 
restriction digest (see section 2.2.4). 
 
2.2.4 Restriction digest  
Restriction digests were performed using 400ng DNA in a total reaction volume of 20µL. 
Samples were incubated with restriction enzymes NdeI and KpnI, with NEB buffer 1 (New 
England BioLabs) according to manufacturer’s instructions for 2 hours at 37°C. Resulting 
fragments (5538bp and 2604bp) were resolved using gel electrophoresis (refer to section 
2.2.5).  
 
2.2.5 Gel electrophoresis 
Restriction enzyme fragments were resolved by separation through a 0.7% agarose 
(Invitrogen, I5510-027) gel in 1X TAE buffer (4mM Tris-Acetate, 1mM EDTA) with 4% 
GelRed (Biotium, 41003). Electrophoresis was performed at 90V for 1 hour 30 minutes, and 
bands visualised under ultra violet light. HyperLadder 1Kb (BioLines, BIO-33053) was used 
to estimate the molecular weight of resolved fragments. 
 
2.2.6 Lentiviral production 
Lenti6/V5 virus particles were produced upon co-transfection of packaging cell line HEK-
293T (kindly donated by Dr Eleni Maniati) with plasmid DNA and ViraPower Packaging Mix 
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(Invitrogen, Life Technologies, K4975-00) according to manufacturer’s instructions. Virus 
containing medium was centrifuged at 3000 x rpm to pellet any remaining cells, and passed 
through a 0.45µm sterile filter before long term storage at -80°C in 1mL aliquots.  
 
2.2.7 Transduction of IOSE cells  
75,000 cells/well were added to a 6 well plate to achieve 30% confluence the following day. 
1mL frozen virus containing medium was thawed on ice and Polybrene (Sigma-Aldrich, 
H9268-5G) added to a final concentration of 8µg/mL. Medium from target cells was replaced 
with virus-containing medium (1mL/well) and cells incubated at 37°C, 5% CO2 for up to 48 
hours. Infection was stopped by replacing virus-containing medium with fresh complete 
NOSE medium. Cells were cultured 24 hours prior to selection of stable clones using 
6µg/mL Blasticidin (Invitrogen, R210-01). Resulting stable colonies were combined to form 
stable mixed pools of transduced IOSE cells.  
 
2.3 DNA analysis 
2.3.1 Genomic DNA extraction 
Genomic DNA extraction was performed using QIAgen DNeasy Blood Tissue Kit (69504) 
according to manufacturer’s instructions. DNA concentration was quantified using the 
NanoDrop spectrometer and stored at 4°C short term, -20°C long term.  
 
2.3.2 Sequencing of codons 175 and 273 
Prior to sequencing, target DNA was polymerase chain reaction (PCR) amplified. To ensure 
amplification of genomic TP53, primers were designed to adhere to intronic DNA not present 
in cDNA transgene. Similarly, to ensure amplification of cDNA transgene, primers were 
designed to adhere across exon-exon boundaries not present in genomic TP53. A summary of 
primers used in can be found in Table 2.3. PCR amplification was performed using Promega 
PCR master mix (M7502) with 200ng DNA in total reaction volume of 25µL according to 
manufacture’s instructions. Thermal cycler conditions (BioRad T100) were set as outlined in 
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Table 2.4. To ensure the integrity of PCR, 5µL of PCR product was resolved on a 2% agarose 
gel (refer to section 2.2.5).  
 
Primer 5’-3’ Sequence 
Genomic TP53 R175H forward GGAGGTGCTTACGCATGTTTG 
Genomic TP53 R175H reverse AACCAGCCCTCGTCTCT 
cDNA transgene R175H forward GTGCAGCTGTGGGTTGATT 
cDNA transgene R175H reverse CATAGGGCACCACCACACTA 
Genomic TP53 R273H forward CAAGGGTGGTTGGGAGTAGA 
Genomic TP53 R273H reverse TAACTGCACCCTTGGTCTCC 
cDNA transgene R273H forward TAGTGTGGTGGTGCCCTATGA 
cDNA transgene R273H reverse CCTCATTCAGCTCTGGAAC 
Table 2.3: Primer sequences 
Table of primers and sequences used in PCR and sequencing. Primers were synthesised by Sigma-Aldrich 
 
Stage Temperature Duration 
Hold 95°C 5 minutes 
Denaturation 95°C 30 seconds  
X35 cycles Primer annealing 60°C 30 seconds 
Extension/ elongation 72°C 30 seconds 
Final extension 72°C 5 minutes 
Hold 4°C 4°C 
Table 2.4: Thermal cycler conditions for PCR 
Thermal cycler conditions for PCR. Temperature and duration of each stage presented. Denaturation, annealing 
and extension/elongation stages repeated a total of 35 cycles.  
 
Following verification of PCR amplification, samples were purified using QIAquick PCR 
purification kit (28104) according to manufacturer’s instructions. To ensure integrity of 
resulting product, samples were resolved on a 2% agarose gel (refer to section 2.2.5). DNA 
concentration of purified PCR product was quantified using the NanoDrop spectrometer and 
5ng/µL DNA added to 2µL primer (10µM) per reaction. Premixed DNA/primer samples 
were sent to Eurofins MWG Operon for DNA sequencing (value read service). Results were 
analysed using Sequencer software.  
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2.3.3 Transgene copy number analysis 
To quantify transgene copy number, relative quantitative real time PCR (RTqPCR) was 
performed against genomic DNA extracted from IOSE cell lines. TaqMan real time PCR 
primers were purchased from Life Technologies to target endogenous genomic TP53, HPRT1 
genomic housekeeper, and transgene cDNA. To ensure amplification of genomic DNA, 
TaqMan primers were selected to adhere to intronic DNA not present in cDNA transgene. 
Similarly, to ensure amplification of cDNA transgene, TaqMan primers were selected to 
adhere across exon-exon boundaries not present in genomic TP53. A list of TaqMan real time 
PCR primers and probes is provided in Table 2.5. RTqPCR was performed in a total reaction 
volume of 20µL as outlined in Table 2.6. PCR was performed using StepOne Plus real time 
PCR machine at thermal cycling conditions outlined in Table 2.7. Threshold detection levels 
were adjusted to 0.3 for all targets to eliminate detection rate bias. 
 
Primer Provider Catalogue number 
Genomic TP53 Life Technologies Hs05506931_cn 
Genomic HPRT1 Life Technologies Hs05608929_cn 
cDNA TP53 transgene Life Technologies Hs01034249_m1 
Table 2.5: TaqMan primers and probes 
Table of TaqMan primers and probes used to assess transgene copy number 
 
Reagent Provider Volume (µL) in 20uL  
2X qPCR Master mix BioRad, 172-5134 10 
20X TaqMan® real time PCR 
primer 
Life Technologies (Table 2.5) 1 
Nuclease free water Ambion, AM9937 4 
10ug genomic DNA NA 5 
Table 2.6: Real time PCR reaction set up 
Quantity of reagents per real time PCR reaction, in a total reaction volume of 20µL 
 
Stage Temperature Duration 
Hold 50°C 2 minutes 
Hold 95°C 10 minutes 
Denaturation 95°C 15 seconds  
X40 cycles Primer annealing and extension 60°C 1 minute 
Table 2.7: Real time PCR thermal cycle conditions 
Thermal cycler conditions for real time PCR using StepOne Plus machine 
 
 63 
2.3.4 Karyotyping 
Cells at 40-50% confluence were arrested in metaphase using 50ng/mL Colcemid (Gibco, 
Life Technologies, 15210-040) in complete NOSE medium for 17 hours, 37°C, 5% CO2. 
Approximately 5x106 cells were harvested following trypsinisation and re-suspended in 5mL 
complete RPMI (10% FBS, 1% P/S). Cells were transported to the Royal London Hospital 
for karyotype analysis by the Cytogenetics Department in collaboration with Marianne 
Grantham.  
 
2.4 Protein analysis  
2.4.1 Protein extraction 
Cell monolayers were washed with PBS and lysed in RIPA buffer (Thermo scientific-Pierce, 
Life Technologies, 87787), containing 1:100 complete mini EDTA protease inhibitor (Roche, 
11836170001) and 1:100 phosphatase inhibitor cocktail (Sigma-Aldrich, P5726). Lysates were 
briefly vortex and centrifuged at 13200 x rpm for 35 minutes, 4°C to pellet cell debris. 
Protein supernatants were transferred to fresh eppendorfs and protein concentration 
determined by bicinchoninic acid assay. 
 
2.4.2 Bicinchoninic acid assay 
 Standard protein concentrations were made using bovine serum albumin (BSA; Sigma-
Aldrich, A4503) containing 0, 0.2, 0.4, 0.6, 0.8 and 1ug/mL protein. Each standard was 
added in triplicate to a 96 well plate. Protein samples were diluted 1:10 and 10µL added in 
triplicate to the 96 well plate. 50 parts bicinchoninic acid solution (Sigma-Aldrich, B9643-L) 
was combined with one part Copper (II) sulphate solution (Sigma-Aldrich, C2284). 200µL of 
this solution added to each sample and incubated at 37°C for 30 minutes. Absorbance was 
read at 595nm using an Opsys MRTM plate reader (Dynex Technologies) and Revelation 
Quicklink software.  
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2.4.3 Western blotting 
Western blotting was performed using 4-12% NuPAGE Bis-Tris pre-cast gels (Invitrogen, 
NP0336BOX). 5µL 4X NuPAGE LDS sample buffer (Invitrogen, NP007) and 2µL 10X 
NuPAGE sample reducing agent (Invitrogen, NP004) were added to 15µg protein in a total 
volume of 20µL. Protein samples were incubated at 70°C for 10 minutes before brief 
centrifugation and loading onto the protein gel. The gel was run at 100V in 1X MOPS SDS 
running buffer (Invitrogen, NP001) prepared to manufacture’s instructions until resolved. 
Samples were run with 8µL ColorPlus pre-stained protein ladder (New England BioLabs, 
P7712) to estimate protein mass (KDa). Resolved proteins were transferred onto 
polyvinylidene fluoride (PVDF) membranes (Perkin Elmer) using the BioRad transfer system. 
The transfer cassette consisted of the gel placed next to the PVDF membrane, sandwiched 
between Whatman chromatography paper and Scotch-Brite pads. The cassette was then placed 
in the transfer tank with an ice pack and filled with 1X NuPAGE MOPS transfer buffer 
(Invitrogen, NP0006) prepared to manufacturers instructions. Electrophoretic protein 
transfer was conducted at 95V for 1 hour 40 minutes at 4°C. 
 
2.4.4 Western blotting- Immunodetection 
Non-specific binding was inhibited by incubation of PVDF membranes in blocking buffer (5% 
skimmed milk powder (Marvel) in 1X TBST (50mM TrisHCl, 150mM NaCl, 0.1% Tween)) 
for 1 hour with gentle shaking at room temperature. After incubation, blocking buffer was 
removed and PVDF membrane incubated with primary antibody diluted in blocking buffer as 
specified in Table 2.8. Membranes were incubated with primary antibody either overnight at 
4°C, or for 1 hour at room temperature. Following 3X 5 minute washes in 1X TBST, PVDF 
membranes were incubated with secondary antibody horseradish peroxidase (HRP) for 1 hour 
at room temperature (Table 2.8). This was followed by 3X 5 minute washes in 1X TBST, 
following which bound HRP activity was visualised by Hyperfilm and ECL Western Blotting 
Detection Reagent (Amersham, GE Healthcare, RPN2106). If appropriate, membranes were 
stripped to remove bound antibody using 1X Re-blot Plus Strong solution (Millipore, 2504) 
for 5-10 minutes before incubation in blocking buffer. Membranes were then re-incubated 
with primary antibodies as described.  
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Antibody Size 
(KDa) 
Dilution Species Provider Catalogue 
number 
p53 53 1:100 Rabbit Dako IS616 
p21 21 1:1000 Rabbit Cell Signalling 2947 
V5-tag  1:5000 Mouse Life 
Technologies 
R960-25 
β-actin 42 1:1000 Rabbit Sigma-Aldrich A1978 
Secondary anti-
rabbit 
N.A 1:2000 Donkey GE Healthcare NA9340V 
Secondary anti-
mouse 
N.A 1:2000 Sheep GE Healthcare NXA931 
Table 2.8: Western blotting antibodies  
Antibody specifications used in western blotting. Dilutions prepared in blocking buffer (5% milk in 1X TBST). 
 
2.4.5 Immunofluorescence 
Cells were grown on 50 X 50nm coverslips in a 6 well plate. The density of cells plated varied 
according to cell confluence required. Cells were fixed using 4% paraformaldehyde for 10-15 
minutes following washing in PBS. After fixation, coverslips were washed twice in PBS and 
stored at 4°C until required. Cells were permeabilised using 0.5% Triton-X-100  (Sigma-
Aldrich, X100-100ML) for 5 minutes, and washed twice in PBS. Non-specific binding was 
inhibited by addition of blocking buffer (2% BSA in PBS) for 1 hour at room temperature. 
Primary antibodies were diluted in blocking buffer as specified in Table 2-9 and incubated at 
room temperature for 1 hour. Following 3X PBS washes, secondary antibody was added 
1:1000 in blocking buffer for 1 hour at room temperature in the dark. Coverslips were 
washed 3X in PBS before addition of Pro-Long DAPI Gold (Invitrogen, P-36931) to mount. 
Slides were left at 4°C overnight prior to confocal microscopy (Zeiss LSM510 confocal 
microscope). 
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Antibody Dilution Duration Species Company Catalogue 
number 
PAX8 1:20 1 hour Rabbit Abcam ab53490 
p53 1:100 1 hour Rabbit Dako IS616 
V5-tag 1:500 1 hour Mouse Life 
Technologies 
R960-25 
Alexa Fluor 568 
Phalloidin 
1:40 20 min NA Life 
Technologies 
A12380 
Secondary anti-mouse 
Alexa Fluor 568 
1:1000 1 hour Donkey Life 
Technologies 
A10037 
Secondary anti-rabbit 
Alexa Fluor 568 
1:1000 1 hour Goat Life 
Technologies 
A11011 
Table 2.9: Immunofluorescence antibodies 
Table of antibody specifications used in immunofluorescence. Dilutions prepared in blocking buffer (2% BSA in 
PBS).  
 
2.4.6 Immunohistochemistry (IHC) 
Immunohistochemistry was performed on paraffin embedded sections. To remove paraffin 
and rehydrate tissue, sections were sequentially added to:  
1. Xylene- 2 x 5 minutes 
2. 100% Ethanol- 2 x 2 minutes 
3. 95% Ethanol- 1 x 2 minutes 
4. 90% Ethanol- 1 x 2 minutes 
5. 70% Ethanol- 2 x 2 minutes 
6. 50% Ethanol- 1 x 2 minutes 
7. Double distilled water (ddH2O)- 1 x 2 minutes  
Antigen retrieval was performed using 1X antigen unmasking solution (Vector Laboratories, 
H-3300) in the pressure cooker for 10 minutes. Following antigen retrieval, slides were rinsed 
in cold tap water for 5 minutes and washed by submersion in 1X wash buffer (Dako, S3006). 
Sections were blocked for endogenous HRP activity using 0.6% hydrogen peroxide in 
methanol for 20 minutes, followed by submersion in 1X in wash buffer. The following steps 
were performed using the Biogenex super sensitive polymer-HRP IHC detection system 
(QD430-XAK). Primary antibody was diluted in antibody diluent (Zytomed Systems, 
ZUCO25-100) to achieve 200µL per section (Table 2.10). Sections were incubated with 
primary antibody for 40 minutes at room temperature, prior to washing by submersion in 1X 
wash buffer (Dako, S3006). 200µL of super enhancer was added to each section and incubated 
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at room temperature for 20 minutes. Sections were washed by submersion in 1X wash buffer 
and 200µL Polymer-HRP SS-label added to each slide prior to incubation at room 
temperature for 30 minutes.  Sections were washed by submersion in 1X wash buffer and 
200µL of 1x DAB solution added per slide and incubated at room temperature for 10 
minutes. Slides were rinsed in cold tap water for 5 minutes and washed by submersion in 1X 
wash buffer. Cell nuclei were haematoxylin stained and sections dehydrated by sequentially 
adding to: 
1. Haematoxylin- 1 x 5 minutes  
2. ddH2O- 1 x 1 minutes 
3. Acid (stops Haematoxylin reaction)- 7 dips  
4. ddH2O- 1 x 1 minutes  
5. Scotts tap solution- 1 x 2 minutes (makes staining clearer, increases contrast)  
6. ddH2O- 1 x 1 minutes 
7. Industrial Methylated Spirit (IMS)- 3 x 2 minutes  
8. Xylene- 2 x 2 minutes  
Sections were then covered with 100 X 50nm coverslips using DPX resin (Sigma-Aldrich, 
44581) and left to dry overnight at room temperature prior to microscopic examination. A list 
of antibodies and dilutions used in immunohistochemistry are presented in Table 2.10. 
 
Antibody Dilution Duration Species Company Catalogue number 
PAX8 1:20 40 min Rabbit Abcam ab53490 
Calretinin Undiluted 40 min Mouse Dako IS627 
WT-1 1:100 40 min Mouse Dako M3561 
CK7 1:100 40 min Mouse Dako M7018 
CK20 1:100 40 min Mouse Dako IS777 
Pan-CK 1:500 40 min Mouse Dako Z0622 
IgG1 1:100 40 min Mouse Dako X0931 
Table 2.10: Antibodies used in immunohistochemistry 
Table of antibody specifications used in immunohistochemistry. Dilutions prepared in antibody diluent (Zytomed 
Systems, ZUCO25-100).  
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2.5 Statistics 
Statistical analysis was performed using GraphPad Prism version 5.0b. Data was assessed for 
normal distribution and parametric or non-parametric analysis conducted accordingly. The 
majority of assays were assessed by 1- or 2-way ANOVA, with Bonferroni or Dunn’s post-hoc 
test. Proliferation assays were assessed by linear regression with comparison of slope 
similarity. P values ≤0.05 were classified as statistically significant and the null hypothesis 
rejected. 
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Chapter 3:  Derivation of IOSE cell lines 
3.1 Introduction 
IOSE progenitor cells (NOSE) were isolated from ovarian brushings taken during surgery for 
non-ovarian related, benign disease [220]. The isolated NOSE cells were assumed to be OSE 
in origin due to the site of surgical brushings. However, the proximity of OSE and fallopian 
fimbriae, combined with the potential for fallopian epithelia to slough onto the surface of the 
ovary, suggests IOSE cell lines could be fallopian derived. In light of the controversy 
surrounding the provenance of HGSC, establishing the origin of IOSE cell lines is of particular 
interest. This chapter outlines the characterisation of IOSE cell lines to determine OSE versus 
fallopian derivation.  
 
3.2 Antibody panel  
A panel of antibodies was used to examine the origin of IOSE cell lines. This panel included 
antibodies to PAX8, calretinin, WT1, CK7 and CK20. Paired homeobox 8 (PAX8) is 
transcription factor used to identify cells of Müllerian (fallopian) origin [226-229]. Calretinin 
is a calcium binding protein and is expressed by the OSE [230, 231]. Wilms’ tumour 1 (WT-
1) is expressed throughout gonadal development and is detected in both ovarian and fallopian 
tissue [232-234]. Cytokeratins (CKs) are expressed by epithelial cells and can be used to 
localise cells to a particular area of the body [235, 236]. In this panel, CK7 was included to 
identify epithelial cells originating from genitourinary (GU) tract, and CK20 was included to 
identify epithelial cells originating from the gastrointestinal (GI) tract [237-240]. Expression 
of WT1 and CK markers was therefore used to localise cells to a particular area of the body, 
while PAX8 and calretinin expression was used to more specifically determine cell type (i.e. 
OSE, fallopian secretory or fallopian ciliated).  
 
3.3 Staining of ovarian and fallopian tissue 
To confirm tissue specific expression of the cell markers, the antibody panel was first tested 
against ovarian and fallopian tissue. Figure 3.1:A, shows a section through an ovary stained 
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with haematoxylin and eosin (H&E). OSE cells appear flattened and cuboidal in shape, with 
bland nuclei. A section of the OSE is detached from the ovarian stroma- a common 
phenomenon upon paraffin embedding. In Figure 3.1:B, both fallopian secretory and fallopian 
ciliated epitheial cells can be seen. Fallopian secetory cells appear columnar in shape, arranged 
perependicular to the basement membrane with bland nuclei. Fallopian ciliated cells also 
appear columnar in shape but have oval nuclei and apical cilia. Upon immunostaining, only 
fallopian secretory cells demonstrated positive nuclear PAX8 expression in addition to 
negative cytoplasmic expression (Figure 3.2:A, H). OSE cells demonstrated positive nuclear 
and cytoplasmic calretinin expression, whereas the fallopian epithelium was entirely negative 
(Figure 3.2:B, I). All epithelial cell types were positive for nuclear WT1 expression (Figure 
3.2:C, J). OSE and fallopian secretory cells were positive for CK7 expression, whereas 
fallopain ciliated cells showed only very faint, or absent CK7 staining (Figure 3.2:D, K). All 
epithelial cell types examined were CK20 negative (Figure 3.2:E, L) and Pan-CK positive 
(Figure 3.2:F, M). The IgG control was negative (Figure 3.2:G, N) and a positive control for 
CK20 staining can be found in Figure 3.3:A.  
 
 
Figure 3.1: Ovarian and fallopian epithelial cell types.  
H&E staining of ovarian (A) and fallopian (B) tissue. OSE, fallopian secretory and fallopian ciliated cells are 
indicated. Representative images of n=2. 
 71 
 
Figure 3.2: Staining of ovarian and fallopian sections  
Ovarian (A-G) and fallopian (H-N) sections stained for PAX8 (A, H), calretinin (B, I), WT1 (C, J), CK7 (D, K), 
CK20 (E, L) and Pan-CK (F, M). IgG1 isotope control included (G, N). Representative images of n=2.  
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Figure 3.3: CK20 expression  
Colon epithelial cells (A) demonstrate positive cytoplasmic CK20 expression. Ovarian (B) and fallopian 
epithelium (C) are negative for CK20 expression. Representative images of colon tissue to n=1, ovarian and 
fallopian epithelium to n=3.  
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3.4 Staining of IOSE cell lines 
To enable use of the same antibody panel, IOSE21 and IOSE25 cell lines were paraffin 
embedded and sectioned for immunohistochemistry. IOSE21 cells demonstrated positive, 
nuclear PAX8 and WT1 expression but were negative for calretinin (Figure 3.4:A-C). 
IOSE21 cells were Pan-CK positive but CK7, CK20 negative (Figure 3.4:D-F). IOSE25 cells 
were also positive for nuclear PAX8 and WT1 expression, but negative for calretinin (Figure 
3.4:H-J). IOSE25 cells were Pan-CK and CK7 positive, CK20 negative (Figure 3.4:K-M). 
IgG1 staining for both cell lines was negative (Figure 3.4:G, N).  
Subsequent to the immunostaining experiments, a fallopian secretory epithelial cell line 
FT318 was acquired. As a cell line, FT318 could be considered a more suitable Müllerian 
control for IOSE cell lines than sections of fallopian tissue. FT318 cells were initially analysed 
for PAX8 expression by immunohistochemistry. FT318 cells demonstrated stronger nuclear 
PAX8 expression than IOSE21 and IOSE25 cell lines (Figure 3.5). To confirm variation in 
nuclear PAX8 expression, analysis was repeated using immunofluorescence (Figure 3.6). 
Upon adjusting microscope settings to FT318 positive control, nuclear PAX8 could no longer 
be detected in IOSE21 and IOSE25 cell lines. This suggests IOSE cell lines demonstrate little 
or negligible nuclear PAX8 expression relative to FT318 positive control. As a result, IOSE21 
and IOSE25 cannot be classified as PAX8 positive.  
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Figure 3.4: Staining of IOSE cell lines  
IOSE21 (A-G) and IOSE25 (H-N) cell lines stained for PAX8 (A, H), calretinin (B, I), WT1 (C, J), CK7 (D, K), 
CK20 (E, L) and Pan-CK (F, M). IgG1 isotope control included (G, N). Representative images of n=3. 
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Figure 3.5: PAX8 expression in IOSE21, IOSE25 and FT318 cell lines 
IOSE21 (A), IOSE25 (B) and FT318 (C) cell lines stained for PAX8. PAX8 is detected in all the cell lines but 
nuclear PAX8 expression is particularly strong in FT318 positive control. Representative images of IOSE cell 
lines to n=3, FT318 n=1. Staining performed in collaboration with Ms Laura Lecker.  
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Figure 3.6: Detection of nuclear PAX8 in IOSE and FT318 cell lines 
Positive control cell line FT318 (G-I) demonstrates strong, nuclear PAX8 expression. IOSE21 (A-C) and IOSE25 
(D-F) cells demonstrate cytoplasmic but not nuclear PAX8 expression. DAPI= blue (A, D, G), PAX8= Red (B, 
E, H). Representative images of n=1. Staining performed in collaboration with Ms Laura Lecker.  
 
3.5 Summary of results 
Marker OSE Fallopian secretory Fallopian ciliated IOSE21 IOSE25 
PAX8 ✗ ✓ ✗ ✗ ✗ 
Calretinin ✓ ✗ ✗ ✗ ✗ 
WT1 ✓ ✓ ✓ ✓ ✓ 
CK7 ✓ ✓ ✗ ✗ ✓ 
CK20 ✗ ✗ ✗ ✗ ✗ 
Pan-CK ✓ ✓ ✓ ✓ ✓ 
Table 3.1: Summary of cell marker expression 
Ticks denote positive expression and crosses denote negative expression as verified by immunohistochemical and 
immunofluorescent analysis. 
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3.6 Discussion 
The expression of several markers included in the antibody panel can be used to assist the 
diagnosis of epithelial ovarian cancers. WT1, CK7 and CK20 can be used to verify the site of 
tumour origin, enabling some discrimination between tumour types. For example, some 
mucinous invasive tumours are secondary neoplasms of the GI tract, staining CK20 positive 
and CK7 negative [241, 242]. OSE and fallopian secretory cells stain WT1 positive, CK7 
positive and CK20 negative [233, 243] (Figure 3.2:C-E, J-L). Fallopian ciliated cells stain 
WT1 positive, CK7 and CK20 negative (Figure 3.2:J-L). Although negative CK7 expression 
may assist the identification of fallopian ciliated cells, similar expression of WT1, CK7 and 
CK20 by OSE and fallopian epithelia reduces the use of these markers to discriminate between 
cell types. In order to more accurately determine cell type, cell specific markers must be 
used. Nuclear PAX8 expression appears to be a discriminatory marker of fallopian secretory 
cells [36, 244] (Figure 3.2:H and Figure 3.5:C). Similarly, calretinin expression is observed at 
the OSE and not fallopian epithelium [230, 244] (Figure 3.2:B). In this respect, PAX8 and 
calretinin expression could be used to discriminate between ovarian and fallopian epithelia. 
IOSE21 and IOSE25 cell lines were negative for calretinin, indicative of extra-ovarian origin 
(Figure 3.4:B, J). Indeed, IOSE cells were originally thought to be PAX8 positive, indicative 
of fallopian secretory origin (Figure 3.4:A, H). This could be considered surprising, as IOSE 
cell lines were obtained from ovarian brushings. However, as the ovaries and fallopian 
fimbriae are located in close proximity, this could increase the likelihood of fallopian epithelia 
being isolated during ovarian brushings. hTERT immortalisation may also have preferentially 
selected out fallopian epithelial cells- although without further investigation this is difficult to 
determine. Towards the end of this project, fallopian secretory cell line FT318 was acquired. 
Upon repeating PAX8 analysis with this cell line, IOSE21 and IOSE25 cell lines demonstrated 
substantially lower nuclear PAX8 expression relative to the positive control (Figure 3.5). 
Examination of PAX8 expression by immunofluorescence supported this observation, with 
adjustment of confocal settings to FT318 eliminating detection of IOSE21 and IOSE25 nuclear 
PAX8 (Figure 3.6). Interpretation of IOSE21 and IOSE25 PAX8 status is therefore 
challenging. Paraffin embedding may have compounded the issue, as cell architecture can be 
difficult to interpret and sectioning can fail to capture cell nuclei in some sections. As a result, 
immunofluorescent staining may be the best method to determine nuclear PAX8 expression. 
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In this respect, IOSE21 and IOSE25 cell lines cannot be classified as fallopian secretory 
derived.  
IOSE21 cells could originate from fallopian ciliated cells. Indeed, IOSE21 cells express an 
immunophenotype consistent with fallopian ciliated epithelium (PAX8-, calretinin-, WT1+, 
CK7-, CK20-, Pan-CK+). However, IOSE21 cells do not appear ciliated, suggesting either 
altered cell morphology, or non-ciliated derivation. IOSE25 cells demonstrate an 
immunophenotype inconsistent with OSE, fallopian secretory or fallopian ciliated cell type 
(IOSE25: PAX8-, calretinin-, WT1+, CK7+, CK20-, Pan-CK+) (Table 3.1). Inability to 
determine cell origin could be due to aberrant expression resulting from cell culture 
conditions or hTERT immortalisation. In this respect, examining the original NOSE 
population may more accurately reflect cell derivation. Alternatively, immunostaining results 
could be misleading. The characterisation of IOSE cell lines as Müllerian or ovarian depends 
greatly on the expression of PAX8 and calretinin. In the absence of more discriminatory 
markers it is difficult to classify IOSE cell lines with a degree of certainty. HOX9A has been 
identified as a potential marker of fallopian epithelium and may be useful to include in future 
analysis [37]. Regardless, IOSE21 and IOSE25 cell lines express a panel of markers that 
confirm ovarian/fallopian origin. In light of the developmental approach to HGSC, 
confirmation of derivation from these epithelia is key rather than classification of specific cell 
type. If the OSE and fallopian epithelium represent a transitional epithelium, expression of the 
markers examined (with the exception of CK20) would represent derivation from this zone. 
In this respect, IOSE cell lines could be considered a suitable model of early HGSC 
irrespective of specific ovarian/fallopian epithelial cell origin. 
 
3.7 Chapter Summary 
Classification of IOSE cell lines as fallopian or ovarian is challenging due to the lack cell 
specific markers. IOSE21 and IOSE25 cell lines demonstrated an immunophenotype 
consistent with fallopian/ovarian derivation, although specific cell type could not be 
determined.  
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Chapter 4: Verification of Transduction 
4.1 Introduction 
The gain and loss of different TP53 mutations in IOSE-TOSE model of early HGSC suggested 
different TP53 mutations could have varying tumourigenic potential [222]. To investigate this 
hypothesis, IOSE21 and IOSE25 cell lines were transduced with different TP53 mutations and 
examined for the acquisition of transformed traits. To introduce the mutations, three 
lentiviral constructs based on the plasmid Lenti6/V5-D-TOPO (Invitrogen) were used. The 
constructs contained a TP53 cDNA transgene, encoding wild type, R175H or R273H mutant 
p53. IOSE21 cells were transduced with R175H, R273H and wild type lentiviral constructs. 
IOSE25 cells were transduced with R273H and wild type constructs only. This is because as at 
the time of transduction, IOSE25 cells were already known to possess a heterozygous R175H 
TP53 mutation [222]. A schematic diagram of the work performed can be found in Figures 
4.1- 4.2. Following lentiviral transduction, cell line nomenclature was adjusted to reflect 
transgene status. For example, plasmid wild type (pWT) transduced cell lines were referred 
to as IOSE-pWT, and non-transduced IOSE cell lines as IOSE-parental.  This chapter outlines 
the generation of IOSE cells lines, exploring the efficacy of transduction and functional status 
of recombinant p53. 
 
 
Figure 4.1: Generation of transduced IOSE21 cell lines  
Schematic diagram representing the generation of IOSE21-R175H, IOSE21-R273H and IOSE21-pWT cell lines 
from non-transduced IOSE21-parental.  
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Figure 4.2: Generation of transduced IOSE25 cell lines  
Schematic diagram representing the generation of IOSE25-R273H and IOSE25-pWT cell lines from non-
transduced IOSE25-parental. IOSE25 cells were not transduced with R175H mutant TP53, as at the time of the 
transduction this cell line was already known to possess a heterozygous R175H TP53 mutation.  
 
4.2 Sequencing of transgene 
To confirm successful transduction, genomic DNA was extracted from IOSE cells lines, PCR 
amplified and sequenced at transgene codons 175 and 273 (Figures 4.3-4.4). To ensure 
amplification of transgene and not endogenous TP53, cDNA primers were designed to bind to 
exon-exon boundaries not present in genomic TP53. Sequencing confirmed transduction of 
IOSE cell lines with the correct lentiviral vector. R175H transduced samples displayed mutant 
CAC at codon 175, and wild type CGT at codon 273. Similarly, R273H transduced samples 
displayed wild type CGC at codon 175 and mutant CAT at codon 273. pWT transduced 
samples displayed wild type CGC at codon 175 and CGT at codon 273, except in the case of 
IOSE21-pWT.  In this instance, the vector appears to have undergone a spontaneous mutation 
at codon 273, substituting cytosine at the first base to an adenine (Figure 4.3). This would 
result in the expression recombinant mutant R273S by IOSE21-pWT cells. 
  
 
 
 
 81 
 
Figure 4.3: Sequencing of transgene at codons 175 and 273 in transduced IOSE21 cell lines 
Base determining codon mutant status is circled in red. Wild type codon 175 = CGC, mutant R175H = CAC. 
Wild type codon 273 = CGT, mutant R273H = CAT. Spontaneous mutation R273S= AGT. Representative 
results of n=2. 
 
 
Figure 4.4: Sequencing of transgene at codons 175 and 273 in transduced IOSE25 cell lines 
Base determining codon mutant status is circled in red. Wild type codon 175 = CGC, mutant R175H = CAC. 
Wild type codon 273 = CGT, mutant R273H = CAT. Representative results of n=2. 
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4.3 Sequencing of endogenous TP53 
IOSE cell lines were further PCR amplified and sequenced to confirm endogenous TP53 
mutant status at codons 175 and 273 (Figures 4.5-4.6). This was performed to achieve an 
overview of TP53 alleles present in IOSE cell lines. To detect endogenous and not plasmid 
DNA, primers were designed to adhere to intronic DNA not present in cDNA transgene. 
Transduced IOSE cell lines displayed the same mutant status as their parental cell line; with 
IOSE21 cell lines demonstrating wild type p53 at codons 175 and 273, and IOSE25 cell lines 
heterozygous R175H as previously reported. A summary of cell line endogenous and 
transgenic TP53 mutant status at codons 175 and 273 is displayed in Figure 4.7. 
 
 
Figure 4.5: Sequencing of endogenous TP53 at codons 175 and 273 in IOSE21 cell lines 
Base determining codon mutant status is circled in red. Wild type codon 175 = CGC, mutant R175H = CAC. 
Wild type codon 273 = CGT, mutant R273H = CAT. Representative results of n=2. 
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Figure 4.6: Sequencing of endogenous TP53 at codons 175 and 273 in IOSE25 cell lines 
Base determining codon mutant status is circled in red. Wild type codon 175 = CGC, mutant R175H = CAC. 
Wild type codon 273 = CGT, mutant R273H = CAT. Representative results of n=2. 
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Figure 4.7: Summary of endogenous and transduced TP53 alleles in IOSE cell lines 
Representative diagram of mutant status of endogenous and transduced TP53 DNA in IOSE cell lines. 
Endogenous DNA is coloured in black and plasmid DNA is coloured in green. Wild type codon 175 is coloured 
in dark blue and mutant R175H in light blue. Wild type codon 273 is coloured in dark orange and mutant 
R273H in light orange. Mutant R273S is coloured in purple. pWT= plasmid wild type transgene. 
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4.4 Detection of recombinant p53 
To determine the expression of recombinant p53, protein lysates were extracted from IOSE 
cell lines and examined for the expression of p53 and V5 tag by western blot (Figures 4.8-
4.9). In the absence of cell stress, wild type p53 is targeted for proteasomal degradation, 
preventing detection of wild type protein by western blot. Mutant p53 however, fails to be 
degraded, enabling detection of mutant protein [245]. TOSE1 and SKOV3ip cell lines were 
included in the analysis as a positive and negative control for mutant p53 as previously 
reported [222]. Western blot against p53 (Figure 4.8) revealed mutant p53 in R175H and 
R273H transduced IOSE cell lines and in TOSE1 positive control. Recombinant mutant p53 
was detected at a slightly higher molecular weight than TOSE1 endogenous mutant p53, likely 
due to the addition of V5 tag fusion protein. IOSE21-pWT cells also displayed recombinant 
mutant p53, supporting sequencing data indicating spontaneous mutation of the wild type 
transgene. Interestingly, endogenous mutant p53 could not be detected in IOSE25-parental 
cell line despite endogenous TP53 mutant status. 
V5 tag is a ~2KDa protein fused to recombinant p53 and as such should only be detected in 
transduced IOSE cell lines. As a p53 recombinant fusion protein, in the absence of cell stress, 
V5 tag should only be detected in p53 mutant cell lines. Western blot against V5 tag (Figure 
4.9) revealed epitope expression in R175H and R273H transduced IOSE cell lines. V5 tag 
expression could also be detected in IOSE21-pWT cells, verifying expression of mutant 
protein from the wild type transgene. These results confirm the expression of recombinant 
mutant p53 in R175H and R273H transduced IOSE cell lines, and the spontaneous mutation 
of IOSE21-pWT transgene.  
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Figure 4.8: Expression of p53 in parental and transduced IOSE cell lines 
Top-most band of p53 staining is recombinant mutant p53. Endogenous mutant p53 is detected at a lower 
molecular weight than recombinant p53, as observed in TOSE1 positive control cell line. No p53 protein is 
detected in SKOV3ip negative control, parental or pWT transduced IOSE cell lines except IOSE21-pWT. In this 
instance, a faint mutant band is detected at the molecular weight of mutant transduced protein, indicative of a 
mutation at the wild type transgene. Representative results of n=3. 
 
 
 
Figure 4.9: Expression of V5 tag in transduced IOSE cells lines  
V5 tag expression is detected in mutant TP53 transduced IOSE cells. No expression is observed in TOSE1, 
SKOV3ip, parental or pWT transduced cell lines except IOSE21-pWT. Expression of V5 tag in IOSE21-pWT is 
indicative of a mutation at the wild type transgene. Representative results of n=3. 
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Expression of recombinant mutant p53 was further confirmed by immunofluorescence against 
p53 (Figures 4.11- 4.12) and V5 tag (Figures 4.13- 4.14). As before, in the absence of cell 
stress, wild type p53 is targeted for proteasomal degradation, preventing detection of wild 
type p53 [245]. Mutant p53 however, fails to be degraded and accumulates at the nucleus. 
Immunofluorescence staining demonstrated nuclear accumulation of p53 and V5 tag in TP53 
mutant transduced IOSE cell lines. Nuclear accumulation of p53 and V5 tag was also detected 
in IOSE21-pWT cells, confirming expression of recombinant mutant protein from wild type 
transgene. As a result, this cell line was eliminated from further analysis. Interestingly, once 
again endogenous mutant p53 could not be detected in IOSE25-parental cell line despite 
mutant TP53 status.  
Quantification of the percentage of cells that expressed recombinant fusion protein V5 tag by 
immunofluorescence was performed to estimate the efficacy of transduction. Efficacy of 
transduction was determined be ~100% and ~95% for IOSE21-R175H and R273H cell lines 
respectively (Figure 4.10). However, efficacy of transduction was lower for IOSE25-R273H 
cell line at ~60%.  
 
 
Figure 4.10: Percentage efficacy of transduction of mutant TP53 in IOSE cell lines  
Percentage of cells that express recombinant fusion protein V5 tag by immunofluorescence. At least 10 images 
quantified per cell line, 200-300 cells in total. Mean ± standard deviation, n=2. 
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Figure 4.11: Immunofluorescent staining of p53 in IOSE21 cell lines  
Nuclear p53 is not detected in IOSE21-parental cell line (A-C). Nuclear p53 is detected in IOSE21-R175H (D-F) 
IOSE21-R273H (G-I), and IOSE21-pWT (J-L) cell lines. Blue= nuclear stain, red=p53. Representative images 
of n=2. 
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Figure 4.12: Immunofluorescent staining of p53 in IOSE25 cell lines 
Nuclear p53 is not detected in IOSE25-parental (A-C) or IOSE25-pWT (G-I) cell lines. Nuclear p53 is detected 
IOSE25-R273H cell line (D-F). Blue= nuclear stain, red= p53. Representative images of n=2. 
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Figure 4.13: Immunofluorescent staining of V5 tag in IOSE21 cell lines 
V5 tag is not detected in IOSE21-parental cell line (A-C). V5 tag is observed in IOSE21-R175H (D-F), IOSE21-
R273H (G-I) and IOSE21-pWT (J-L) cell lines.  Blue= nuclear stain, red= V5 tag. Representative images of 
n=2. 
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Figure 4.14: Immunofluorescent staining of V5 tag in IOSE25 cells  
V5 tag is not detected in IOSE25-parental (A-C) or IOSE25-pWT (G-I) cell lines. V5 tag is observed in IOSE25-
R273H cell line (D-F). Blue= nuclear stain, red= V5 tag. Representative images of n=2. 
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4.5 Functional status of recombinant p53 
To confirm the functional status of recombinant p53, IOSE cell lines were treated with 
cisplatin and examined for the induction of p53 and p21 by western blot. Cisplatin treatment 
induces DNA damage that brings about the activation and stabilisation of wild type p53. This 
enables the detection of wild type p53 by western blot. Active, wild type p53 will translocate 
to the nucleus and transactivate p21 [246]. Mutant p53 however, fails to be activated and fails 
to transactivate p21. Expression of p21 therefore serves as an indicator of wild type p53 
activity.  
IOSE21 cell lines were treated with cisplatin for 48 hours (Figure 4.15). IOSE21-parental cell 
line demonstrated increased expression of endogenous p53 and p21 in response to cisplatin 
treatment. Although p21 expression was fairly high at the zero hour/untreated time point, 
p21 expression did increase with prolonged cisplatin treatment. These results indicate 
endogenous wild type p53 activity in IOSE21-parental cell line. Conversely, IOSE21-R175H 
and IOSE21-R273H demonstrated sustained expression of recombinant mutant p53 in 
response to cisplatin treatment. IOSE21-R175H and IOSE21-R273H also failed to induce 
p21, indicating loss of wild type p53 activity in these cell lines.     
 
 
Figure 4.15: Cisplatin induced activation of p53 and p21 in IOSE21 cell lines  
A: Detection of p53 in IOSE21-parental, IOSE21-R175H and IOSE21-R273H cell lines following 48 hours 
cisplatin treatment. Top-most band of p53 staining is recombinant p53 whereas endogenous mutant p53 appears 
to be detected at a lower molecular weight. B: Detection of p21 in IOSE21-parental, IOSE21-R175H and 
IOSE21-R273H cell lines following 48 hours cisplatin treatment. 
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IOSE25 cells were treated with cisplatin for 72 hours rather than 48 due to decreased 
sensitivity relative to IOSE21 cell lines. IOSE25-parental cell line demonstrated increased 
expression of endogenous p53 in response to cisplatin treatment (Figure 4.16). IOSE25-
R273H demonstrated sustained expression of recombinant mutant p53, whereas IOSE25-
pWT failed to express or stabilise recombinant wild type p53 in response to cisplatin 
treatment. Failure to detect recombinant wild type p53 suggests IOSE25-pWT cells were not 
successfully transduced or have silenced transgene expression. As a result, this cell line was 
eliminated from further analysis. All IOSE25 cell lines demonstrated strong p21 expression at 
non-treated, zero hour cisplatin time point, which was subsequently reduced at 24 and 48 
hours, followed by an increase at 72 hours (Figure 4.16). This increase was greatest in the 
IOSE25-parental cell line, indicative of greater wild type p53 activity. To confirm this, 72-
hour p21 expression was quantified by densitometry (Figure 4.17). The results suggest some 
retention of wild type p53 activity in IOSE25-R273H cell line, but not as great as that of 
IOSE25-parental.   
 
 
Figure 4.16: Cisplatin induced activation of p53 and p21 in IOSE25 cell lines  
A: Detection of p53 in IOSE25-parental, IOSE25-R273H and IOSE25-pWT cell lines following 72 hours 
cisplatin treatment. Top-most band of p53 staining is recombinant p53 whereas endogenous mutant p53 appears 
to be detected at a lower molecular weight. B: Detection of p21 in IOSE25-parental, IOSE25-R273H and 
IOSE25-pWT following 72 hours cisplatin treatment. 
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Figure 4.17: Densitometry of p21 expression by IOSE25-parental and IOSE25-R273H cell lines 
Expression of p21 by IOSE25-parental and IOSE25-R273H cell lines following 72 hours cisplatin treatment. 
Expression determined relative to β-actin loading control. Densitometry performed on western blot presented in 
Figure 4.14-B. 
 
4.6 Transgene copy number 
During lentiviral transduction, multiple plasmid constructs can insert into the genome of a 
single cell. As a result, transgene copy number can vastly exceed that of endogenous, genomic 
TP53. To estimate transgene copy number, relative quantitative real time PCR (RTqPCR) was 
performed using genomic DNA. Endogenous, genomic TP53 was amplified using primers that 
annealed across intron 1, preventing amplification of cDNA transgene. TP53 transgene was 
detected using primers that annealed across exon-exon boundaries, preventing amplification 
of genomic TP53. IOSE21-R175H and IOSE21-R273H demonstrated 1-2 copies of transgene 
to every copy of genomic TP53 (Figure 4.18). IOSE25-R273H demonstrated a slightly lower 
transgene copy number, at 0-1 copies to every copy of genomic TP53. Overall, transduced 
IOSE cell lines demonstrated a ~1:1 ratio of transgene to endogenous, genomic TP53 (Figure 
4.19). 
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Figure 4.18: TP53 transgene copy number in IOSE21 cell lines 
Relative fold change of TP53 transgene compared to genomic TP53 in IOSE21 cell lines. No TP53 transgene is 
detected in IOSE21-parental cell line. 1-2 copies of TP53 transgene are detected to every copy of genomic TP53 
in IOSE21-R175H and IOSE21-R273H cell lines. Mean ± standard deviation, n=2. 
 
 
 
Figure 4.19: TP53 transgene copy number in IOSE25 cell lines 
Relative fold change of TP53 transgene compared to genomic TP53 in IOSE25 cell lines. No TP53 transgene is 
detected in IOSE25-parental cell line. 0-1 copy of TP53 transgene is detected to every copy of genomic TP53 in 
IOSE25-R273H cell line. Mean ± standard deviation, n=2. 
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4.7 Summary of results 
• IOSE21 cells were successfully transduced with R175H and R273H mutant TP53 
• IOSE25 cells were successfully transduced with R273H mutant TP53 
• The efficacy of transduction was higher in IOSE21 cell lines than IOSE25 
• Wild type transgene spontaneously mutated in IOSE21-pWT cells, generating 
recombinant mutant protein R273S 
• IOSE25-pWT cells failed to express recombinant wild type p53 in response to cell 
stress 
• IOSE25 endogenous mutant p53 could not be detected at the protein level 
• Expression of recombinant mutant p53 abolished or significantly reduced expression 
of p21 following cisplatin treatment 
• TP53 transgene was present in the transduced IOSE cells lines at a ~1:1 ratio with 
endogenous, genomic TP53 
 
 
IOSE21-
parental 
IOSE21-
R175H 
IOSE21-
R273H IOSE21-pWT 
Efficacy of transduction N.A 100% 95% N.A 
Transgene detected by 
sequencing N.A ✓ ✓ 
✓ (R273S 
mutation) 
Recombinant protein 
detected N.A ✓ ✓ 
✓ (R273S 
mutation) 
Transactivation of p21 
observed ✓ ✗ ✗ N.A 
Transgene copy number N.A 2- 3 copies 2-3 copies N.A 
Table 4.1: Summary of transduction data for IOSE21 cell lines 
Transgene and recombinant protein data for IOSE21 cell lines. ✓= detected/observed, ✗= not 
detected/observed.  
 
IOSE25-
parental 
IOSE25-
R273H 
IOSE25-
pWT 
Efficacy of transduction N.A 60% N.A 
Transgene detected by sequencing N.A ✓ ✓	
Recombinant protein detected N.A ✓ ✗ 
Transactivation of p21 observed ✓ ✓ (some) ✗ 
Transgene copy number N.A 0-2 copies N.A 
Table 4.2: Summary of transduction data for IOSE25 cell lines 
Transgene and recombinant protein data for IOSE25 cell lines. ✓= detected/observed, ✗= not 
detected/observed.  
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4.8 Discussion 
IOSE cell lines were successfully transduced with R175H and R273H mutant TP53. 
Sequencing of cell line genomic DNA confirmed the presence of TP53 cDNA transgene, and 
western blot and immunofluorescence data confirmed the expression of recombinant mutant 
p53 (Figures 4.3- 4.14). Efficacy of transduction was determined to be between 95-100% for 
IOSE21-R175H and IOSE21-R273H cell lines, and ~ 60% for IOSE25-R273H (Figure 4.10). 
The reduced efficacy of transduction for IOSE25-R273H is surprising considering blasticidin 
selection of stable clones. It is possible that a bystander effect may have taken place, in which 
transduced cells conferred antibiotic resistance to neighbouring, non-transduced cells. In the 
future it may be useful to clone out this cell line to isolate the transduced population.  
Transduction of IOSE cell lines with wild type TP53 proved unsuccessful. IOSE21-pWT cells 
demonstrated spontaneous mutation of the wild type transgene, resulting in the expression of 
R273S recombinant mutant p53 (Figures 4.3, 4.8-9, 4.11 & 4.13). IOSE25-pWT cells 
initially appeared successfully transduced, with sequencing data confirming genomic insertion 
and no mutant p53 detected in unstressed cells (Figures 4.4, 4.8-4.9, 4.12 & 4.14). However, 
upon cisplatin treatment, wild type recombinant p53 could not be detected in IOSE25-pWT 
cells, indicative of failure to express or stabilise wild type p53 (Figure 4.16: A). As a result, 
both IOSE21-pWT and IOSE25-pWT cells were excluded from further analysis. Inability to 
transduce cell lines with wild type TP53 could be a reflection of the detrimental effect of the 
overexpression of p53. The rapid turn over of p53 in normal cells would support this, with 
cells tightly controlling the activation and stabilisation of p53 [247]. This may have facilitated 
the selection of cells that silenced or mutated wild type transgene in IOSE21-pWT and 
IOSE25-pWT cell lines. Sequencing of IOSE21-pWT suggests some cells may possess un-
mutated transgene (a wild type cytosine allele peak can be observed in addition to the mutant 
adenine) that could be cloned out (Figure 4.3). However, if overexpression of wild type p53 
is detrimental to the cells, the transgene may be silenced or mutated again. In this respect, it is 
possible that further expansion of the cell line would eventually select out the wild type 
transduced population.  
In terms of p53 functional status, IOSE21-parental cells induced the stabilisation of 
endogenous p53 and transactivation of p21 in response to cisplatin treatment as expected 
(Figure 4.13). Recombinant mutant R175H and R273H p53 also appeared to function in the 
anticipated manner, demonstrating sustained expression and failure to transactivate p21 in 
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IOSE21-R175H and IOSE21-R273H cell lines (Figure 4.15). Failure to induce p21 suggests 
loss of wild type p53 activity. Loss of wild type p53 activity is commonly reported in 
heterozygous mutant TP53 cells, ascribing dominant-negative status to mutant p53 [248]. The 
active form of p53 is a tetramer, consisting of a dimer of a dimer [63]. Mutant TP53 supplies 
the tetramer with mutant monomers that impair wild type p53 function [133]. The high 
efficacy of transduction in IOSE21-R175H and IOSE21-R273H cell lines, coupled with 
transgene expression from a CMV promoter, would oversupply the cell with mutant p53 
monomers, outnumbering endogenous wild type and enhancing the dominant-negative effect. 
In this respect, the observation of loss of wild type p53 activity in IOSE21-R175H and 
IOSE21-R273H cell lines is as expected.  
Sequencing of endogenous TP53 confirmed previous reports that IOSE25 cells were 
heterozygous mutant R175H [222] (Figure 4.6). However, despite mutant gene status, 
endogenous mutant p53 could not be detected at the protein level (Figures 4.8 & 4.12). 
Failure to detect mutant p53 in TP53 mutant cells has previously been reported in several 
cancers, including 11% of TP53 mutant breast cancers [249]. Inability to detect mutant p53 
has also been observed in TP53 mutant mouse cell lines [250, 251]. In these cells, mutant p53 
was only detected upon prolonged exposure to cell stress, as mutant p53 demonstrated 
greater half-life than wild type p53. This is because during cell stress, mutant p53 fails to 
activate Mdm2 in a negative feedback loop. As a result, as basal levels of Mdm2 become 
insufficient to reduced levels of mutant p53 as quickly a p53 wild type, enabling prolonged 
accumulation of mutant protein [250]. As a result, increasing the duration of cisplatin 
treatment could increase the likelihood of detecting endogenous mutant p53 in IOSE25 cell 
lines.  
IOSE25-R273H demonstrated sustained expression of recombinant mutant p53 in response to 
cisplatin treatment as expected (Figure 4.16:A). Both IOSE25-parental and IOSE25-R273H 
cell lines demonstrated an initial decline prior to an increase in p21 expression at 72 hours 
(Figure 4.16:B). This increase was greatest in the IOSE25-parental cell line, although 
induction of p21 by IOSE25-R273H suggested retention of some wild type p53 activity. 
Considering the presence of both endogenous and transgenic mutant TP53, the retention of 
wild type p53 activity could be considered surprising. This is especially considering the 
dominant-negative effect of mutant p53. However, different TP53 mutations could have 
varying dominant-negative activity. For example, DNA binding mutants such as R273H 
appear less able to impair wild type p53 than other p53 mutants, with reports of up to three 
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mutant monomers required to inactive the p53 tetramer [252]. This may partially explain the 
retention of wild type p53 activity in IOSE25-R273H cell line. However, the expression of 
recombinant mutant p53 from a CMV promoter should, theoretically, oversupply cells with 
mutant p53. More likely, the retention of wild type p53 activity in IOSE25-R273H cell line is 
a reflection of the low transduction efficacy (Figure 4.10). Nearly 40% IOSE25-R273H cells 
do not express recombinant mutant p53 and would respond to cisplatin in a similar manner to 
IOSE25-parental cell line. IOSE25-R273H demonstrated reduced intensity of p21 expression 
at 72 hours compared to IOSE25-parental. This is likely a reflection of the percentage of 
successfully transduced cells failing to activate p21. Indeed, densitometry of the western blot 
confirms intensity of expression is roughly half that of the parental cell line, reflecting ~60% 
transduction efficacy (Figure 4.17). Although tempting to clone out transduced IOSE25-
R273H cells, the lower percentage of transduced cells may have serendipitously generated a 
model more reminiscent of pathological disease. If the R273H mutation is advantageous to the 
cells, the transduced mutant population could be selected out over the non-transduced, 
reflecting clonal evolution during tumourigenesis. In this respect, the presence of non-
transduced IOSE25-R273H population may serve as an internal control for the beneficial 
nature of recombinant mutant p53 in cell transformation. 
Plasmid copy number can influence transgene expression. During lentiviral infection it is 
possible for several plasmid constructs to insert into the genome of a single cell. This would 
increase transgene copy number relative to genomic TP53. IOSE21-R175H cells appeared to 
have 1-2 copies of transgene to every copy of genomic TP53. Comparatively, IOSE21-R273H 
cells appeared to have 0-1 copies of transgene to every copy of genomic TP53. Variation 
between the cell lines is probably a reflection of transduction efficacy, with non-transduced 
IOSE25-R273H cells lowering the average transgene copy number. Furthermore, the absence 
of absolute values is probably a reflection of intra cell line heterogeneity, with some cells 
harbouring a more or less transgene, impacting on the average value of transgene copy 
number. However, RTqPCR analysis revealed that overall, transduced IOSE cell lines 
demonstrated similar transgene copy number to genomic TP53  (~1:1 ratio). 
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4.9 Chapter summary 
IOSE cell lines were successfully transduced with R175H and R273H mutant TP53. Efficacy of 
transduction appeared greater in IOSE21 cell lines than IOSE25. This may enhance the 
transformative potential of recombinant mutant p53 in IOSE21-R175H and IOSE21-R273H 
cell lines relative to IOSE25-R273H. However, the mixed population of transduced and non-
transduced cells in IOSE25-R273H may provide a better model of tumourigenesis, by 
enabling clonal evolution of the cell line if the transgene proves beneficial. IOSE cells were 
not successfully transduced with wild type transgene. As a result, IOSE21-pWT and IOSE25-
pWT were excluded from further analysis. Methodology and cell lines examined in the 
subsequent chapter are outlined in Figure 4.20. 
 
 
Figure 4.20: Generation of IOSE cell lines examined for transformed traits 
Description of work to generate IOSE cell lines examined for the expression of transformed traits in chapter 5.  
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Chapter 5:  Assessment of transformed traits  
5.1 Introduction 
Tumour cells are associated with the expression of a number of traits not observed in normal 
cells. Acquisition of some or all of these traits is referred to as transformation and can be used 
to identify transformed cells [253]. To determine the transformative potential of recombinant 
mutant p53, IOSE cell lines were assessed for the transformed traits listed below: 
1. Anchorage independent growth 
2. Loss of contact inhibition 
3. Altered cell morphology 
4. Genomic instability 
5. Increased migration 
6. Increased proliferation 
7. Tumourigenicity in immunodeficient mice  
This chapter outlines the acquisition of transformed traits by IOSE cell lines and examines the 
role of mutant p53 in transformation. TOSE cells were included in the analysis as a 
comparison for IOSE25 cell lines and as a general positive control for many of the assays as 
previously reported [223]. 
 
5.2 Anchorage independent growth 
Anchorage independent growth describes the ability of a cell to proliferate in the absence of 
adherence to a cell surface substrate [254]. This characteristic is commonly assessed using the 
soft agar assay, in which cells are prevented from adhesion to a surface substrate by suspension 
in soft agar [254]. Only cells capable of anchorage independent growth will proliferate and 
form colonies in the agar. No colonies were observed for IOSE21-R273H, IOSE25-parental 
and IOSE25-R273H cell lines (Figure 5.1). IOSE21-parental and IOSE21-R175H formed 
colonies in soft agar, indicative of anchorage independent growth. IOSE21-R175H formed 
significantly more colonies than IOSE21-parental, matching that of TOSE1 and exceeding that 
of TOSE4 positive controls (Figure 5.2). IOSE21-R175H formed significantly larger colonies 
than IOSE21-parental, although not as large as TOSE1 or TOSE4 (Figure 5.2). IOSE21-
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R175H therefore demonstrated greater anchorage independent growth than IOSE21-parental, 
but not as great as TOSE1 or TOSE4.  
 
 
 
Figure 5.1: Anchorage independent growth of IOSE cell lines in soft agar 
Large, frequent colonies are observed in TOSE1 (F) and TOSE4 (G) positive control cell lines. Small, infrequent 
colonies are observed in IOSE21-parental cell line (A). Larger, more frequent colonies are observed in IOSE21-
R175H cell line (C). No colonies are observed in IOSE21-R273H (D), IOSE25-parental (B) and IOSE25-R273H 
(E) cell lines. Representative images of n=3. 
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Figure 5.2: Average number and size of soft agar colonies  
A: Average number of colonies formed in soft agar: IOSE21-R175H formed significantly more colonies than 
IOSE21-parental cell line, matching that of TOSE1 and exceeding that of TOSE4 positive control cell lines. 
Mean ± standard deviation, n=3. B: Average size (area) of colonies formed in soft agar: IOSE21-R175H formed 
significantly larger colonies than IOSE21-parental cell line, although not as large as TOSE1 or TOSE4 positive 
control cell lines. Median ± interquartile range, n=2. ***= p <0.001, **= p 0.001-0.01, *= p  0.01-0.05, ns= 
p>0.05. 
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5.3 Loss of contact inhibition 
Cell-cell contacts formed by a dense population of normal cells can inhibit further cell growth 
and migration [166]. This is more commonly referred to as contact inhibition. Cancer cells 
frequently demonstrate loss of contact inhibition, continuing to proliferate and migrate 
despite close proximity. To assess loss of contact inhibition, IOSE cell lines were seeded to the 
same cell density and pictures taken over 10 days to assess cell monolayer and foci formation 
(Figure 5.3). Dense cell monolayers are associated with loss of contact inhibition as cells 
acquire increased tolerance to cell proximity. Cell proximity can induce selective pressure for 
the isolation of non-contact inhibited cells, causing foci formation as non-contact inhibited 
cells undergo clonal expansion [255]. Foci formation is therefore indicative of cell lines 
experiencing contact inhibition. At day 1, IOSE cell lines appeared evenly distributed and 
proliferative. By day 5, all IOSE cell lines had reached ~100% confluence. By day 10, 
IOSE21-parental cell line formed a moderately dense cell monolayer in which a few cell foci 
could be observed. IOSE21-R175H and IOSE21-R273H cell lines formed a more compact, 
dense cell monolayer in which no cell foci could be observed. IOSE25-parental and IOSE25-
R273H cells lines failed to form dense cell monolayers, instead forming raised cell foci. 
TOSE1 and TOSE4 cell lines formed dense cell monolayers in which no cell foci were 
observed. The reduced monolayer and increased foci formation by IOSE21-parental and 
IOSE25 cell lines is indicative of contact inhibition. In comparison, dense cell monolayer and 
reduced foci formation by IOSE21-R175H, IOSE21-R273H and TOSE cell lines is indicative 
of delayed onset or loss of contact inhibition.  
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Figure 5.3: Cell monolayer and foci formation by IOSE cell lines 
Formation of cell monolayers and/or cell foci by IOSE21-parental (A-C), IOSE21-R175H (D-F), IOSE21-
R273H (G-I), IOSE25-parental (J-L), IOSE25-R273H (M-O), TOSE1 (P-O) and TOSE4 (S-U) cell lines over 10 
days. Representative images of n=3. 
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To confirm variation in the point of onset of contact inhibition, IOSE cell lines were cultured 
for two weeks and total viable cell counts taken every ~3 days. The plateau of the resulting 
growth curves provided an indication of the point at which cell lines were likely to have 
undergone contact inhibition. IOSE21-parental cell line plateaued earlier than IOSE21-R175H 
and IOSE21-R273H, between days 6 and 9 (Figure 5.4). Growth curves of IOSE21-R175H 
and IOSE21-R273H appeared not to plateau, demonstrating a slight increase in cell density 
between days 12 and 14. This is indicative of delayed onset, or loss of contact inhibition by 
IOSE21-R175H and IOSE21-R273H cell lines. IOSE25-parental, IOSE25-R273H and 
TOSE1/4 cell lines plateaued around day 9, although differing cell densities were achieved at 
the point of plateau. This suggests IOSE25 and TOSE cell lines may undergo contact inhibition 
at the same time, but the threshold of induction is likely to differ, with significantly greater 
cell density, and hence greater cell proximity, required to induce contact inhibition in TOSE 
cell lines.  
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Figure 5.4: Growth curves of IOSE and TOSE cell lines 
Growth curves of IOSE21 (A), IOSE25 (B) and TOSE (C) cell lines over 14 days. Total number of viable cells 
normalised to 24 hours. Plateau of growth curve indicative of cessation of proliferation. Mean ± standard 
deviation, n=3. 
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To assess variation in the threshold of induction of contact inhibition, IOSE cell lines were 
seeded to the same cell density and viable cell counts calculated after 9, 12 and 14 days in 
culture (Figure 5.5). IOSE21-R175H and IOSE21-R273H achieved significantly greater cell 
densities than IOSE21-parental cell line across all time points examined, with the exception of 
IOSE21-R273H day 9 count. This suggests the threshold of induction of contact inhibition is 
significantly greater in IOSE21-R175H and IOSE21-R273H cell lines than IOSE21-parental. 
IOSE21-R175H achieved significantly greater cell densities than IOSE21-R273H at day 9, 12 
and 14, indicative of greater tolerance to cell proximity than IOSE21-R273H. No significant 
difference in cell density was observed between IOSE25-parental and IOSE25-R273H cell 
lines, indicative of similar thresholds of induction of contact inhibition. TOSE cells achieved 
significantly greater cell densities than IOSE25 cell lines, with TOSE1 demonstrating greater 
cell densities than TOSE4. This suggests that the threshold of induction of contact inhibition is 
significantly greater in TOSE than IOSE25 cell lines, with TOSE1 achieving greater tolerance 
to cell proximity than TOSE4. IOSE21-R175H, IOSE21-R273H and TOSE cell lines 
therefore demonstrate delayed onset and higher threshold of induction of contact inhibition 
than their respective parental cell lines.  
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Figure 5.5: Day 9-14 IOSE and TOSE cell densities 
A: Density of IOSE21 cell lines: IOSE21-R175H and IOSE21-R273H achieved significantly greater cell densities 
than IOSE21-parental cell line across all time points examined, with the exception of IOSE21-R273H day 9 
counts. IOSE21-R175H consistently achieved significantly greater cell densities than IOSE21-R273H. Mean ± 
standard deviation, n=2. B: Density of IOSE25 and TOSE cell lines: No significant difference in cell density was 
observed between IOSE25-parental and IOSE25-R273H. TOSE1 and TOSE4 cells lines demonstrated 
significantly greater cell densities than IOSE25 and IOSE25-R273H across all time points examined. TOSE1 
achieved significantly greater cell densities than TOSE4. Mean ± standard deviation, n=2.  
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To confirm variation in induction of contact inhibition, IOSE cell lines were examined for the 
expression of contact inhibition associated marker β-galactosidase [256, 257]. To assess β-
galactosidase activity, IOSE cell lines were treated at day 9, 12 and 14 with X-gal. β-
galactosidase will hydrolyse X-gal, resulting in the generation of a blue substrate [257, 258] 
(Figure 5.6). To determine percentage positive β-galactosidase cells, DMSO was added to 
stained cells and absorbance read at 695nm (Figure 5.7). At day 9, IOSE21-R175H and 
IOSE21-R273H cell lines demonstrated significantly greater β-galactosidase activity than 
IOSE21-parental. At day 12, only IOSE21-R175H cell line demonstrated significantly greater 
β-galactosidase activity than IOSE21-parental, and by day 14, no significant difference was 
observed between IOSE21 cell lines. No significant difference was observed between IOSE21-
R175H and IOSE21-R273H cell lines across all time points examined. IOSE25-R273H cells 
demonstrated significantly greater β-galactosidase activity than IOSE25-parental cell line 
across all time points, exceeding that of TOSE4. No significant difference was observed 
between IOSE25-R273H and TOSE1 cell lines at day 9 and day 14. TOSE1 cell line 
demonstrated significantly greater β-galactosidase activity than TOSE4 at days 12 and 14. 
Overall, the data indicate increased β-galactosidase activity by transduced IOSE and TOSE cell 
lines. 
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Figure 5.6: IOSE cell line β-galactosidase activity at day 12  
β-galactosidase (blue) activity following 12 days in culture in IOSE21 (A), IOSE21-R175H (C), IOSE21-R273H 
(D), IOSE25 (B), IOSE25-R273H (E), TOSE1 (F) and TOSE4  (G) cell lines. Representative images of n=3. 
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Figure 5.7: Day 9-14 β-galactosidase activity 
A: IOSE21 cell lines β-galactosidase activity: IOSE21-R175H demonstrated significantly greater β-galactosidase 
activity than IOSE21-parental at day 9 and 12 but not day 14. IOSE21-R273H demonstrated significantly greater 
β-galactosidase activity than IOSE21-parental at day 9 but not day 12 or day 14. No significant difference was 
observed between IOSE21-R175H and IOSE21-R273H. Mean ± standard deviation, n=2. B: IOSE25 and TOSE 
cell lines β-galactosidase activity: IOSE25-R273H demonstrated significantly greater β-galactosidase activity 
across all time points examined. TOSE1 and TOSE4 cell lines demonstrated similar levels of β-galactosidase 
activity to IOSE25-parental cell line, with the exception of significantly greater activity by TOSE1 at day 9, and 
significantly less activity by TOSE4 at day 14. IOSE25-R273H demonstrated significantly greater β-galactosidase 
activity than TOSE1 cell line across all time points except day 12. IOSE25-R273H demonstrated significantly 
greater β-galactosidase activity than TOSE4 cell line across all time points examined. TOSE1 demonstrated 
significantly greater β-galactosidase expression than TOSE4 at day 12 and day 14 time points.  Mean ± standard 
deviation, n=2.  
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5.4 Cell morphology 
Transformed cells often demonstrate altered morphology; with tumour cells classically 
exhibiting a more rounded and condensed morphology. To assess morphological variation, 
IOSE cell lines were seeded to the same cell density and images taken 24 hours later (Figure 
5.8). Every cell that could be clearly discriminated was outlined in ImageJ and measured to 
assess average cell circularity and length [224]. IOSE21-R175H and IOSE21-R273H cell lines 
were significantly circular and shorter than IOSE21-parental, indicative of morphological 
transformation (Figure 5.9). No significant difference was observed between IOSE25-parental 
and IOSE25-R273H cell lines (Figure 5.10). TOSE cells were significantly more circular and 
shorter than IOSE25 cell lines, indicative of morphological transformation as previously 
reported (Dr Kyra Archibald, PhD thesis) (Figure 5.10). To further illustrate variations in 
IOSE and TOSE morphology, F-actin filaments were Phalloidin stained (Figure 5.11). F-actin 
staining supported variation in IOSE and TOSE morphology as described above.  
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Figure 5.8: Morphology of IOSE cell lines  
Images of IOSE21 (A), IOSE21-R175H (C), IOSE21-R273H (D), IOSE25 (B), IOSE25-R273H (E), TOSE1 (F) 
and TOSE4  (G) cell lines used to assess average circularity and cell length (Figures 5.8-5.9). Representative 
images of n=3. 
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Figure 5.9: Morphology of IOSE21 cell lines 
A: Average cell circularity: IOSE21-R175H and IOSE21-R273H cell lines were significantly more circular than 
IOSE21-parental (complete circle=1). IOSE21-R175H cell line was significantly more circular than IOSE21-
R273H. Median, ± interquartile range, n=3. B: Average cell length: IOSE21-R175H and IOSE21-R273H cell 
lines were significantly shorter than IOSE21-parental. No significant difference was observed between IOSE21-
R175H and IOSE21-R273H cell lines. Median, ± interquartile range, n=3. ***= p <0.001, **= p 0.001-0.01, 
*= p 0.01-0.05, ns= p>0.05. 
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Figure 5.10: Morphology of IOSE25 cell lines 
A: Average cell circularity: TOSE1 and TOSE4 were significantly more circular than IOSE25 cell lines (complete 
circle=1). No significant difference was observed between IOSE25-parental and IOSE25-R273H cell lines. No 
significant difference was observed between TOSE1 and TOSE4 cell lines. B: Average cell length: TOSE1 and 
TOSE4 were significantly shorter than IOSE25 cell lines. No significant difference was observed between 
IOSE25-parental and IOSE25-R273H cell lines. No significant difference was observed between TOSE1 and 
TOSE4 cell lines. Median, ± interquartile range, n=3. ***= p <0.001, **= p 0.001-0.01, *= p 0.01-0.05, ns= 
p>0.05. 
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Figure 5.11: F-actin staining of IOSE and TOSE cell lines 
Nuclear DAPI stain (blue) and F-actin stain (Red) of IOSE21 (A-I), IOSE25 (J-O) and TOSE (P-U) cell lines. 
Representative images of n=2.   
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5.5 Genomic instability 
Cancer cells are associated with an increased frequency of genetic alterations [166]. This is 
referred to as genomic instability and can be divided into 3 major subtypes: nucleotide, 
microsatellite and chromosome instability. The latter is most commonly documented and 
refers to a high frequency of structural and numerical chromosome alterations. Chromosome 
instability can be readily detected by karyotype analysis, and was performed in collaboration 
with Marianne Grantham at The Royal London Hospital, Cytogenetics Department.   
IOSE21 cell lines demonstrated an enlarged chromosome 1 centromere (1q12) thought to be 
an extreme normal variant. IOSE21-parental cell line demonstrated a stable, normal 
karyotype (46, XX) indicative of no chromosome instability (Figure 5.12). In comparison, 
IOSE21-R175H demonstrated an unstable, abnormal karyotype, displaying significant cell-cell 
variation indicative of chromosome instability [259]. To generate a representative karyotype 
for IOSE21-R175H cell line, whole chromosome gains and structural alterations were scored 
if observed in at least 2 metaphase spreads, and chromosome deletions if observed in at least 
3. The most consistent alterations were trisomy 5 and 19, resulting in the composite 
karyotype 48, XX, +5, +19 (Figure 5.13- 5.14). IOSE21-R273H also demonstrated an 
abnormal karyotype of 47, XX +5 [5] (Figure 5.15). The karyotype appeared stable as no 
variation was observed between metaphase spreads, indicative of no chromosome instability. 
IOSE21-R175H is therefore the only IOSE21 cell line to demonstrate genomic instability.  
IOSE25-parental cell line demonstrated significant structural and numerical chromosome 
alterations with large cell-cell variation indicative of chromosome instability. A near-diploid 
population with near-triploid sideline clone was detected, indicative of clonal evolution. The 
near-diploid population demonstrated additional material of unknown origin on the short arm 
of chromosome 8, loss of chromosomes 4, 10 and 19, and four marker chromosomes of 
unknown origin. The near-triploid population demonstrated extra copies of chromosomes X, 
2, 3, 7, 8, 9, 14, 18, 19 and 22, loss of chromosomes 11 and 16, and an isochromosome of 
the long arm of chromosome 17 (Figure 5.16). Due to poor chromosome morphology and 
significant cell-cell variation, an incomplete, composite karyotype was generated based on 
both the near-diploid and the near-triploid populations: - 45, XX, -4, -10, add(8)(p1), -19, 
+4 mar[1]/ 77 <3n>, XXX, +X, +2, +3, +7, +8, add(8)(p1), +9, -11, +14, -16, 
i(17)(q10), +18, +19, +22, +4mar, inc[cp5].  
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Similar to IOSE25-parental, IOSE25-R273H also demonstrated structural and numerical 
chromosome alterations with large cell-cell variation indicative of chromosome instability. 
However, in contrast to IOSE25-parental, a single, complex near-triploid clone was detected 
in IOSE25-R273H. The population demonstrated additional material of unknown origin on 
the short arm of chromosome 3, extra copies of chromosomes 3, 7, 8, 10, 12, 14, 18, 19, 20, 
21 and 22, loss of chromosomes 11, 13 and 16, and two copies of a structurally abnormal 
chromosome 8 with material of unknown origin on the short arm (Figure 5.17). As the 
chromosome number varied between 73-78, a composite karyotype was generated based on 
the triploid number of chromosomes (69 chromosomes): 73~78 <3n>, XXX, +3, 
add(3)p13), +7, +8, add(8)(p1)x2, +10, -11, +12, -13, +14, -16, +18, +19, +20, +21, 
+22, inc[cp15]. The cytogeneticist’s opinion was that this cell line demonstrated slightly 
greater structural alterations than IOSE25-parental. As a result, IOSE25-R273H demonstrates 
slightly greater genomic instability than IOSE25-parental cell line.  
 
Figure 5.12: Karyotype of IOSE21-parental cell line 
Chromosomes from a metaphase spread of an IOSE21-parental cell. Chromosomes arranged in order from 
chromosome 1-22, X and Y. The cell demonstrates a normal karyotype (46, XX), representative of the whole 
cell line. IOSE21 cells also demonstrated and enlarged chromosome 1 centromere, possibly an extreme normal 
variant.  
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Figure 5.13: Karyotype of IOSE21-R175H cell line 
Chromosomes from a metaphase spread of an IOSE21-R175H cell. Chromosomes arranged in order from 
chromosome 1-22, X and Y. The cell demonstrates an abnormal karyotype, with trisomy 5 and 19 representative 
of the composite karyotype 48, XX +5, +19. The cell also demonstrates loss of chromosome 16, although this 
was not observed in other cells. An enlarged chromosome 1 centromere as also detected, as observed in other 
IOSE21 cell lines.  
 
 
Figure 5.14: Incidence of trisomy 5 and 19 in IOSE21-R175H cell line 
A: Incidence of trisomy 5 across karyotyped IOSE21-R175H cells. B: Incidence of trisomy 19 across karyotyped 
IOSE21-R175H cells. Trisomy was incorporated into the composite karyotype if detected in 2 or more cells.  
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Figure 5.15: Karyotype of IOSE21-R273H cell line 
Chromosomes from a metaphase spread of an IOSE21-R273H cell. Chromosomes arranged in order from 
chromosome 1-22, X and Y. The cell demonstrates a stable, abnormal karyotype, showing trisomy 5 (47, XX, 
+5). An enlarged chromosome 1 centromere is detected, as observed in other IOSE21 cell lines.  
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Figure 5.16: Karyotype of IOSE25-parental cell line 
Chromosomes from a metaphase spread of an IOSE25-parental cell. Chromosomes arranged in order from 
chromosome 1-22, X and Y. The cell demonstrates an abnormal karyotype, representative of the near-triploid- 
composite karyotype. Additional marker (‘mar’) chromosomes are detected that cannot be classified due to 
severe structural abnormalities. 
 
 
 
 
 
 
 
 123 
 
 
 
 
 
 
Figure 5.17: Karyotype of IOSE25-R273H cell line 
Chromosomes from a metaphase spread of an IOSE25-parental cell. Chromosomes arranged in order from 
chromosome 1-22, X and Y. The cell demonstrates an abnormal, near-triploid karyotype, with significant 
structural and numerical chromosome alterations.  
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5.6 Increased migration  
Malignant cells are associated with increased migration. To determine the migratory potential 
of IOSE cell lines, scratch assays were performed. In this assay, cells are grown to confluence 
prior to a scratch or ‘wound’ being inflicted in the cell monolayer. The physical space 
provided by the wound creates an area into which cells can migrate. The rate at which the 
‘wound’ is recovered is indicative of cell migratory potential. IOSE21-R175H and IOSE21-
R273H cell lines achieved significantly greater percentage closure at 5 hours post-scratch than 
IOSE21-parental cell line, indicative of greater migratory behaviour (Figure 5.18). IOSE21-
R175H achieved significantly greater percentage closure than IOSE21-R273H, indicative of 
greater migratory potential (Figure 5.18). IOSE25 cell lines responded poorly to the initial 
media change post-scratch, delaying assessment of percentage closure to 12 hours. No 
significant difference in percentage closure was observed between IOSE25-parental and 
IOSE25-R273H cell lines, suggestive of similar migratory behaviour (Figure 5.19). TOSE1 
cells demonstrated significantly greater percentage closure than IOSE25-parental cell line, 
whereas TOSE4 cells demonstrated significantly less. Interestingly, no significant difference 
was observed between IOSE25-R273H and TOSE cell lines, suggesting that IOSE25-R273H 
may demonstrate a trend towards slightly greater migration than IOSE25-parental. 
IOSE and TOSE cell lines also demonstrated variation in cell migratory style to recover the 
scratch. TOSE cells demonstrated cohesive migration, forming a distinct leading edge from 
which the scratch was recovered (Figure 5.19). IOSE21-parental and IOSE25 cell lines 
demonstrated single cell migration, failing to form a leading edge and moving into the gap as 
single cells. IOSE21-R175H and IOSE21-R273H cell lines formed an intermediate migratory 
style, demonstrating some cohesive migratory behaviour but not as defined as TOSE1 and 
TOSE4 cell lines (Figure 5.18).  
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Figure 5.18: Scratch assay- IOSE21 cell lines 
A: IOSE21 cell lines post-scratch: Images at 0, 5 and 24 hours post-scratch. A more defined leading edge is 
observed in IOSE21-R175H and IOSE21-R273H cell lines. Representative images of n=3. B: Percentage closure 
5 hours post-scratch: IOSE21-R175H and IOSE21-R273H demonstrated significantly greater percentage closure 
at five hours post-scratch than IOSE21-parental cell line (p=<0.001). Mean ± standard deviation, n=3. ***= p 
<0.001, **= p 0.001-0.01, *= p 0.01-0.05, ns= p>0.05. 
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Figure 5.19: Scratch assay- IOSE25 and TOSE cell lines 
A: IOSE25 cell lines post-scratch: Images at 0, 5 and 24 hours post-scratch. A more defined leading edge is 
observed in TOSE1 and TOSE4 cell lines. Representative images of n=3. B: Percentage closure 12 hours post-
scratch: No significant difference in percentage closure is observed between IOSE25-parental and IOSE25-
R273H cell lines. IOSE25-parental exhibits significantly less percentage closure than TOSE1, although no 
significant difference is observed relative to TOSE4. No significant difference is observed between IOSE25-
R273H and TOSE cell lines. TOSE1 exhibits significantly greater percentage closure than TOSE4. Mean ± 
standard deviation, n=3. ***= p <0.001, **= p 0.001-0.01, *= p 0.01-0.05, ns= p>0.05. Non-capped 
statistics are relative to IOSE25-parental cell line.  
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The density of cells required to perform the scratch assay could influence cell migratory 
behaviour. As a result, cell migration was also assessed using the transwell migration assay 
(Figure 5.20). In this assay, non-confluent cells were examined for migration through a 
porous membrane (8µm diameter pores) from supplement and serum free medium, towards 
complete medium. Migratory cells were crystal violet stained and absorbance read at 595nm. 
IOSE21-R175H and IOSE21-R273H cell lines demonstrated greater migration than IOSE21-
parental, and IOSE21-R273H demonstrated slightly greater migration than IOSE21-R175H. 
IOSE25-R273H demonstrated significantly greater migration than IOSE25-parental, and 
TOSE4 demonstrated significantly greater migration than TOSE1, but both TOSE cell lines 
demonstrated greater migration than IOSE25 cell lines. These results, in conjunction with 
scratch assay analysis, suggest IOSE21-R175H, IOSE21-R273H and IOSE25-R273H 
demonstrate greater migratory behaviour than their respective parental cell lines. TOSE1 and 
TOSE4 also demonstrate greater migration than IOSE25-parental as previously reported (Dr 
Kyra Archibald, PhD thesis), but TOSE1 demonstrate greater migratory behaviour than 
TOSE4.  
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Figure 5.20: Transwell migration of IOSE and TOSE cell lines 
Migration of IOSE21 (A), IOSE25 and TOSE (B) cell lines from serum and supplement free medium towards 
complete culture medium. Mean ± standard deviation, n=3. ***= p <0.001, **= p 0.001-0.01, *= p 0.01-
0.05, ns= p>0.05. 
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5.7 Increased proliferation 
Malignant cells are commonly associated with increased proliferation [166]. To assess the 
growth rate of IOSE cell lines, IOSE cells were seeded at low cell density and viable cell 
counts calculated every 3 days. The exponential growth phase of IOSE cells was determined to 
be between days 1- 9. IOSE21-R175H and IOSE21-R273H demonstrated significantly greater 
proliferation than IOSE21-parental cell line (Figure 5.21). IOSE25-R273H cells grew 
significantly slower than IOSE25-parental, and TOSE cell lines demonstrated the greatest 
proliferation of the cell lines examined (Figure 5.21).  
 
 
Figure 5.21: Exponential growth of IOSE cell lines 
A: Growth of IOSE21 cell lines: IOSE21-R175H and IOSE21-R273H grew significantly faster than IOSE21-
parental cell line. Mean ± standard deviation, n=2. B: Growth of IOSE25 and TOSE cell lines: IOSE25-R273H 
grew significantly slower than IOSE25-parental cell line. TOSE cells grew significantly faster than IOSE25 cell 
lines. No significant difference was observed between TOSE1 and TOSE4. Mean ± standard deviation, n=3. 
***= p <0.001, **= p 0.001-0.01, *= p 0.01-0.05, ns= p>0.05. 
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5.8 Tumourigenicity in immunodeficient mice  
Cells are classified as malignant upon demonstration of tumourigenicity in a suitable animal 
host. To determine the tumourigenic potential of IOSE cell lines, 5x106 cells were 
subcutaneously injected into NOD-SCID immunodeficient mice. Due to the expense of 
working with this animal model, not all IOSE cell lines could be examined. As IOSE21-
R175H demonstrated the greatest acquisition of transformed traits so far, only IOSE21-
R175H was selected for analysis and compared to IOSE21-parental cell line. Animals were 
monitored for 9 weeks post-transplantation but no tumours were observed.  
 
5.9  Summary of results 
IOSE cell lines were examined for the expression of a number of transformed traits. A 
summary of the results is presented in Table 5.1. IOSE21-R175H and IOSE21-R273H 
demonstrated greater acquisition of transformed traits than IOSE21-parental cell line. 
IOSE21-R175H demonstrated greater acquisition of transformed traits than IOSE21-R273H. 
IOSE25-R273H failed to demonstrate increased acquisition of transformed traits relative to 
IOSE25-parental cell line, with the possible exception of increased migration.  
 
 
Trait 
Relative to IOSE21-parental Relative to IOSE25-parental 
IOSE21-R175H IOSE21-R273H IOSE25-R273H TOSE1 TOSE4 
Anchorage independence ✓ ✗ ✗ ✓ ✓ 
Loss of contact inhibition ✓ ✓ ✗ ✓ ✓ 
Altered morphology ✓ ✓ ✗ ✓ ✓ 
Genomic instability ✓ ✗ ✓ ✓ ✓ 
Increased migration ✓ ✓ ✓ ✓ ✓ 
Increased proliferation ✓ ✓ ✗ ✓ ✓ 
Tumourigenicity in mice ✗ N.A N.A ✗ ✗ 
 
Table 5.1: Acquisition of transformed traits by transduced IOSE and TOSE cell lines 
Expression of transformed traits by transduced IOSE and TOSE cell lines relative to non-transduced, parental 
control. ✓= acquisition of/increased expression of transformed trait relative to parental cell line, ✗= 
equal/reduced expression of transformed trait relative to parental cell line. TOSE1/4 were previously reported 
to be genomically unstable and not form tumours in immunodeficient mice [222]. 
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5.10  Discussion 
IOSE cell lines were assessed for the acquisition of a number of transformed traits in attempt 
to determine the transformative potential of mutant p53. The traits examined are discussed 
below. 
 
5.10.1 Anchorage independent growth 
Anchorage independent growth defines the ability of a cell to proliferate in the absence of 
adherence to a surface substrate [254]. Of the IOSE cell lines, only IOSE21-parental and 
IOSE21-R175H formed colonies in soft agar, indicative of anchorage independent growth 
(Figure 5.1). IOSE21-R175H formed significantly larger, more frequent colonies than 
IOSE21-parental, indicative of greater anchorage independent growth than IOSE21-parental 
cell line (Figure 5.2). The number of IOSE21-R175H colonies exceeded that of TOSE4 and 
matched that of TOSE1 positive control cell lines, although TOSE cells formed significantly 
larger colonies than IOSE21-R175H. Disparity in colony size could be due to variation in cell 
proliferation. Adhered IOSE21-R175H cells proliferate faster than IOSE21-parental, and 
TOSE cells faster than IOSE21-R175H (Figure 5.19). Enhanced colony size could therefore be 
a reflection of propensity for cell proliferation rather than increased anchorage independent 
growth. In this respect, colony number may better reflect acquisition of the transformed trait 
than colony size. Regardless, IOSE21-R175H demonstrated greater anchorage independent 
growth than IOSE21-parental cell line, indicative of greater transformation.  
Anchorage independent growth reflects propensity to bypass anoikis, a subset of apoptosis 
triggered by inadequate or inappropriate cell matrix contact [254, 260, 261]. Anoikis is 
reported to occur by intrinsic or extrinsic apoptotic pathways [254]. Activation of p53 is 
classically associated with the intrinsic pathway, although p53 regulated genes are also 
implicated in the extrinsic pathway [262]. As a result, loss of wild type p53 could be 
associated with the induction of anchorage independent growth. Increased anchorage 
independent growth by p53 mutant IOSE21-R175H, TOSE1 and TOSE4 cell lines would 
support this. However, IOSE21-parental cell line demonstrated soft agar colony formation 
despite wild type p53 status, and IOSE21-R273H and IOSE25 cell lines failed to form colonies 
despite mutant p53 status (Figure 5.1). This suggests that although there may be an association 
between mutant p53 and anchorage independent growth, other mutations are likely to 
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influence acquisition of the transformed trait. Indeed, constitutive activation of PI3K/AKT 
pathway is the most common mechanism of anoikis resistance [261]. The significance of other 
mutations to anchorage independent growth is supported by disparity in colony formation by 
TOSE cell lines. TOSE1 demonstrated significantly greater anchorage independent growth 
than TOSE4 despite both cell lines expressing of R273H mutant p53. In this respect, the data 
can be used to demonstrate that IOSE21-R175H had acquired a more transformed phenotype 
than IOSE21-parental, but not comment on the role of mutant p53 in acquisition of the 
transformed trait.  
 
5.10.2 Loss of contact inhibition 
Cell-cell contacts formed by dense populations of normal cells suppress further cell growth 
and migration [166]. This is more commonly referred to as contact inhibition, or more 
specifically, contact inhibition of proliferation (CIP) and locomotion (CIL) [255, 263]. Cancer 
cells classically demonstrate loss of contact inhibition, continuing to proliferate and migrate 
despite close proximity. Loss of CIP and CIL can be assessed by monolayer and cell foci 
formation. Dense cell monolayers are associated with loss of contact inhibition as cells acquire 
increased tolerance to cell proximity. Cell proximity can induce selective pressure for the 
isolation of non-contact inhibited cells, resulting in foci formation as non-contact inhibited 
cells undergo clonal expansion [255]. Foci formation is therefore indicative of cells 
experiencing contact inhibition. IOSE21-parental and IOSE25 cell lines demonstrated reduced 
monolayer and increased foci formation, indicative of contact inhibition. IOSE21-R175H, 
IOSE21-R273H and TOSE cell lines demonstrated more compact, dense cell monolayers in 
which no cell foci were observed. This is indicative of delayed onset, or loss of contact 
inhibition. To assess variation in the onset of contact inhibition, growth curves of IOSE cells 
line were examined.  
Induction of contact inhibition is demonstrated by growth curve plateau, as cells enter 
reversible cell cycle arrest, inhibiting exponential growth [255, 264]. Growth curves of 
IOSE21-parental cell line plateaued earlier than IOSE21-R175H and IOSE21-R273H cell 
lines, indicative of earlier onset of contact inhibition. Indeed, growth curves of IOSE21-
R175H and IOSE21-R273H appeared not to plateau, demonstrating a slight increase in cell 
density between days 12 and 14, indicative of loss of contact inhibition. IOSE25-parental, 
IOSE25-R273H and TOSE cell lines plateaued around day nine, although differing cell 
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densities were achieved at the point of plateau. This suggests IOSE25 and TOSE cell lines 
undergo contact inhibition at the same time, but the threshold of induction is likely to differ, 
with significantly greater cell density, and hence greater cell proximity, required to induce 
contact inhibition in TOSE cell lines. 
To confirm variation in the threshold of induction of contact inhibition, cell density at the 
point of plateau was assessed. IOSE21-R175H and IOSE21-R273H cell lines achieved 
significantly greater cell densities than IOSE21-parental, indicative of greater threshold of 
induction of contact inhibition (Figure 5.5). TOSE cell lines demonstrated significantly greater 
cell densities than IOSE25 cell lines, indicative of greater threshold of induction of contact 
inhibition (Figure 5.6). The enhanced proliferate rate of TOSE cells is likely to account for 
their ability to achieve the higher cell densities required to induce contact inhibition at the 
same time point as less proliferative, lower density of induction IOSE25 cell lines. IOSE21-
R175H, IOSE21-R273H and TOSE cell lines therefore demonstrate greater loss of contact 
inhibition than their respective parental cell lines.  
Variation in the onset and threshold of induction of contact inhibition could be due to cell 
morphology. IOSE21-R175H, IOSE21-R273H and TOSE cell lines demonstrate significantly 
more circular and less elongated morphologies than IOSE21-parental and IOSE25 cell lines 
(Figure 5.8- 5.10). These compact morphologies could enhance monolayer formation, as 
more cells are able to occupy the physical space. Increased tolerance to cell proximity could 
therefore be the reflection of reduced physical constraint, facilitated by cell morphology.   
To confirm variation in onset of contact inhibition, IOSE cells lines were examined for β-
galactosidase activity. Interestingly, IOSE21-R175H, IOSE21-R273H and IOSE25-R273H cell 
lines demonstrated greater β-galactosidase activity than their respective parental cell lines 
(Figure 5.7). This would appear to contradict previous contact inhibition data by suggesting 
IOSE21-R175H, IOSE21-R273H and IOSE25-R273H cell lines undergo earlier onset or 
experience greater contact inhibition than their respective parental cell lines. However, β-
galactosidase activity was assessed at pH6.0, a condition more commonly associated with 
senescence associated β-galactosidase (SA-β-galactosidase) than β-galactosidase [265]. 
Although variation between SA-β-galactosidase and β-galactosidase is unclear, activity of the 
latter is more commonly reported at ~pH4.5, with markedly lower activity observed at 
pH6.0 [266]. In this respect, IOSE cell lines have been examined for SA-β-galactosidase rather 
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than β-galactosidase. SA-β-galactosidase is not detected in pre-senescent, quiescent or 
immortal cells [267]. Contact inhibition is associated with reversible cell cycle arrest, 
reminiscent of quiescence. The data acquired may therefore reflect percentage senescent cells 
rather than percentage contact inhibited. Although deviating from the original experimental 
aim, this suggests IOSE21-R175H, IOSE21-R273H and IOSE25-R273H cell lines experience 
greater cellular senescence than their parental cell lines. This could be due to increased 
mitotic catastrophe resulting from greater genomic instability (Figures 5.12-17) [268]. 
Indeed, IOSE21-R175H and IOSE25-R273H demonstrated greater genomic instability than 
their respective parental cell lines. However, TOSE and IOSE25-parental cell lines also 
demonstrated genomic instability, but did not demonstrate high SA-β-galactosidase activity. It 
also seems contradictory that IOSE21-R175H and IOSE21-R273H cell lines could be more 
proliferative, and simultaneously more senescent. It is possible that genomic instability could 
increase cellular heterogeneity, enabling a population of cells to acquire enhanced 
proliferation, and concurrently a population of cells that induce cellular senescence. The data 
may therefore reflect cell line heterogeneity- although without further investigation, this is 
difficult to determine.  
Contact inhibition of locomotion (CIL) refers to directional change in cell migration upon 
contact with another cell [269, 270]. The typical sequence of events are: i) cell-cell contact, ii) 
inhibition of cell protrusion at the site of contact, iii) generation of cell protrusion away from 
the site of contact, iv) migration in the direction of the new protrusion [263]. This sequence of 
events classically refers to the collision of single cells. In a cell monolayer, locomotion of cells 
at the centre is entirely inhibited as cell-cell adhesion prevents protrusion in any direction 
[263, 270]. Only cells at the exposed edge of a monolayer will be able generate protrusions 
orientated towards the exposed space. This results in a form of directional migration referred 
to as cohesive migration, in which cells remain physically connected through cell junctions and 
migrate via a leading edge in a singular direction [271]. This can be observed in the scratch 
assay, in which IOSE21-R175H, IOSE21-R273H and TOSE cell lines demonstrated greater 
cohesive migration than IOSE21-parental and IOSE25 cell lines (Figure 5.18-5.19). This 
suggests IOSE21-parental and IOSE25 cell lines experience less CIL, reducing cohesive 
migration. Reduction in CIL is likely a reflection of the inability of IOSE21-parental and 
IOSE25 cell lines to form dense cell monolayers. Reduced monolayer formation is associated 
with decreased cell-cell adhesion, promoting cellular transformation [271]. The apparent 
increase in cell-cell adhesion by IOSE21-R175H, IOSE21-R273H and TOSE cells could 
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therefore be considered surprising. However, contrary to most epithelial cancers, ovarian 
cancer has been associated with increased expression of cell-cell adhesion markers such as E-
cadherin [272-275]. Most cancers undergo epithelial to mesenchymal transition (EMT), down 
regulating E-cadherin and up-regulating the expression of mesenchymal markers such as N-
cadherin [276]. As a result, ovarian cancer is often associated with mesenchymal to epithelial 
transition (MET) [271]. Adoption of a more epithelial phenotype would increase cell-cell 
adhesion and thereby propensity for CIL and cohesive migration [277]. This may seem 
counterintuitive, as cancer dissemination is more commonly associated with mesenchymal 
traits. However, cohesive migration has been associated with increased invasive potential 
[271]. Increased expression of epithelial cell characteristics by IOSE21-R175H and IOSE21-
R273H cell lines could therefore be indicative of greater transformation. Increased epithelial 
expression is supported by the adoption of more rounded morphologies by IOSE21-R175H, 
IOSE21-R273H and TOSE cell lines (Figures 5.8- 5.10). To verify these observations, cell 
lines could be examined for the expression of epithelial-mesenchymal markers N-cadherin and 
E-cadherin.  
Increasing cell density induces cell stress, resulting in the activation of wild type p53, 
promoting cell cycle arrest [264]. As a result, loss of wild type p53 could promote loss of 
contact inhibition. Increased cell density and delayed onset of contact inhibition in p53 mutant 
cell lines IOSE21-R175H, IOSE21-R273H, TOSE1 and TOSE4 would support this (Figures 
5.4- 5.5). However, despite the presence of mutant p53, IOSE25 cell lines demonstrated 
similar onset of contact inhibition and cell density to p53 wild type cell line, IOSE21-parental. 
Data could be reconciled by correlation to specific p53 mutation. Indeed, IOSE21-R175H 
demonstrated significantly greater cell densities than IOSE-R273H, indicative of greater 
threshold of induction of contact inhibition. However, R273H mutant TOSE cells 
demonstrated greater loss of contact inhibition than their derivative R175H mutant IOSE25-
parental cell line. Loss of contact inhibition can therefore not be directly correlated to 
expression of mutant p53 or to specific TP53 mutations. As a result, the data indicates 
IOSE21-R175H and IOSE21-R273H demonstrate greater loss of contact inhibition relative 
IOSE21-parental cell line, but cannot verify the role of mutant p53 in the acquisition of the 
transformed trait. 
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5.10.3 Cell morphology 
Morphological variation is often used to discriminate cancer cells from normal cells [278]. 
IOSE21-R175H and IOSE21-R273H demonstrated significantly more circular, less elongated 
morphologies than IOSE21-parental cell line, indicative of transformation (Figure 5.9). 
IOSE21-R175H demonstrated a significantly more circular morphology than IOSE21-R273H 
cell line, indicative of greater transformation (Figure 5.9). TOSE cells demonstrated a 
significantly more circular and less elongated morphology than IOSE25 cell lines, although no 
significant difference was observed between IOSE25-parental and IOSE25-R273H cell lines 
(Figure 5.10) [223]. It is important to remember that cell culture conditions are likely to 
influence cell morphology. Cell substrate has a significant impact on cytoskeletal structure and 
IOSE cell lines were examined on tissue culture plastic- a substrate significantly stiffer than 
any living tissue [279, 280]. Morphological analysis on different cell substrates and could 
therefore yield further analysis of cell shape.  
Morphological transition by IOSE21-R175H, IOSE21-R273H and TOSE cell lines suggests an 
association between mutant p53 and cell morphology. Wild type p53 regulates the expression 
of Rho-GTPases, critical mediators of cell shape [281]. Loss of p53 induces activation of Rho-
GTPases cdc42 and RhoA, promoting cell circularity as observed in p53 mutant IOSE cell 
lines [282, 283]. Mutant p53 therefore influences the acquisition of the transformed trait. 
However, TOSE cells demonstrated increased circularity and reduced cell length relative to 
p53 mutant IOSE25 cell lines (Figure 5.10). This suggests other molecular events are required 
in addition to mutant p53 to enhance morphological transformation. In this respect, mutant 
p53 increases the acquisition of the transformed trait but other molecular events are likely to 
influence cell morphology. 
 
5.10.4 Genomic instability 
Genomic instability is a major hallmark of cancer and is particularly prevalent in HGSC [166, 
284]. Genomic instability can mediate tumour evolution by the generation of genetic variation 
necessary to adapt to selective pressure [166, 285]. As a result, genomic instability frequently 
correlates with tumour progression and poor prognosis [286, 287]. The trait encompasses a 
number of genetic alterations, which can be divided into 3 major subtypes: nucleotide, 
microsatellite and chromosome instability [288]. Nucleotide instability refers to an increase in 
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DNA mutations as a result of defective DNA repair. Microsatellite instability refers to an 
increase microsatellite alterations as a result of defective mismatch repair. Chromosome 
instability refers to acceleration in structural and numerical chromosome alterations, resulting 
in the gain or loss of whole chromosomes (aneuploidy), inversions, deletions, duplications and 
translocations of chromosome regions. Chromosome instability can be readily detected by 
karyotype analysis and is the most commonly documented of the subtypes.  
IOSE21-parental cell line demonstrated a normal 46, XX karyotype, indicative of no 
chromosome instability (Figure 5.12). IOSE21-R175H cell line demonstrated an abnormal 
karyotype, with cell-cell variation indicative of chromosome instability. The most consistent 
alterations were trisomy 5 and 19, resulting in the composite karyotype 46, XX, +5, +19 
(Figure 5.13). Trisomy 5 was also observed in IOSE21-R273H cell line, although the 
karyotype appeared stable (Figure 5.15). This suggests that although chromosomal instability 
may have occurred during acquisition of the supernumerary chromosome, chromosome 
instability is not on going. As a result, only IOSE21-R175H cell line demonstrated acquisition 
of the transformed trait.  
IOSE25-parental cell line could be divided in two populations: a population of cells with a 
near diploid karyotype, and a population of cells with a near-triploid karyotype (Figure 5.16). 
Only the latter was observed in derivative IOSE25-R273H cell line, indicative of greater 
genomic instability (Figure 5.17). This is supported by the slight increase structural 
chromosome alterations observed in the IOSE25-R273H cell line (communications with 
cytogeneticist). However, IOSE25-R273H was generated by clonal expansion of transduced 
IOSE25-parental cells, enabling selection of the more chromosomally unstable, near-triploid 
population. Increased genomic instability observed in IOSE25-R273H cell line could therefore 
be a reflection of the transduction process rather than expression of recombinant R273H 
mutant p53. 
Interestingly, the near-triploid side clone of IOSE25-parental cells demonstrated 
isochromosome 17(q10). This is a chromosome in which the short arm of chromosome 17 is 
deleted and replaced with a mirror image of the long arm. The TP53 gene is located on the 
short arm of chromosome 17 (17p13), such that isochromosome 17(q10) would result in the 
deletion of TP53 gene. This may contribute to inability to detect endogenous mutant p53 in 
IOSE25-parental cell line as previously reported (refer to Chapter 4).  
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IOSE25 cell lines demonstrated greater chromosome instability than IOSE21 cell lines. The 
abnormalities observed were reminiscent of TOSE cells, indicative of similar evolutionary 
pathways [223]. For example, TOSE cells demonstrated marker chromosomes and gains of 
chromosomes X, 7, 14, 16, and 19 as observed in IOSE25 cell lines. However, with such 
prevalent chromosome instability, the likelihood that some of the aberrations observed would 
overlap is increased. In this respect, without further examination of IOSE25 and TOSE 
metaphase spreads, it is difficult to determine karyotype similarities. 
Wild type p53 is integral to the maintenance of genomic integrity [289]. As such, loss of wild 
type p53 is associated with increased genomic instability [290]. There is a strong correlation 
between mutant p53 and aneuploid karyotypes [291]. In some cancers, and premalignant 
conditions such as Barrett’s oesophagus, mutant p53 is acquired prior to onset of aneuploidy 
[292]. Diploid cells often inactivate p53 and become aneuploid during cell culture, and cells 
from p53-null mice are frequently aneuploid [293, 294]. As such, it is hardly surprising that 
wild type p53 inhibits of the propagation and expansion of aneuploid cells [295]. However, it 
remains controversial if mutant p53 is obligatory for aneuploid karyotypes. Many aneuploid 
cells do not express mutant p53 and aneuploidy has been observed prior to acquisition of 
mutant p53 [295, 296]. It is possible that in these instances, wild type p53 is impaired by 
upstream or down stream signalling; for example, overexpression of MDM2 or inactivation of 
stress response kinases such as ATM [61, 297, 298]. Discussion regarding the role of mutant 
p53 in aneuploidy reflects on-going debate regarding the permissive versus passive role of 
genetic background in the generation of genomic instability. In this respect, it is unclear if 
mutant p53 directly induces aneuploidy or is permissive of aneuploidy-promoting events. The 
acquisition of supernumerary chromosomes following expression of mutant p53 by IOSE21-
R175H and IOSE21-R273H cell lines suggests the former. However, several studies have 
highlighted the inability of mutant p53 to directly induce aneuploidy [299]. For example, 
IOSE25-parental cell line was previously reported to be karyotypically normal, despite the 
presence of mutant p53 [223]. Therefore, despite a correlation between mutant p53 and 
aneuploidy, it is unclear if mutant p53 is directly responsible the karyotypes observed.  
 
5.10.5 Increased migration 
Cell migration is required for many physiological processes, including immune surveillance, 
tissue repair and regeneration [300]. Aberrant migration is associated with the progression of 
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many diseases, including cancer invasion and metastasis. To examine variation in cell 
migration, IOSE cell lines were assessed using the scratch assay (Figures 5.18- 5.19). IOSE21-
R175H and IOSE21-R273H cell lines recovered the scratch significantly faster than IOSE21-
parental cell line, indicative of greater migratory potential. No significant difference was 
observed between IOSE25-parental and IOSE25-R273H cell lines. TOSE1 cells demonstrated 
significantly greater percentage closure than IOSE25-parental cell line, whereas TOSE4 cells 
demonstrated significantly less. Interestingly, no significant difference was observed between 
IOSE25-R273H and TOSE cell lines, suggesting that IOSE25-R273H may demonstrate 
slightly greater migration than IOSE25-parental. However, as TOSE cells did not display the 
same distressed phenotype as IOSE25 cells post-scratch, it may not be suitable to draw 
comparison between these cell lines.  
The scratch assay possesses certain limitations in the assessment of cell migration. Monolayer 
formation can have a significant impact on cell migratory style (E.g. cohesive migration) and 
cell scraping can induce mechanical injury. Geometry of the wound area can also vary 
between experiments, confounding data [301]. As a result, cell migration was also assessed 
using the transwell migration assay. Cells were seeded in transwells in serum and supplement 
free media and examined for migration towards complete medium (Figure 5.20). As cells are 
not to grown to confluence, the assay enables assessment of single cell migration. IOSE21-
R175H and IOSE-R273H demonstrated significantly greater migration than IOSE21-parental 
cell line. IOSE25-R273H cells demonstrated significantly greater migration than IOSE25-
parental cell line, and TOSE cells greater migration than IOSE25 cell lines. This suggests 
greater migratory potential by transduced IOSE and TOSE cell lines. However, transwell 
migration could be influenced by chemotaxic components in the tissue culture medium. As a 
result, transwell migration could reflect response to chemotaxic gradients instead of de novo 
migration. Cell migration may be better assessed using time-lapse microscopy of low-density 
cells. This would eliminate the issue of cell density and chemotaxis as confounded by the 
scratch and transwell migration assays. 
Acquisition of a more motile phenotype is associated with increased metastatic potential. Wild 
type p53 regulates the expression of Rho-GTPases, critical mediators of cell migration [281]. 
Loss of p53 facilitates the activation of RhoA, increasing rounded, amoeboid migration [302, 
303]. p53 deficient cells also demonstrate enhanced cdc42 activation, facilitating filopodia 
formation [283, 304, 305]. Mutant p53 is therefore likely to influence acquisition of the 
transformed trait. Indeed, mutant p53 has been associated with the induction of cell migration 
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through gain-of-function activity. Mutant p53 inhibits p63, increasing the expression of pro-
migratory mediators [154, 156]. This gain-of-function activity suggests different TP53 
mutations could have varying affects on cell migration. Greater transwell migration observed 
by R273H cell lines suggests R273H mutant p53 could enhance single cell migration. 
Similarly, greater cohesive migration by IOSE21-R175H cell line suggests R175H mutant p53 
could increase cohesive migration. However, R273H mutant TOSE cells demonstrated the 
greatest cohesive migration of the cell lines examined. Therefore, mutant p53 may influence 
acquisition of the transformed trait, but the role of different TP53 mutations in cell migration 
remains unclear.   
 
5.10.6 Increased proliferation 
A central trait of cancer cells is their ability to sustain chronic proliferation [166]. IOSE21-
R175H and IOSE21-R273H cell lines demonstrated significantly greater proliferation than 
IOSE21-parental (Figure 5.21). IOSE25-R273H proliferated significantly slower than 
IOSE25-parental, and TOSE cells demonstrated the greatest proliferation of the cell lines 
examined (Figure 5.21). Reduced proliferation by IOSE25-R273H relative to IOSE25-
parental could be the result of mitotic catastrophe, induced by greater genomic instability 
[268]. Increased proliferation by IOSE21-R175H, IOSE21-R273H and TOSE cell lines 
suggests mutant p53 enhances proliferation. This is likely a reflection of the loss of the growth 
suppressive function of wild type p53 [166]. TOSE1 and TOSE4 cell lines demonstrated the 
greatest proliferation of cell lines examined, exceeding that of other TP53 mutant cell lines. 
This suggests other molecular events are required for greater proliferation. TOSE cells 
previously demonstrated up-regulation of epidermal growth factor receptor (EGFR) [223]. 
This could enhance growth receptor signalling, promoting proliferation [166, 306]. In this 
respect, mutant p53 may be permissive of greater proliferation, but other mutations are 
required for greater acquisition of the transformed trait.  
 
5.10.7 Tumourigenicity in immunodeficient mice 
Cells are classified as malignant upon demonstration of tumourigenicity in a suitable animal 
host. Due to the expense of working with immunodeficient mice, not all IOSE cell lines could 
be examined for tumourigenic potential. IOSE21-R175H demonstrated the greatest 
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acquisition of transformed traits, and as such was the only cell line to be assessed for 
tumourigenicity (Table 5.1). IOSE21-R175H failed to form tumours in immunodeficient 
mice, preventing classification as a malignant cell line. Reduced expression of transformed 
traits by other IOSE cell lines suggests other IOSE cells would also fail to demonstrate 
tumourigenic potential. As such, none of the IOSE cell lines could be classified as malignant.  
The expression of a number of transformed traits by IOSE21-R175H and IOSE21-R273H cell 
lines enables ‘premalignant’ classification. In this respect, despite demonstrating the greatest 
acquisition of transformed traits, IOSE21-R175H would be assigned the same transformed 
status as IOSE21-R273H. ‘Premalignant’ therefore fails to reflect the extent of cell 
transformation. Indeed, the transformed traits have not been correlated to different stages of 
tumour progression. Many of the transformed traits reflect invasive, metastatic disease, 
despite inability to assign malignant status. Assessment of transformed traits therefore fails to 
measure early transformative events. As mutant TP53 is thought to be an early event in 
HGSC, the transformed traits examined may fail to capture early mutant p53-mediated 
effects. However, premalignant transformation of IOSE21-R175H and IOSE21-R273H cell 
lines supports an association between mutant p53 and the acquisition of transformed traits, 
even if an exact mechanism of induction could not always be found.  
 
5.11 Chapter summary 
IOSE cell lines were examined for the expression of a number of transformed traits in attempt 
to determine the transformative potential of mutant p53. Premalignant transformation of 
IOSE21-R175H and IOSE21-R273H cell lines supports a role for mutant p53 in early 
transformation. However, it is unclear if mutant p53 directly induced the acquisition of 
transformed traits, or facilitated their induction via other molecular events. Furthermore, 
TOSE cells demonstrated greater acquisition of transformed traits than transduced IOSE cell 
lines, despite similar mutant TP53 status. This suggests other molecular events may enhance 
the expression of transformed traits.  
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Chapter 6: Expansion of soft agar colonies 
6.1 Introduction 
Despite displaying the greatest acquisition of transformed traits, IOSE21-R175H failed to 
form tumours in immunodeficient mice. In attempt to generate a more malignant population, 
soft agar colonies of IOSE21-R175H were isolated and examined for increased expression of 
transformed traits. A total of six soft agar colonies were successfully isolated and renamed 
IOSE21-R175H soft agar colonies (SAC) 1-6. A schematic diagram below illustrates the 
generation of IOSE21-R175H SAC cell lines (Figure 6.1).  
 
 
Figure 6.1: Generation of IOSE21-R175H SAC1-6  
IOSE21-R175H cells were cultured in soft agar. A total of six soft agar colonies were isolated, re-cultured and 
re-named IOSE21-R175H SAC1-6.  
 
6.2 Anchorage independent growth 
IOSE21-R175H SAC1-6 were cultured in soft agar for 3-4 weeks and assessed for colony 
formation. All IOSE21-R175H SAC cell lines formed colonies in soft agar (Figure 6.2) but 
only IOSE21-R175H SAC6 formed significantly more colonies than IOSE21-R175H (Figure 
6.3). The remaining SAC cell lines formed significantly fewer colonies than IOSE21-R175H, 
with the exception of IOSE21-R175H SAC3, in which there was no significant difference 
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(Figure 6.3). Despite forming fewer colonies, IOSE21-R175H SAC cell lines formed 
significantly larger colonies than IOSE21-R175H, with the exception of IOSE21-R175H SAC5 
and SAC6, in which no significant difference was observed (Figure 6.3).  
 
 
Figure 6.2: Anchorage independent growth of IOSE21-R175H SAC1-6 
Soft agar colonies of IOSE21-R175H and IOSE21-R175H SAC1-6 cell lines. All the cell lines formed colonies in 
soft agar. Representative images of n=2. 
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Figure 6.3: Number and size IOSE21-R175H SAC1-6 colonies in soft ager 
A: Average number of colonies formed in soft agar: IOSE21-R175H SAC6 formed significantly more colonies in 
soft agar than IOSE21-R175H. There was no significant difference in colony number between IOSE21-R175H 
and IOSE21-R175H SAC3. The remaining SACs demonstrated reduced colony formation relative to IOSE21-
R175H. B: Size (area) of colonies formed in soft agar: IOSE21-R175H SAC1-4 formed significantly larger 
colonies than IOSE21-R175H. No significant difference in colony size was observed between IOSE21-R175H 
and IOSE21-R175H SAC5-6. Mean ± standard deviation, n=2. ***= p<0.001, **= p0.001-0.01, *= p0.01-
0.05, ns= p>0.05 
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6.3 Cell morphology 
IOSE21-R175H SAC cell lines displayed a range of cell morphologies (Figure 6.4). IOSE21-
R175H SAC1, SAC2, SAC3 and SAC6 demonstrated significantly more elongated, less 
circular morphologies than IOSE21-R175H (Figure 6.5). In contrast, IOSE21-R175H SAC4 
and SAC5 displayed more rounded, condensed cell morphologies, similar to IOSE21-R175H 
(Figure 6.5). IOSE21-R175H SAC cell lines therefore did not demonstrate greater 
morphological transformation than IOSE21-R175H. 
 
 
Figure 6.4: Morphology of IOSE21-R175H SAC1-6 cell lines 
Representative images of IOSE-R175H SAC1-6 cell lines used to assess average cell circularity and length (Figure 
6.5). Representative images of n=3. 
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Figure 6.5: Morphology of IOSE21- R175H SAC1-6 cell lines  
A: Average cell circularity: IOSE21-R175H SAC1-3 and SAC6 are significantly less circular than IOSE21-R175H 
cell line (complete circle=1). No significant difference in cell circularity is observed between IOSE21-R175H 
and IOSE21-R175H SAC4-5 B: Average cell length: IOSE21-R175H SAC1-3 and SAC6 are significantly longer 
than IOSE21-R175H. No significant difference in cell length is observed between IOSE21-R175H and IOSE21-
R175H SAC4-5. Median, ± interquartile range, n=3. ***= p<0.001, **= p0.001-0.01, *= p0.01-0.05, ns= 
p>0.05. 
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6.4 Loss of contact inhibition 
To assess loss of contact inhibition, IOSE21-R175H SAC cell lines were cultured for ten days 
and images taken every ~3 days to examine cell monolayer and foci formation. IOSE21-
R175H SAC1, SAC3 and SAC6 formed moderate-low cell density monolayers, with IOSE21-
R175H SAC6 forming cell foci. IOSE21-R175H SAC2, SAC4 and SAC5 formed denser cell 
monolayers, reminiscent of IOSE21-R175H. Reduced monolayer and increased foci formation 
by IOSE21-R175H SAC1, SAC3 and SAC6 is indicative of earlier onset of contact inhibition. 
Increased monolayer and reduced foci formation by IOSE21-R175H SAC2, SAC4 and SAC5 is 
indicative of delayed onset or loss of contact inhibition, similar to IOSE21-R175H. 
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Figure 6.6: IOSE-R175H SAC1-6 cell monolayer and foci formation 
IOSE21-R175H SAC1, SAC3 and SAC6 formed less dense cell monolayers than IOSE21-R175H SAC2, SAC4 
and SAC5. IOSE21-R175H SAC4 and SAC5 formed the most dense cell monolayers. IOSE21-R175H SAC6 was 
the only SAC cell line to from cell foci. Representative images of n=3. 
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To assess variation in the onset and threshold of induction of contact inhibition, IOSE21-
R175H cell lines were cultured for two weeks and viable cells/mL counted after 9, 12 and 14 
days in culture. Plateau of resulting cell counts is indicative of the onset of contact inhibition, 
with cell density at point of plateau indicative of the threshold of induction. Cell counts of 
IOSE21-R175H SAC6 decreased between days 12 and 14, indicative of onset of contact 
inhibition. Cell counts of IOSE21-R175H and SAC1-5 appeared not to plateau, indicative of 
delayed onset or loss of contact inhibition.  IOSE21-R175H SAC1-6 achieved significantly 
lower cell densities than IOSE21-R175H, indicative of reduced tolerance to cell proximity 
and earlier threshold of induction of contact inhibition. IOSE21-R175H SAC1-6 therefore 
demonstrated reduced acquisition of transformed trait relative to IOSE21-R175H. 
 
 
 
Figure 6.7: IOSE21-R175H SAC1-6 cell density following 9, 12 and 14 days in culture 
IOSE21-R175H and IOSE21-R175H SAC cell lines continued to proliferate and increase cell density across day 
9-14 time points, with the exception of SAC6 in which there was a decline between day 9 and day 14. IOSE21-
R175H SAC cell lines achieved significantly lower cell densities than IOSE21-R175H, with the exception of 
IOSE21-R175H SAC1 day 9 and IOSE21-R175H SAC3 day 14 in which there was no significant difference. 
Mean, ± standard error, n=2, ***= p<0.001, **= p0.001-0.01, *= p0.01-0.05, ns= p>0.05. 
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6.5 Proliferation 
To assess cell proliferation, IOSE21-R175H cell lines were cultured for two weeks and viable 
cells/mL counted every 3 days. Proliferation was measured over the exponential growth 
phase deemed to be between days 1-9. Upon linear regression analysis, most of the IOSE21-
R175H SAC cell lines (SAC1 and SAC3-5) demonstrated no significant difference relative to 
IOSE21-R175H (Figure 6.8). However, IOSE21-R175H SAC2 demonstrated significantly 
greater proliferation, and IOSE21-R175H SAC6 significantly reduced proliferation relative to 
IOSE21-R175H (Figure 6.8). 
 
 
 
Figure 6.8: Proliferation of IOSE21-R175H SAC cell lines. 
IOSE21-R175H SAC2 grew significantly faster than IOSE21-R175H cell line. IOSE21-R175H SAC6 grew 
significantly slower than IOSE21-R175H cell line. No significant difference was observed between IOSE21-
R175H and the proliferation of IOSE21-R175H SAC1 and SACs3-5. Mean ± standard deviation, n=2, ***= 
p<0.001, **= p0.001-0.01, *= p0.01-0.05, ns= p>0.05. 
 
 
 
 
 
 151 
6.6 Transgene copy number 
Transgene copy number could have a significant impact on the expression of recombinant 
mutant p53 and the acquisition of transformed traits. To assess transgene copy number, 
RTqPCR was performed against endogenous genomic and transgenic TP53. IOSE21-R175H 
and the majority of IOSE21-R175H SAC cell lines demonstrated similar transgene copy 
number at 1-2 copies for every copy of genomic TP53 (2-4 copies per cell) (Figure 6.9). 
IOSE21-R175H SAC5 demonstrated the highest transgene copy number, at nearly 3 copies 
for every copy of endogenous TP53 (4-6 copies per cell) (Figure 6.9). IOSE21-R175H SAC1 
demonstrated the lowest transgene copy number at roughly 1 copy to every 2 copies of 
endogenous TP53 (0-2 copies per cell) (Figure 6.9).  
 
 
Figure 6.9: TP53 transgene copy number in IOSE21-R175H SAC cell lines 
Relative fold change of TP53 transgene compared to genomic TP53 in IOSE21 cell lines. No TP53 transgene is 
detected in negative control cell line IOSE21-parental. 0-1 copy of transgene is detected to every copy of 
genomic TP53 in IOSE21-R175H SAC1 cell line. 1-2 copies of transgene are detected to every copy of genomic 
TP53 in IOSE21-R175H SAC2-4 and SAC6. 2-3 copies of transgene are detected to every copy of genomic TP53 
in IOSE21-R175H SAC5. Mean ± standard deviation, n=2. 
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6.7 Expression of recombinant mutant p53 
IOSE21-R175H SAC cell lines demonstrated slight variations in transgene copy number. To 
determine if this affected recombinant mutant p53 expression, IOSE21-R175H SAC cell lines 
were examined for the expression of V5 tag by western blot (Figure 6.10:A). IOSE21-R175H 
SAC cell lines demonstrated similar expression levels of V5 tag, although densitometry 
analysis revealed IOSE21-R175H SAC5 achieved slightly greater, and IOSE21-R175H SAC1 
slightly lower expression than other SAC cell lines (Figure 6.10:B). Variation in V5 tag 
expression levels correlated to greater or lower transgene copy number as observed by 
RTqPCR (Figure 6.9).  
 
 
 
Figure 6.10: Expression of recombinant p53 in IOSE21-R175H SAC cell lines 
A: V5-tag western blot: Expression levels recombinant mutant p53 assessed by V5-tag western blot. IOSE21-
R175H SAC1-6 demonstrate similar expression levels of recombinant mutant p53. Representative image of n=2. 
B: Densitometry analysis of V5-tag western blot: Densitometry analysis of V5-tag expression relative to β-actin 
loading control. Densitometry confirms similar expression levels of recombinant p53 in IOSE21-R175H SAC 
cell lines, although slightly greater expression is observed in IOSE21-R175H SAC5 and slightly lower expression 
is observed in IOSE21-R175H SAC1. Representative data of n=2. 
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6.8  Summary of results  
Transformed trait SAC1 SAC2 SAC3 SAC4 SAC5 SAC6 
Anchorage independent growth ✗ ✗ ✓ ✗ ✗ ✓ 
Circular and condensed morphology ✗ ✗ ✗ ✗ ✗ ✗ 
Loss of contact inhibition ✗ ✗ ✗ ✗ ✗ ✗ 
Increased proliferation ✗ ✓ ✗ ✗ ✗ ✗ 
Table 6.1: Acquisition of transformed traits relative to IOSE21-R175H 
Comparison of IOSE21-R175H SAC cell lines (SAC1-6) to IOSE21-R175H for the expression of transformed 
traits. ✓ = greater acquisition relative to IOSE21-R175H. ✗= the same or reduced acquisition relative to 
IOSE21-R175H 
 
6.9 Discussion 
Despite displaying the greatest acquisition of transformed traits, IOSE21-R175H failed to 
form tumours in immunodeficient mice. In an attempt to isolate a more malignant population, 
soft agar colonies of IOSE21-R175H were isolated and examined for increased expression of 
transformed traits. 
The first transformed trait to be examined was anchorage independent growth using the soft 
agar colony formation assay. The majority of IOSE21-R175H SAC cell lines demonstrated 
reduced colony number and increased colony size relative to IOSE21-R175H (Figure 6.2). 
Variation in colony size could be due to cell proliferation, with faster growing cell lines 
forming larger colonies in soft agar. As a result, colony number may be a better assessment 
anchorage independent growth. Assessment by colony number suggests the majority of 
IOSE21-R175H SAC cell lines demonstrated reduced anchorage independent growth relative 
to IOSE21-R175H. However, despite the greatest proliferation (Figure 6.8), IOSE21-R175H 
SAC2 failed to form the largest colonies in soft agar. This suggests other factors may influence 
colony size, preventing elimination of colony size as a measure of anchorage independent 
growth. Contrary to colony number, colony size suggests the majority of IOSE21-R175H 
SAC cell lines demonstrated greater anchorage independent growth than IOSE21-R175H. 
Inconsistency between colony size and colony number poses a challenge in determining the 
relative anchorage independent growth of IOSE21-R175H SAC cell lines. IOSE21-R175H 
SAC3 and SAC6 could be an exception to this rule, with both colony size and number 
indicative of slightly greater anchorage independent growth. IOSE21-R175H SAC6 formed 
significantly more colonies in soft agar than IOSE21-R175H, although no significant difference 
was observed in colony size (Figure 6.2). IOSE21-R175H SAC3 demonstrated no significant 
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difference in colony number but significantly greater colony size (Figure 6.2). This suggests 
that on average, IOSE21-R175H SAC3 and SAC6 demonstrated slightly greater anchorage 
independent growth than IOSE21-R175H. However, inconsistency in the data for the 
majority of IOSE21-R175H SAC cell lines limits use of anchorage independent growth as a 
measure IOSE21-R175H SAC transformation. It is therefore difficult to state if IOSE21-
R175H SAC cell lines demonstrate greater or reduced acquisition of anchorage independent 
growth relative to IOSE21-R175H. 
Analysis of cell morphology revealed that none of the IOSE21-R175H SAC cell lines had 
acquired a more circular or condensed morphology than IOSE21-R175H (Figure 6.5). In fact, 
the majority of IOSE21-R175H SAC cell lines demonstrated significantly more elongated and 
less circular morphologies than IOSE21-R175H. This deviation could be considered 
surprising, especially considering derivation from a circular and condensed cell line. It is 
possible that soft agar selection may have contributed to the isolation of more elongated cell 
types. Elongated, flattened cells are associated with increased integrin signalling, a mechanism 
of anoikis bypass [261].  However, anchorage independent growth has also been associated 
with more condensed cell morphologies, as cells reduce ECM interactions, limiting cell 
spreading [261].  An explanation for the variation in cell shape by soft agar culture is therefore 
challenging. However, overall, data suggests IOSE21-R175H SAC cell lines do not 
demonstrate greater morphological transformation than IOSE21-R175H. 
Loss of contact inhibition was first assessed by cell monolayer and foci formation. Dense cell 
monolayers are indicative of loss of contact inhibition as cells acquire increased tolerance to 
cell proximity. Cell proximity can also induce selective pressure for the isolation of non-
contact inhibited cells, resulting in the formation cell foci [255]. IOSE21-R175H, IOSE21-
R175H SAC2, SAC4 and SAC5 demonstrated dense cell monolayers with no cell foci, 
indicative of delayed onset or loss of contact inhibition (Figure 6.6). In contrast, IOSE21-
R175H SAC1, SAC3 and SAC6 demonstrated reduced monolayer and increased foci 
formation, indicative of earlier onset of contact inhibition (Figure 6.6). To confirm variation 
in the onset of contact inhibition, IOSE cell lines were cultured for two weeks and cell 
densities measured at day 9, 12 and 14. With the exception of IOSE21-R175H SAC6, cell 
counts for all IOSE21-R175H cell lines increased across the time points examined, indicative 
of delayed onset of contact inhibition (Figure 6.7). However, IOSE21-R175H SAC1-6 
demonstrated significantly lower cell densities than IOSE21-R175H, indicative of earlier onset 
or reduced tolerance to cell proximity (Figure 6.7). This suggests that extension of analysis to 
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later time points may yield evidence of earlier onset of contact inhibition by IOSE21-R175H 
SAC1-5 cell lines relative to IOSE21-R175H. Similarly, reduction in cell density between 
days 12 and 14, combined with the observation of cell foci at day 10, suggests IOSE21-R175H 
SAC6 undergo earlier onset of contact inhibition than IOSE21-R175H. IOSE21-R175H SAC 
cell lines therefore demonstrate reduced acquisition of the transformed trait relative to 
IOSE21-R175H. 
To assess potential variation in cell proliferation, IOSE21-R175H cell lines were grown for 
two weeks and cell counts compared over the exponential growth phase. With the exception 
of IOSE21-R175H SAC2 and SAC6, the majority of IOSE21-R175H SAC cell lines 
demonstrated no significant difference in proliferation relative to IOSE21-R175H (Figure 
6.8). IOSE21-R175H SAC2 was the only cell line to demonstrate significantly greater 
proliferation than IOSE21-R175H, and IOSE21-R175H SAC6 significantly less (Figure 6.8). 
As a result, IOSE21-R175H SAC2 demonstrated greater acquisition and IOSE21-R175H 
SAC6 reduced acquisition of the transformed trait relative to IOSE21-R175H.  
Overall, IOSE21-R175H SAC cell lines failed to consistently demonstrate increased 
expression of transformed traits relative IOSE21-R175H (Table 6.1). As a result, it is unlikely 
that IOSE21-R175H SAC cell lines would demonstrate greater tumourigenic potential in 
immunodeficient mice. Although failing to identify a more malignant cell line, analysis of 
transformed traits did reveal surprising variability between IOSE21-R175H SAC cell lines. As 
derivatives of the IOSE21-R175H cell line, this variability could be indicative of IOSE21-
R175H cell line heterogeneity. In attempt to explain cell line heterogeneity and correlate 
variability in expression of transformed traits to mutant p53, IOSE21-R175H SAC cell lines 
were examined for transgene copy number and expression levels of recombinant mutant p53.  
Lentiviral vectors are associated with a low genomic insertion rate, reducing the likelihood of 
high transgene copy number. Indeed, IOSE21-R175H and the majority of SAC cell lines 
demonstrated low transgene copy number (Figure 6.9), at 1-2 copies for every copy of 
genomic TP53 (2-4 copies per cell). IOSE21-R175H SAC5 demonstrated the highest 
transgene copy number at 2-3 copies for every copy of genomic TP53 (4-6 copies per cell); 
and IOSE21-R175H SAC1 the lowest, at 0-1 copies per copy of genomic TP53 (0-2 copies per 
cell). Transgene copy number also appeared to correlate with the expression level of 
recombinant mutant p53 (Figure 6.10). The majority of IOSE21-R175H SAC cell lines 
demonstrated similar expression levels, with IOSE21-R175H SAC5 demonstrating the highest 
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and IOSE21-R175H SAC1 the lowest. If the expression level of mutant p53 is responsible for 
the extent of acquisition of transformed trait, IOSE21-R175H SAC5 should demonstrate the 
greatest, and IOSE21-R175H SAC1 the lowest acquisition. Neither cell line was found to 
consistently demonstrate higher or lower expression of transformed traits relative to other 
IOSE21-R175H SAC cell lines. This suggests the expression level of recombinant mutant p53 
does not significantly influence the extent of cell transformation. However, as transgene 
expression is regulated from a CMV promoter, all transduced IOSE cell lines overexpress 
recombinant mutant p53. In this respect, comparison of the functional affect of differential 
expression of an overexpressed protein is unlikely to yield functional effect. Comparison of 
IOSE21-R175H SAC cell lines to endogenous TP53 mutants may yield greater information 
regarding the significance of overexpression of mutant p53.  
It is also interesting to note that transgene copy numbers are not absolute values. This suggests 
that within each cell line transgene copy number varies between cells. In Chapter 5, this was 
assumed to be due to the isolation mixed pools rather than individual clones of transduced 
IOSE cells. In contrast, IOSE21-R175H SAC cell lines are derived from single cell colonies of 
anchorage independent IOSE21-R175H cells. As such, it would be reasonable to assume that 
IOSE21-R175H SAC cell lines would demonstrate absolute copy number values. The absence 
of absolute values could be due to the manner in which soft agar colonies were selected. Soft 
agar colonies of IOSE21-R175H were selected by the naked eye, and hence, larger soft agar 
colonies were likely to have been preferentially selected over smaller ones. Larger colonies 
could have arisen following the merger of smaller ones, or from small clusters of cells caused 
by non-homogenous cell suspension during experimental setup. IOSE21-R175H SAC cell 
lines could therefore be derived from mixed pools rather than individual clones of anchorage 
independent cells. Alternatively, genomic instability could have facilitated the gain or loss of 
TP53 transgene. Indeed, it would be interesting to assess IOSE21-R175H SAC cell lines for 
karyotype abnormalities. Genomic instability within the IOSE21-R175H cell line is likely to 
account for cell line heterogeneity. Assessment of IOSE21-R175H SAC cell lines for copy 
number variation could confirm the extent of genomic divergence and provide an explanation 
for the manifestation of phenotypic variation.  
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6.10 Chapter summary 
Overall, IOSE21-R175H SAC cell lines failed to demonstrate greater acquisition of 
transformed traits relative to IOSE21-R175H (Table 6.1). In some instances, IOSE21-R175H 
SAC cell lines demonstrated reduced acquisition, reminiscent of TP53 wild type cell line 
IOSE21-parental. For example, IOSE21-R175H SAC6 demonstrated a more spindle-like 
morphology, earlier onset of contact inhibition and reduced proliferation relative to IOSE21-
R175H. Inability to identify a more transformed cell line suggests mutant TP53 is insufficient 
to induce malignant transformation. Although failing to identify a more malignant population, 
IOSE21-R175H SAC cell lines demonstrate the importance of working with heterogeneous 
cell lines. Homogenous SAC cell lines demonstrated divergent expression of transformed 
traits relative to heterogeneous IOSE21-R175H. This suggests that diversity in the genomic 
landscape could influence the expression of transformed traits. Indeed, primary human 
tumour samples frequently demonstrate greater heterogeneity than their derivative tumour 
cell lines. This is associated with greater diversity in cell behaviour, accredited to the ability of 
tumour samples to select and expand sub-populations according to selective pressure [178]. In 
this respect, heterogeneous IOSE21-R175H cell line is more representative of human disease 
than IOSE21-R175H SACs. IOSE21-R175H is therefore a better model of early HGSC and 
the influence of mutant TP53 in cell transformation.  
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Chapter 7: Discussion 
7.1 Introduction 
The spontaneous gain and loss of different TP53 mutations in the IOSE-TOSE model of HGSC 
suggested different TP53 mutations could have varying transformative potential [222]. To 
investigate this hypothesis, this project aimed to: 
§ Transduce IOSE cell lines from different patients (IOSE21 and IOSE25) with R175H 
and R273H mutant TP53 
§ Assess transduced IOSE cell lines for the acquisition of transformed traits relative to 
non-transduced cell lines to determine the transformative potential of mutant TP53 
§ Assess transduced IOSE cell lines for the acquisition of transformed traits relative to 
each other to determine the transformative potential of different TP53 mutations 
A summary of the data acquired regarding the acquisition of transformed traits is presented in 
Chapter 5 and reproduced in the table below (Table 7.1). 
 
 
Trait 
Relative to IOSE21-parental Relative to IOSE25-parental 
IOSE21-R175H IOSE21-R273H IOSE25-R273H TOSE1 TOSE4 
Anchorage independence ✓ ✗ ✗ ✓ ✓ 
Loss of contact inhibition ✓ ✓ ✗ ✓ ✓ 
Altered morphology ✓ ✓ ✗ ✓ ✓ 
Genomic instability ✓ ✗ ✓ ✓ ✓ 
Increased migration ✓ ✓ ✓ ✓ ✓ 
Increased proliferation ✓ ✓ ✗ ✓ ✓ 
Tumourigenicity in mice ✗ N.A N.A ✗ ✗ 
Table 7.1: Acquisition of transformed traits by transduced IOSE and TOSE cell lines 
Expression of transformed traits by transduced IOSE and TOSE cell lines relative to non-transduced, parental 
control. ✓= acquisition of/increased expression of transformed trait relative to parental cell line, ✗= 
equal/reduced expression of transformed trait relative to parental cell line. TOSE1/4 were previously reported 
to be genomically unstable and not form tumours in immunodeficient mice [222]. 
 
7.2 Transduction of IOSE cell lines 
IOSE cell lines were originally transduced with R175H, R273H and wild type (pWT) TP53 
(Chapter 4). Inclusion of a wild type construct was initially performed to provide a control for 
the overexpression of p53 and possible side effects arising from lentiviral transduction. 
However, transduction of pWT proved unsuccessful, with the transgene spontaneously 
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mutating in IOSE21-pWT cell line (Figure 4.4) and failing to be expressed in IOSE25-pWT 
(Figure 4.16). Inability to transduce IOSE cell lines with pWT could be a reflection of the 
detrimental effects of overexpressing wild type p53. The rapid turn over of p53 in normal 
cells would support this, with cells tightly controlling the activation and stabilisation of p53 
[247]. This may have facilitated the selection of cells that had silenced or mutated the wild 
type transgene in pWT cells. As a result, IOSE21-pWT and IOSE25-pWT were eliminated 
from further analysis. However, inclusion of a control vector is important to eliminate 
potential side effects arising from lentiviral transduction. As a result, future work should 
include the generation of control vector by introducing a nonsense mutation into the TP53 
transgene of Lenti6/V5-D-TOPO plasmid (Invitrogen). IOSE cell lines could then be 
transduced with the control vector and examined for the acquisition of transformed traits.  
Transduction of IOSE cell lines with R175H and R273H mutant TP53 proved more successful. 
Recombinant mutant p53 was shown to behave in the anticipated manner, failing to 
transactivate p21 in response to DNA damage (Figures 4.15- 4.16). Efficacy of transduction 
for IOSE21-R175H and IOSE21-R273H cell lines also appeared fairly high, at 95-100% 
(Figure 4.10). However, efficacy of transduction for IOSE25-R273H appeared substantially 
lower, at just ~60% (Figure 4.10). This suggests nearly half IOSE25-R273H cells do not 
express recombinant mutant p53. Serendipitously however, this may have generated a useful 
model to examine the tumourigenic potential of recombinant mutant p53. If the R273H 
mutation is advantageous to the cells, the transduced mutant population would be selected out 
over time, reflecting clonal evolution during tumourigenesis. In this respect, re-evaluation of 
the percentage of transduced cells in late passage IOSE25-R273H cells could determine the 
tumourigenic significance of mutant TP53. 
 
7.3 The transformative potential of mutant TP53 
The transformative potential of mutant TP53 can be assessed by comparing transduced IOSE 
cell lines to their non-transduced parental control. Ideally, cells should have a wild type 
genomic background so phenotypic variation following transduction of mutant TP53 can be 
correlated to the expression of recombinant protein. As IOSE25 cell lines are thought to have 
an endogenous R175H TP53 mutation, these cells may not be the best model to assess the 
transformative potential of mutant TP53. IOSE21 were confirmed to be TP53 wild type by 
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gene sequencing at codons 175 and 273 (Figure 4.5). This suggests IOSE21 may represent a 
better model to assess the transformative potential of mutant TP53. However, future work 
should include whole genome sequencing to confirm wild type status.  
IOSE21-R175H and IOSE21-R273H demonstrated greater acquisition of transformed traits 
than IOSE21-parental cell line. This suggests mutant TP53 can facilitate the acquisition of 
transformed traits. However, the cells did not demonstrate greater tumourigenicity in 
immunodeficient mice, suggesting mutant TP53 is insufficient to induce complete, malignant 
transformation. In this respect, mutant TP53 is likely to influence the acquisition of 
premalignant traits associated with benign disease. Previous studies have indicated that the 
point at which mutant TP53 is acquired could influence the tumourigenic potential of mutant 
TP53. Early TP53 mutations appear to be associated with increased proliferation, whereas late 
TP53 mutations appear to promote tumour invasion and metastasis [128]. In this respect, as an 
‘early’ event in the transformation of IOSE21 cell lines, mutant p53 would be expected to 
elicit premalignant, proliferative effects. Indeed, IOSE21-R175H and IOSE21-R273H cell 
lines demonstrated greater proliferation than IOSE21-parental (Figure 5.21). Other 
transformed traits could also be associated with the acquisition of enhanced proliferation. For 
example, pro-survival signals produced during cell growth could promote anoikis by-pass, 
facilitating anchorage independent growth [261]. In this respect, the proliferative influence of 
mutant p53 could determine acquisition of other transformed traits in IOSE21-R175H and 
IOSE21-R273H cell lines. However, mutant TP53 could not always be directly, or 
mechanistically, linked to the expression of transformed traits. For example, mutant TP53 was 
associated with the acquisition of a genomically unstable, aneuploid karyotype, but it remains 
unclear if mutant p53 directly induces aneuploidy [299]. Furthermore, despite an association 
between mutant TP53 and morphological alterations, TP53 mutant TOSE cell lines 
demonstrated greater morphological alteration than IOSE21-R175H and IOSE21-R273H 
(Figures 5.8- 5.10). This suggests other molecular events may enhance the expression of 
transformed traits following the acquisition of mutant TP53. As a result, this data suggests 
mutant TP53 is permissive of other tumourigenic events necessary for premalignant 
transformation, rather than direct induction of transformation itself.  
This ‘permissive’ role for TP53 in premalignant transformation could be a reflection of the 
dominant-negative activity of mutant p53. This would enable the capitalisation of sporadically 
occurring tumourigenic events through the loss of wild type p53 tumour suppression. For 
example, loss of wild type p53 would impair cell ability to activate cell cycle arrest in 
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response to DNA damage. This would facilitate the propagation of aberrant DNA, promoting 
tumourigenesis [307-309]. Other models of HGSC support this theory, with mutant p53 
proposed to contribute to the acquisition of genomic instability, facilitating the accumulation 
of genetic alterations necessary for malignant transformation [173]. Indeed, IOSE21-R175H 
cell line demonstrated chromosome instability, and IOSE21-R273H demonstrated an 
abnormal karyotype (Figure 5.13 and Figure 5.15). In this respect, mutant p53 could facilitate 
premalignant transformation by enabling the propagation of sporadically occurring 
tumourigenic events. However, mutant p53 does have gain-of-function activity. TP53 mutant 
cells demonstrate greater tumour formation in mice than TP53-null, suggesting mutant TP53 
confers a tumourigenic advantage [138, 139, 141]. In order in more accurately assess the 
dominant-negative versus gain-of-function activity of mutant p53; TP53-null cell lines could 
be used. TP53-null cells would recapitulate the dominant-negative activity of mutant p53, 
such that additional tumourigenic effects observed in TP53 mutant cell lines are likely to be 
the result of gain-of-function activity. Future work could therefore include the generation of 
TP53-null cell lines.  
 
7.4 Transformative potential of different TP53 mutations 
The transformative potential of different TP53 mutations can be examined by assessing 
transduced IOSE cell lines for the expression of transformed traits relative to each other. 
Again, comparison of a cell lines with a wild type genomic background would increase the 
ease of interpretation. As a result, IOSE21 cell lines may once again represent a better cell line 
model to assess the transformative potential of mutant TP53.  
IOSE21-R175H demonstrated greater acquisition of transformed traits than IOSE21-R273H 
(Table 7.1). This suggests R175H mutant TP53 may have greater transformative potential than 
R273H. This is contrary to the IOSE-TOSE model, in which R273H mutant TP53 was 
associated with greater transformation [222]. Discrepancy between the cells lines could be due 
to variation in cell genomic background, with IOSE21 cells more susceptible to R175H 
mutant p53. Genomic background has previously been shown to influence p53 function, with 
MEFs inducing apoptosis instead of cell cycle arrest in response to DNA damage following 
introduction of oncogenic Myc [128]. This suggests varying genomic background could 
influence the tumourigenic function of mutant p53. To verify this, IOSE21-R175H and 
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IOSE21-R273H cell lines could be assessed for altered expression of transformed traits 
following the introduction of other genetic alterations, or the mutations could be introduced 
into other cell lines.  
Despite the absence of a wild type genomic background, IOSE25 cell lines may still represent 
a useful model to assess the transformative potential of different TP53 mutations. In the IOSE-
TOSE model, cell transformation was associated with the loss of the R175H TP53 mutation 
and acquisition of R273H [222]. As a result, if R273H mutant TP53 is responsible for the 
generation of TOSE cells from an R175H mutant background, IOSE25-R273H would be 
expected to demonstrate greater acquisition of transformed traits than IOSE25-parental. 
However, IOSE25-R273H demonstrated limited acquisition of transformed traits relative to 
IOSE25-parental. This could be due to the low transduction efficacy of IOSE25-R273H as 
previously reported, or be a reflection of the importance of other tumourigenic events in the 
transformation process. In this respect, the results obtained for IOSE25-R273H cell line 
reinforce the idea that mutant TP53 is insufficient to induce premalignant transformation in 
isolation of other genetic events. It also suggests that other molecular events may have 
determined the spontaneous transformation of IOSE25 to generate TOSE1 and TOSE4 cell 
lines. As a result, further examination of genetic alterations in TOSE cells could reveal other 
potential mediators of cell transformation.  
 
7.5 Summary conclusions 
The data obtained from this thesis suggest mutant TP53 is permissive of other tumourigenic 
events necessary for premalignant transformation. The tumourigenic potential of different 
TP53 mutations could not be determined due to disparity between IOSE21 and IOSE25 cell 
lines. Further investigation is required to determine the transformative potential of different 
TP53 mutations. 
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Chapter 8: Future work 
A number of future experiments have been highlighted during the course of this thesis, 
including: 
§ Generation of a Lenti6/V5-D-TOPO (Invitrogen) control vector with a nonsense 
TP53 transgene to account for potential side effects arising from lentiviral 
transduction 
§ Sequencing of IOSE cell lines to determine wild type genomic status 
§ Evaluation of the percentage of transduced cells in late passage IOSE25-R273H to 
determine the selective advantage of R273H mutant p53 
§ Generation of TP53-null cell lines to assist verification of dominant-negative versus 
gain-of-function activity of mutant p53 
§ Introduction of additional mutations into transduced IOSE cell lines to assess the role 
of genomic background in p53 ‘mediated’ transformation 
§ Introduction of different TP53 mutations into other cell lines 
§ Examination of TOSE cell lines for other potential mediators of cell transformation 
However, despite these future experiments, a number issues remain regarding the existing 
model system; namely, the modelling of p53 biology. Expression of TP53 from a CMV 
promoter, coupled with varying transgene copy number, means recombinant mutant p53 is 
vastly overexpressed in transduced IOSE cell lines. The model system therefore fails to 
accurately recapture naturally occurring TP53 mutations. In order to better assess mutant 
TP53, model systems that introduce mutant TP53 to an endogenous TP53 allele could be used. 
This would require use of gene editing techniques such as CRISPR (clustered regularly 
interspaced short palindromic repeat). However, CRISPR would require multiple 
transfections of IOSE cell lines with various plasmid constructs [310]. As slow growing cell 
lines, IOSE cells are difficult to transfect, limiting their suitability for CRISPR. As a result, the 
adoption of faster growing cell lines, such as fallopian secretory FT318, would be useful to 
assess the transformative potential of different TP53 mutations. The additional benefit of using 
this cell line is that whereas the exact origin of IOSE cell lines could not be determined 
(Chapter 3) FT318 cells were shown to express nuclear PAX8 consistent with fallopian 
secretory derivation (Figure 3.5- 3.6). Furthermore, considering the increasing support for 
the fallopian origin of HGSC, adoption of a fallopian secretory cell line would be in keeping 
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with current opinion. Therefore, to assess the transformative potential of different TP53 
mutations, I propose using a CRISPR gene editing system to generate TP53-wild type, TP53-
null, TP53-R175H and TP53-R273H FT318 cell lines. The cell lines could then be carefully 
passaged to generate early, intermediate and late passage stocks. The stocks could then be 
assessed for the acquisition of transformed traits in attempt to identify the expression of 
transformed traits over time. Early, intermediate and late passage stocks could also be 
examined by gene expression microarray to identify potential transcriptome variations arising 
over time and as a result of the expression of different TP53 mutations. Specific transcriptome 
signatures could also be correlated to the acquisition of different transformed traits, enabling 
greater understanding the mechanisms of induction of cell transformation. Comparison of the 
transcriptomes of TP53 mutant and TP53-null cell lines could also provide an indication of the 
dominant-negative versus gain-of-function activity of mutant TP53. Transcriptome data could 
also be used to cluster cells according to immunoreactive, differentiated, mesenchymal and 
proliferative subtypes associated with HGSC [42]. Early, intermediate and late passage cell 
stocks could also be assessed for copy number variations using array CGH (comparative 
genomic hybridisation). This could give an indication of when genomic instability manifests 
during transformation, and provide an indication as to the significance of different TP53 
mutations in the acquisition of the transformed trait. Copy number variations could also be 
indicative of the acquisition of other molecular alterations, enabling correlation between 
transformation and different tumourigenic events. Additional mutations could also be 
introduced, such as BRCA1/2. This could determine the significance of other mutations in cell 
transformation. In this respect, this model system aims to not only assess the transformative 
potential of different TP53 mutations but also gain a better understating of the sequential 
events in cell transformation. In summary, this model would be produced by: 
§ Generation of TP53-wild type, TP53-null, TP53-R175H and TP53-R273H FT318 cell lines  
§ Generation of early, intermediate and late passage stocks 
§ Assessment of acquisition of transformed traits 
§ Assessment of gene expression profiles (microarray) 
§ Assessment of copy number variations (array CGH) 
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Appendix I: Plasmid maps 
 
 
Appendix Figure 1.1: Plasmid Lenti6-V5 TP53 WT 
Main features of lentiviral expression vector TP53 wild type (WT) 
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Appendix Figure 1.2: Plasmid Lenti6-V5 TP53 R175H 
Main features of lentiviral expression vector TP53 R175H 
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Appendix Figure 1.3: Plasmid Lenti6-V5 TP53 R273H 
Main features of lentiviral expression vector TP53 R273H 
 
 
 
 
 
